Methods and systems for allele typing
By comparing the sequence reads of the subject's chromosome with known allelic sequences, the allelic superset is generated, and the problem of uncertain HLA genotyping results in the prior art is solved, and accurate allelic typing is achieved and individual-specific diagnosis.
Patent Information
- Application Number
- CN202380032979.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2023-03-02
- Filing Date
- 2023-04-06
- Publication Date
- 2024-11-15
AI Technical Summary
The existing HLA genotyping methods have problems with insufficient sequencing and unclear haplotype phase, which leads to uncertain results, especially in population genetics and evolution studies, which are difficult to accurately perform allelic genotyping.
By determining more than one known allele sequence, the sequence reads of the target region of the subject's chromosome are compared with the known allele sequence, the superset of allele is generated based on the alignment results, and the Quantity determines the presence of alleles to achieve accurate allelic typing.
This method can accurately determine the HLA allele type of the subject, improve the accuracy and reliability of genotyping, and is suitable for guiding individual disease diagnosis and treatment decisions.
Smart Images

Figure CN118974828A_ABST
Abstract
Description
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS
[0002] This application claims the benefit of U.S. Provisional Application No. 63 / 228,681, filed April 7, 2022, and U.S. Provisional Application No. 63 / 487,926, filed March 2, 2023. Both are incorporated by reference in their entirety for all purposes.
[0003] background
[0004] The human leukocyte antigen (HLA) genes encoding the proteins of the human major histocompatibility complex are located in the short arm of chromosome 6. These encoded HLA proteins are displayed on the cell surface and can be divided into two different categories. Class I HLA proteins (A, B and C) present intracellular antigens derived from viruses or tumors to cytotoxic T lymphocytes. Class II HLA proteins (DR, DQ and DP) present extracellular antigens to T helper cells. HLA genes are highly polymorphic and play an important role in immune-mediated diseases, tumor development processes, transplanted organ or tissue survival determination, and drug hypersensitivity reactions.
[0005] Due to the extreme polymorphism degree in the major histocompatibility complex family, HLA genotyping is a complex procedure. The most polymorphic region known as core exons is exon 2 and 3 in HLA class I genes and exon 2 in HLA class II genes. The sequence of core exons is the most popular target for genotyping because they are considered to be the basic determinants of antigen specificity, which provides information for transplantation. However, in population genetics and evolutionary studies, many polymorphisms in other exons, introns and UTRs have been identified and contribute to the creation of HLA nomenclature. Currently, DNA-based methods are used to perform HLA typing, including SSP-(sequence-specific primers), SSO-(sequence-specific oligonucleotides) and RFLP-PCR (restriction fragment length polymorphism polymerase chain reaction) and sequence-based typing (SBT). Due to insufficient sequencing and unclear haplotype phasing, SBT produces uncertain results.
[0006] Therefore, methods that use sequence information for accurate allele typing are needed.
[0007] Overview
[0008] Methods of allele typing are disclosed. Methods of treatment based on allele typing are disclosed.
[0009] Methods are disclosed, including determining more than one known allele sequence, determining more than one sequence reads of a target region of a chromosome of a subject, wherein the target region of the chromosome comprises one or more loci, aligning the more than one sequence reads with the more than one known allele sequence, determining, for each known allele sequence in the more than one known allele sequence based on the alignment, the number of sequence reads aligned with each known allele sequence, and determining, for one or more loci, the known allele sequence present at the one or more loci based on the number of sequence reads aligned with each known allele sequence.
[0010] Methods are disclosed, including determining more than one known allele sequence, determining more than one sequence reads of a target region of a chromosome of a subject, wherein the target region of the chromosome comprises one or more loci, aligning the more than one sequence reads with the more than one known allele sequence, determining, based on the alignment, for each known allele sequence of the more than one known allele sequence, the number of sequence read families aligned with each known allele sequence (i.e., the number of nucleic acid molecules - a sequence read family can be a group of sequence reads corresponding to a single nucleic acid molecule), and determining, for one or more loci, based on the number of sequence read families aligned with each known allele sequence, the known allele sequence present at the one or more loci.
[0011] Methods are disclosed, including determining more than one known human leukocyte antigen (HLA) allele sequence, determining more than one sequence read of a target region of a chromosome of a subject, wherein the target region of the chromosome comprises one or more loci, aligning the more than one sequence read with the more than one known HLA allele sequence, determining, for each known HLA allele sequence in the more than one known HLA allele sequence based on the alignment, the number of sequence reads aligned to each known HLA allele sequence, generating one or more supersets of known HLA allele sequences based on the number of sequence reads aligned to each known HLA allele sequence, and determining, for one or more loci, the known HLA allele sequence present at the one or more loci based on the number of different reads in the one or more supersets of known HLA allele sequences.
[0012] Methods are disclosed, including determining more than one known human leukocyte antigen (HLA) allele sequence, determining more than one sequence read of a target region of a chromosome of a subject, wherein the target region of the chromosome comprises one or more loci, aligning the more than one sequence read with the more than one known HLA allele sequence, determining, for each known HLA allele sequence in the more than one known HLA allele sequence based on the alignment, a number of sequence read families aligned to each known HLA allele sequence, generating one or more supersets of known HLA allele sequences based on the number of sequence read families aligned to each known HLA allele sequence, and determining, for one or more loci, a known HLA allele sequence present at the one or more loci based on the number of different read families in the one or more supersets of known HLA allele sequences.
[0013] Methods are disclosed, including determining more than one known killer cell immunoglobulin-like receptor (KIR) allele sequences, determining more than one sequence reads of a target region of a chromosome of a subject, wherein the target region of the chromosome comprises one or more loci, aligning the more than one sequence reads with the more than one known KIR allele sequences, determining, for each known KIR allele sequence in the more than one known KIR allele sequences based on the alignment, the number of sequence reads aligned with each known KIR allele sequence, generating one or more supersets of known KIR allele sequences based on the number of sequence reads aligned with each known KIR allele sequence, and determining, for one or more loci, the known KIR allele sequences present at the one or more loci based on the number of different reads in the one or more supersets of known KIR allele sequences.
[0014] Methods are disclosed, including determining more than one known killer cell immunoglobulin-like receptor (KIR) allele sequences, determining more than one sequence reads of a target region of a chromosome of a subject, wherein the target region of the chromosome comprises one or more loci, aligning the more than one sequence reads with the more than one known KIR allele sequences, determining, for each known KIR allele sequence in the more than one known KIR allele sequences, a number of sequence read families aligned to each known KIR allele sequence based on the alignment, generating one or more supersets of known KIR allele sequences based on the number of sequence read families aligned to each known KIR allele sequence, and determining, for one or more loci, the known KIR allele sequences present at the one or more loci based on the number of different read families in the one or more supersets of known KIR allele sequences.
[0015] Methods are disclosed, including determining more than one known allele sequence, determining more than one sequence reads of a target region of a subject's chromosome, wherein the target region of the chromosome comprises one or more loci, aligning the more than one sequence reads with the more than one known allele sequence, determining, for each known allele sequence in the more than one known allele sequence based on the alignment, the number of sequence reads aligned with each known allele sequence, generating one or more supersets of the known allele sequences based on the number of sequence reads aligned with each known allele sequence, and determining, for one or more loci, the known allele sequence present at the one or more loci based on the number of different reads in the one or more supersets of the known allele sequences.
[0016] A method is disclosed, comprising determining more than one known allele sequence, determining more than one sequence reads of a target region of a chromosome of a subject, wherein the target region of the chromosome comprises one or more loci, aligning the more than one sequence reads with the more than one known allele sequence, determining, for each known allele sequence in the more than one known allele sequence based on the alignment, a number of sequence read families aligned with each known allele sequence, generating one or more supersets of the known allele sequences based on the number of sequence read families aligned with each known allele sequence, and determining, for one or more loci, a known allele sequence present at the one or more loci based on the number of different read families in the one or more supersets of the known allele sequences.
[0017] In some embodiments, the result of system and method disclosed herein is used as input to generate a report. The report can be in paper or electronic format. For example, the determination of the allele type (e.g., allele sequence) determined by method and system disclosed herein can be directly presented in such a report.
[0018] The various steps of the methods disclosed herein, or steps performed by the systems disclosed herein, can be performed at the same or different times, in the same or different geographic locations such as countries, and / or by the same or different persons. BRIEF DESCRIPTION OF THE DRAWINGS
[0020] The accompanying drawings, which are incorporated into and constitute a part of this specification, illustrate certain embodiments and are used together with the written description to explain certain principles of the methods, computer-readable media, and systems disclosed herein. The description provided herein can be better understood when read in conjunction with the accompanying drawings, which are included by way of example and not by way of limitation. It should be understood that, unless the context otherwise indicates, the same reference numerals represent the same components in all the drawings. It should also be understood that some or all of the drawings may be schematic representations for illustrative purposes and do not necessarily depict the actual relative sizes or positions of the elements shown.
[0021] Figure 1A is a flow chart schematically depicting exemplary method steps for allele typing.
[0022] Figure 1B is a flow chart schematically depicting another exemplary method steps for allele typing.
[0023] Figure 2 An example of a system for allele typing is shown.
[0024] Figure 3 An example k-mer data structure is shown.
[0025] Figure 4 An example Hasse diagram is shown.
[0026] Figure 5 An example graph data structure is shown.
[0027] Figure 6 An example graph data structure is shown.
[0028] Figure 7 An example graph data structure is shown.
[0029] Figure 8 An example superset comparison is shown.
[0030] Fig. 9 An example method is shown.
[0031] Fig.10 An example method is shown.
[0032] Fig.11 Examples of different alleles with high homology are shown. Fig.11 Alleles in a gene can encode different products at the protein level, even if most of their genomic content is identical. For example, two alleles encoding different proteins may actually differ in only one or two bases.
[0033] Fig.12The example flow chart of the disclosed method is shown. The disclosed method can be configured to run with one or more modes. For example, "build index" mode (to generate kmer atlas database) and "call allele" mode (to call the allele on the input sample).
[0034] Fig.13 An example showing the hierarchical structure of allele names. HLA allele names are encoded by a string such as A*01:02:03:04, which contains the gene name (A, for HLA-A) and up to four sets of numbers. When examining two allele names:
[0035] ● Match the first two sets of numbers: Alleles encode the same protein, but they can have different genomic contents at the exon level.
[0036] • Match the first three sets of numbers: the alleles have the same genomic content at the exon level (their bases are identical in the exons).
[0037] • Matching all four sets of numbers: the alleles have identical genomic content in both exons and introns.
[0038] Fig.14 Shown is a screen capture of the Integrative Genomics Viewer, which shows an allele called by Kmerizer and a collection of all supporting reads for the called allele. This view contains only sequence reads that fully match the called allele (regardless of alignment with the reference genome).
[0039] Fig.15 The analysis performance of kmerizer for two simulated sets of 100 samples each is shown, matching the sensitivity of HISAT-genotype. The "conventional" set contains 100 simulated samples, with a simulated error rate of 0.1%, and reads in 14 HLA genes (HISAT-genotype does not call genes in DRB3, DRB4, and DRB5). The "difficult" set contains 100 simulated samples, with a simulated error rate of 0.1%, and reads in 8 HLA genes, which are selected from pools of alleles known to share a high level of homology.
[0040] Fig.16 The analysis performance of Kmerizer on a simulated set of 100 samples is shown. The set contains 100 simulated samples with a simulated error rate of 0.1% and reads in 17 KIR genes.
[0041] Fig.17The analytical performance of Kmerizer for 19 samples with known HLA status for four HLA genes (HLA-A, HLA-B, HLA-C, and HLA-DQB1) is shown, matching the performance of HISAT genotyping.
[0042] Fig.18 Shown is a comparison of HLA germline allele prevalence between methylation epigenome probing samples (n=2004) and Allele Frequency Net Database (AFND) genotype data from different geographic regions.
[0043] Fig.19 Shown are the count distributions of germline HLA alleles that predict immunogenic neoantigens.
[0044] Fig. 20 Shown are the overall germline HLA allele distributions for all methylation epigenome assayed samples.
[0045] Fig.21 Shown is the random assignment of germline alleles and homozygous / heterozygous status based on AFND to generate germline reads using a reference from the IMGT / HLA database; somatic mutations are then randomly generated at exonic positions, and mutant reads are then generated from the altered reference.
[0046] Fig. 22 Variant allele frequency (AF) distributions of detected variants are shown.
[0047] Fig.23 TMB v. predicted neoepitope affinity across genes is shown. Spearman correlations for each group are listed.
[0048] Fig.24 The distribution of neoantigen binding affinity by cancer type is shown.
[0049] I. definition
[0050] In order to more easily understand the present disclosure, some terms are first defined below. The following terms and other definitions of other terms can be set forth through the specification. If the definition of a term set forth below is inconsistent with the definition in a patent application or a patent issued by reference, the definition set forth in this application should be used to understand the meaning of the term.
[0051] As used in this specification and the appended claims, the singular forms "a", "an", and "the" include plural references unless the context clearly indicates otherwise. Thus, for example, reference to "a method" includes one or more methods and / or types described herein and / or steps that will become apparent to one of ordinary skill in the art after reading the present disclosure, etc. It should also be understood that there is an implicit "about" before the temperature, concentration, time, number of bases or base pairs, coverage, etc. discussed in the present disclosure, so that equivalents of minor and insubstantial differences are within the scope of the present disclosure. In this application, unless otherwise expressly stated, the use of the singular includes the plural. In addition, the use of "comprise", "comprises", "comprising", "contain", "contains", "containing", "include", "includes", and "including" is not intended to be limiting.
[0052] It should also be understood that the terms used herein are only for the purpose of describing specific embodiments and are not intended to be limiting. In addition, unless otherwise defined, all technical terms and scientific terms used herein have the same meanings as those commonly understood by those of ordinary skill in the art to which the present disclosure belongs. When describing and claiming these methods, computer-readable media, and systems, the following terms and their grammatical variants will be used according to the definitions set forth below.
[0053] About: As used herein, "about" or "approximately" applied to one or more values or elements of interest refers to a value or element similar to the reference value or element. In certain embodiments, the term "about" or "approximately" refers to a series of values or elements that fall within 25%, 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1% or less of the reference value or element in either direction (greater than or less than) of the reference value or element, unless otherwise stated or otherwise apparent from the context (unless such a number exceeds 100% of the possible value or element).
[0054] Adaptor: As used herein, "adapter" or "adaptor" refers to a short nucleic acid (e.g., less than about 500 nucleotides, less than about 100 nucleotides, or less than about 50 nucleotides in length) that is typically at least partially double-stranded and used to connect either or both ends of a given sample nucleic acid molecule. An adaptor may include a primer binding site that allows amplification of nucleic acid molecules flanked by adaptors at both ends, and / or a sequencing primer binding site, including primer binding sites for sequencing applications such as various next-generation sequencing (NGS) applications. An adaptor may also include a binding site for a capture probe, such as an oligonucleotide attached to a flow cell support, etc. An adaptor may also include a nucleic acid tag as described herein. Nucleic acid tags are typically positioned relative to amplification primers and sequencing primer binding sites so that the nucleic acid tag is included in the amplicon and sequencing read of a given nucleic acid molecule. Adapters of the same or different sequences may be connected to the corresponding ends of a nucleic acid molecule. In certain embodiments, in addition to the different sequences of the nucleic acid tags, the same adaptors are connected to the corresponding ends of the nucleic acid molecules. In some embodiments, the adapter is a Y-shaped adapter, one end of which is blunt-ended or tailed as described herein for attachment to a nucleic acid molecule that is also blunt-ended or tailed with one or more complementary nucleotides. In yet other exemplary embodiments, the adapter is a bell-shaped adapter, comprising a blunt-ended or tailed end for attachment to a nucleic acid molecule to be analyzed. Other exemplary adapters include T-tailed and C-tailed adapters.
[0055] Administration: As used herein, "administering" or "administering" a therapeutic agent (e.g., an immunotherapeutic agent, a DNA damage response (DDR) inhibitor (e.g., a poly (ADP-ribose) polymerase (PARP) inhibitor (PARPi)), etc.) to a subject means giving, applying, or contacting a composition with a subject. Administration can be accomplished by any of a number of routes, including, for example, topical, oral, subcutaneous, intramuscular, intraperitoneal, intravenous, intrathecal, and intradermal.
[0056] Alignment: As used herein, in the context of nucleic acids, "alignment," "alignment," and "aligning" refer to arranging sequences of DNA or RNA to identify regions of similarity. Similarity can be related to nucleotide sequence, structure, function, and / or evolutionary relationships between sequences. Alignment of DNA sequences includes alignment of the genomic DNA of one sequence with the genomic DNA of at least one other sequence. Such an alignment may not include non-genomic DNA, such as molecular barcodes, filler bases, and the like. For example, the genomic DNA of a sequence read can be aligned with the genomic DNA of a reference DNA sequence, excluding any molecular tags or adapter sequences that may be attached to the sequence read.
[0057] As used herein, a statement that a nucleotide "corresponds to" a nucleotide in a sequence refers to the nucleotide that is identified when aligned to the sequence to maximize identity using a standard alignment algorithm, such as the GAP algorithm.
[0058] As used herein, "sequence identity", "sequence homology" or "identity" refers to the number of identical or similar nucleotide bases in the comparison between two or more polynucleotide sequences. In a non-limiting example, "at least 90% identical to ... " refers to 90% to 100% identity percentage relative to a reference polynucleotide. The identity indication at 90% or higher levels is such a fact that, assuming that for example purposes, a test polynucleotide of 100 nucleotide lengths is compared with a reference polynucleotide, the nucleotides that are no more than 10% (that is, 10 of 100) in the test polynucleotide are different from the nucleotides of the reference polynucleotide. Such differences can be represented as point mutations randomly distributed over the entire length of the nucleotide sequence, or they can be clustered at one or more variable length positions, which can reach a maximum allowed value at the longest, for example, 10 / 100 nucleotide differences (approximately 90% identity). Differences are defined as replacements, insertions or deletions of nucleic acids.
[0059] Sequence identity can be determined by the sequence alignment of nucleotide sequence to identify the region with similarity or identity. For the purpose of this paper, sequence identity is usually determined by alignment to identify the same base. Alignment can be local or global. Matching, mispairing and the space between the sequences compared can be identified. The space is the empty nucleotide inserted between the bases of the sequence compared so that the same or similar characters are aligned. Generally, there can be internal and terminal spaces. Sequence identity can be determined as the length x100 of the quantity / shortest sequence of the same bases by taking the space into consideration. When using a gap penalty, sequence identity can be determined without penalty for the terminal space (for example, the terminal space is not penalized). Alternatively, sequence identity can be determined as the length x100 of the quantity / total comparison sequence of the same position without taking the space into consideration.
[0060] As used herein, "global alignment" is an alignment in which two sequences are aligned from beginning to end, with each base in each sequence aligned only once. Alignment occurs regardless of whether there is similarity or identity between sequences. For example, 50% sequence identity based on "global alignment" means that 50% of the bases are identical in the full sequence alignment of two compared sequences each having a length of 100 nucleotides. It should be understood that global alignment can also be used to determine sequence identity even when the lengths of the aligned sequences are not the same. The differences at the ends of the sequences will be considered when determining sequence identity, unless "no penalty for terminal gaps" is selected. Typically, global alignment is used for sequences that have significant similarity over most of their lengths. Exemplary algorithms for performing global alignment include the Needleman-Wunsch algorithm (Needleman et al. J. Mol. Biol. 48: 443 (1970)). Exemplary programs for performing global alignments are publicly available and include the Global Sequence Alignment Tool available at the National Center for Biotechnology Information (NCBI) website (ncbi.nlm.nih.gov / ) and the program available at deepc2.psi.iastate.edu / aat / align / align.html.
[0061] As used herein, a "local alignment" is an alignment of two sequences, but only those portions of the sequences that have a common similarity or identity. Thus, a local alignment determines whether sub-segments of one sequence exist in another sequence. If there is no similarity, no alignment will be returned. Local alignment algorithms include BLAST or Smith-Waterman algorithms (Adv. Appl. Math. 2:482 (1981). For example, a 50% sequence identity based on a "local alignment" means that in a full sequence alignment of two comparison sequences of any length, a region of similarity or identity of 100 nucleotides in length has 50% of the bases that are the same in the region of similarity or identity.
[0062] Allele: As used herein, "allele" or "allelic variant" refers to a specific gene variant at a defined genomic position or locus. Allelic variants typically occur at a frequency of 50% (0.5) or 100%, depending on whether the allele is heterozygous or homozygous. For example, germline variants are inherited and typically have a frequency of 0.5 or 1. However, somatic variants are acquired variants and typically have a frequency of <0.5. The major allele and minor allele of a genetic locus refer to nucleic acids having a site in which the site is occupied by nucleotides of a reference sequence and variant nucleotides that are different from the reference sequence, respectively. Measurements at a site can take the form of an allele fraction (AF), which measures the frequency at which an allele is observed in a sample.
[0063] Amplification: As used herein, "amplify" or "amplification" in the context of nucleic acids refers to the production of multiple copies of a polynucleotide or a portion of a polynucleotide, typically starting from a small amount of polynucleotide (e.g., a single polynucleotide molecule), wherein the amplification product or amplicon is typically detectable. Amplification of polynucleotides includes a variety of chemical and enzymatic processes.
[0064] Barcode: As used herein, "barcode" in the context of nucleic acids refers to a nucleic acid molecule with a sequence that can be used as an identifier for a molecule (molecular barcode), an identifier for a partition (partition barcode), or an identifier for a sample (sample barcode or sample index). For example, during next-generation sequencing (NGS) library preparation, a single "barcode" sequence is often added to DNA fragments so that each read can be identified and sorted prior to final data analysis.
[0065] Cell-free nucleic acid: As used herein, "cell-free nucleic acid" refers to nucleic acids that are not contained in cells or otherwise bound to cells. In some embodiments, "cell-free nucleic acid" refers to nucleic acids that are not contained in cells or otherwise bound to cells when separated from a subject. Cell-free nucleic acids may include, for example, all unencapsulated nucleic acids derived from body fluids (e.g., blood, plasma, serum, urine, cerebrospinal fluid (CSF), etc.) from a subject. Cell-free nucleic acids include DNA (cfDNA), RNA (cfRNA) and hybrids thereof, including cfDNA or cfRNA derived from genomic DNA, mitochondrial DNA, circulating DNA, siRNA, miRNA, circulating RNA (cRNA), tRNA, rRNA, small nucleolar RNA (snoRNA), Piwi-interacting RNA (piRNA), long non-coding RNA (long ncRNA) and / or fragments of any of these. Cell-free nucleic acids may be double-stranded, single-stranded, or hybrids thereof. Cell-free nucleic acids may be released into body fluids by secretion or cell death procedures, such as cell necrosis, apoptosis, and the like. Some cell-free nucleic acids are released from cancer cells into body fluids, such as circulating tumor DNA (ctDNA). Others are released from healthy cells. ctDNA can be unencapsulated tumor-derived fragmented DNA. Another example of cell-free nucleic acids is fetal DNA that circulates freely in the maternal bloodstream, also referred to as cell-free fetal DNA (cffDNA). Cell-free nucleic acids can have one or more epigenetic modifications, for example, cell-free nucleic acids can be acetylated, 5-methylated, ubiquitinated, phosphorylated, sumoylated, ribosylated and / or citrullinated.
[0066] Cellular origin: As used herein, in the context of cell-free nucleic acids, "cell origin" refers to the type of cell from which a given cell-free nucleic acid molecule is derived or otherwise originates (e.g., via an apoptotic process, a necrotic process, etc.). In certain embodiments, for example, a given cell-free nucleic acid molecule can be derived from a tumor cell (e.g., a cancerous lung cell, etc.) or a non-tumor or normal cell (e.g., a non-cancerous lung cell, etc.).
[0067] Classifier: As used herein, "classifier" generally refers to an algorithmic computer code that receives test data as input and produces as output a classification of the input data as belonging to one or another class (e.g., having DNA damage repair deficiency (DDRD) or not having DDRD, tumor DNA or non-tumor DNA).
[0068] Contiguous sequence: As used herein, "contiguous sequence" or "contig" refers to a set of consecutive nucleic acid bases (which may be overlapping) that together represent the consensus sequence of a region of nucleic acid. It can refer to any continuous segment of sequence data of a sequence read, or a reference interval, or a construct from a read and / or a reference segment (such as an assembled read).
[0069] Copy number variant: As used herein, "copy number variant," "CNV," or "copy number variation" refers to the phenomenon that certain segments of the genome are repeated, and the number of repeats in the genome varies between individuals in the population under consideration.
[0070] Coverage: As used herein, the terms "coverage," "total molecule counts," or "total allele counts" are used interchangeably. They refer to the total number of nucleic acid molecules at a specific genomic location in a given sample.
[0071] Deoxyribonucleic acid or ribonucleic acid: As used herein, "deoxyribonucleic acid" or "DNA" refers to a natural or modified nucleotide having a hydrogen group at the 2'-position of the sugar portion. DNA generally includes a chain of nucleotides comprising deoxyribonucleosides, which contain one of the four types of nucleobases, i.e., adenine (A), thymine (T), cytosine (C) and guanine (G). As used herein, "ribonucleic acid" or "RNA" refers to a natural or modified nucleotide having a hydroxyl group at the 2'-position of the sugar portion. RNA generally includes a chain of nucleotides comprising ribonucleosides, which contain one of the four types of nucleobases, i.e., A, uracil (U), G and C. As used herein, the term "nucleotide" refers to a natural nucleotide or a modified nucleotide. Certain pairs of nucleotides specifically bind to each other in a complementary manner (called complementary base pairing). In DNA, adenine (A) pairs with thymine (T) and cytosine (C) pairs with guanine (G). In RNA, adenine (A) pairs with uracil (U) and cytosine (C) pairs with guanine (G). When a first nucleic acid chain is combined with a second nucleic acid chain consisting of nucleotides complementary to those in the first chain, the two chains combine to form a double strand. As used herein, "nucleic acid sequencing data", "nucleic acid sequencing information", "sequence information", "nucleic acid sequence", "nucleotide sequence", "genomic sequence", "genetic sequence" or "fragment sequence" or "nucleic acid sequencing read" means any information or data indicating the order and identity of nucleotide bases (e.g., adenine, guanine, cytosine and thymine or uracil) in a molecule (e.g., a whole genome, a whole transcriptome, an exome, an oligonucleotide, a polynucleotide or a fragment) of a nucleic acid such as DNA or RNA. It should be understood that the present teachings contemplate sequence information obtained using all available techniques, platforms or technologies, including but not limited to capillary electrophoresis, microarrays, ligation-based systems, polymerase-based systems, hybridization-based systems, direct or indirect nucleotide identification systems, pyrosequencing, ion- or pH-based detection systems, and electronic signature-based systems.
[0072] Detection: As used herein, "detect," "detecting," or "detection" refers to the act of determining the existence or presence of one or more target nucleic acids (e.g., nucleic acids having a targeted mutation or other marker) in a sample.
[0073] Enriched sample: As used herein, "enriched sample" refers to a sample that has been enriched for a particular region of interest. This can be accomplished by amplifying the region of interest or by using single-stranded DNA / RNA probes or double-stranded DNA probes that can hybridize to nucleic acid molecules of interest (e.g., In some embodiments, the enriched sample refers to a subset or portion of the processed sample that is enriched, wherein the subset or portion of the processed sample that is enriched comprises nucleic acid molecules from the cell-free polynucleotide or polynucleotide sample.
[0074] Gene: As used herein, "gene" refers to any segment of DNA associated with a biological function. Thus, a gene comprises a coding sequence and optional regulatory sequences required for its expression. A gene also optionally comprises a non-expressed DNA segment, such as forming a recognition sequence for other proteins.
[0075] Genomic region: As used herein, "genomic region" means a fixed position on a chromosome or a portion of a chromosome, such as the position of a gene or genomic marker. Exemplary genomic markers include transcription factor binding regions (e.g., CTCF binding regions, etc.), distal regulatory elements (DREs), repetitive elements (e.g., microsatellites, etc.), intron-exon junctions or exon-intron junctions, transcription start sites (TSSs), etc.
[0076] Insertion / deletion (Indel): As used herein, "Indel" refers to a mutation involving the insertion or deletion of a nucleotide position in the genome of a subject.
[0077] k-mer: As used herein, "k-mer" refers to a string (or substring) of length k contained within a genomic sequence. In some embodiments, the length k can be 100 bp or less, 150 bp or less, 200 bp or less, or 250 bp or less.
[0078] Match: As used herein, "match" means that at least a first value or element is at least approximately equal to at least a second value or element. In certain embodiments, for example, when there is at least a substantial or approximate match between the cfDNA fragment characteristic distribution of the test sample and the cfDNA fragment characteristic distribution of the reference sample, the cellular origin of at least a subset of DNA molecules from the cfDNA sample is determined.
[0079] Mutation: As used herein, "mutation", "nucleic acid variant", "variant", "genetic aberration" or "genetic damage" refers to a variation from a known reference sequence, and includes mutations such as, for example, single nucleotide variants (SNVs), copy number variants or variations (CNVs) / aberrations, insertions / deletions (indels), truncations, gene fusions, transversions, translocations, frameshifts, duplications, repeat expansions, and epigenetic variants. Mutations can be germline mutations or somatic mutations. In some embodiments, the reference sequence used for comparison purposes is the wild-type genomic sequence of the species of the subject providing the test sample, typically the human genome. In some cases, the mutation or variant is a "tumor-associated genetic variant" that causes or at least contributes to tumorigenesis. A driver mutation can be a mutation associated with cancer or another abnormal biological condition. The presence of a driver mutation can indicate a cancer diagnosis, subtype stratification of a subject, tumor burden, tumors in a tissue or organ, tumor metastasis, therapeutic efficacy, or resistance to treatment.
[0080] Next Generation Sequencing: As used herein, "Next Generation Sequencing" or "NGS" refers to a massively parallel sequencing technology with increased throughput compared to traditional Sanger and capillary electrophoresis-based methods, e.g., the ability to generate hundreds of thousands of relatively small sequence reads at a time. Some examples of next generation sequencing technologies include, but are not limited to, sequencing by synthesis, sequencing by ligation, and sequencing by hybridization.
[0081] Nucleic acid tag: As used herein, a "nucleic acid tag" refers to a short nucleic acid (e.g., less than about 500, about 100, about 50, or about 10 nucleotides in length) that is used to label nucleic acid molecules to distinguish nucleic acids from different samples (e.g., representing a sample index), or different nucleic acid molecules of different types or undergoing different treatments in the same sample (e.g., representing a molecular tag). Nucleic acid tags can be single-stranded, double-stranded, or at least partially double-stranded. Nucleic acid tags optionally have the same length or different lengths. Nucleic acid tags can also include double-stranded molecules with one or more blunt ends, including 5' or 3' single-stranded regions (e.g., overhangs), and / or include one or more other single-stranded regions at other locations within a given molecule. Nucleic acid tags can be attached to one or both ends of other nucleic acids (e.g., sample nucleic acids to be amplified and / or sequenced). Nucleic acid tags can be decoded to reveal information such as the sample source, form, or treatment of a given nucleic acid. Nucleic acid tags can also be used to realize the collection and / or parallel processing of multiple samples containing nucleic acids with different nucleic acid tags and / or sample indexes, wherein nucleic acid is subsequently deconvoluted by reading nucleic acid tags. Nucleic acid tags can also be referred to as molecular identifiers or labels, sample identifiers, index tags and / or barcodes. Additionally or alternatively, nucleic acid tags can be used to distinguish different molecules in the same sample. For example, this includes uniquely labeling different nucleic acid molecules in a given sample, or non-uniquely labeling these molecules. In the case of non-uniquely labeled applications, labels with a limited number of different sequences can be used to label nucleic acid molecules, so that different molecules can be distinguished based on, for example, the combination of the starting position and / or the end position of the reference genome selected and at least one nucleic acid tag. Typically, using a sufficient number of different nucleic acid tags, any two molecules will have the same starting position and / or end position and also have a low probability of the same nucleic acid tag (for example, less than about 10%, less than about 5%, less than about 1%, or less than about 0.1% probability). Some nucleic acid tags contain more than one molecular identifier to mark samples, forms of nucleic acid molecules within samples, and nucleic acid molecules within forms with the same starting and ending positions. Such nucleic acid tags can be referenced using the exemplary form "A1i", where capital letters indicate sample types, Arabic numerals indicate forms of molecules within samples, and lower case Roman numerals indicate molecules within forms.
[0082] Polynucleotide: As used herein, "polynucleotide", "nucleic acid", "nucleic acid molecule" or "oligonucleotide" refers to a linear polymer of nucleosides (including deoxyribonucleosides, ribonucleosides or their analogs) connected by internucleoside bonds. Typically, a polynucleotide contains at least three nucleosides. The size of an oligonucleotide generally ranges from a few monomeric units, such as 3-4, to hundreds of monomeric units. Whenever a polynucleotide is represented by a string of letters such as "ATGCCTG", it will be understood that the nucleotides are in the order of 5'→3' from left to right, and in the case of DNA, "A" represents deoxyadenosine, "C" represents deoxycytidine, "G" represents deoxyguanosine, and "T" represents deoxythymidine, unless otherwise specified. As is standard in the art, the letters A, C, G and T can be used to refer to a base itself, a nucleoside, or a nucleotide comprising a base.
[0083] Prevalence: As used herein, "prevalence" in the context of nucleic acid variants refers to the degree, prevalence, or frequency with which a given nucleic acid variant is or has been observed in a given sample (e.g., a given bodily fluid sample, a given non-bodily fluid sample, etc.) or other population (e.g., a given bodily fluid sample population, a given non-bodily fluid sample population, etc.).
[0084] Reference sample: As used herein, a "reference sample" or "reference cfDNA sample" refers to a sample of known composition and / or having or known to have or lack a particular property (e.g., a known nucleic acid variant, a known cell of origin, a known tumor fraction, a known coverage, and / or the like) that is analyzed together with or compared to a test sample in order to evaluate the accuracy of an analytical procedure. A reference sample data set typically includes at least about 25 to at least about 30,000 or more reference samples. In some embodiments, the reference sample data set includes about 50, 75, 100, 150, 200, 300, 400, 500, 600, 700, 800, 900, 1,000, 2,500, 5,000, 7,500, 10,000, 15,000, 20,000, 25,000, 50,000, 100,000, 1,000,000 or more reference samples.
[0085] Reference sequence: As used herein, "reference sequence" or "reference genome" refers to a known sequence for the purpose of comparison with an experimentally determined sequence. For example, the known sequence can be an entire genome, a chromosome, or any segment thereof. The reference sequence typically includes at least about 20, at least about 50, at least about 100, at least about 200, at least about 250, at least about 300, at least about 350, at least about 400, at least about 450, at least about 500, at least about 1000, at least about 10,000, at least about 100,000, at least about 1,000,000, at least about 10,000,000, at least about 100,000,000, at least about 1,000,000,000 or more nucleotides. The reference sequence can be aligned to a single continuous sequence of a genome or chromosome, or can include non-continuous segments aligned to different regions of a genome or chromosome. Exemplary reference sequences include, for example, the human genome, such as hG19 and hG38.
[0086] Sample: As used herein, "sample" refers to any biological sample that can be analyzed by the methods and / or systems disclosed herein. In certain aspects of the present disclosure, the sample is a body fluid sample, such as whole blood or fractions thereof, lymph, urine, and / or cerebrospinal fluid, as well as other body fluid types from which cell-free (circulating, not contained in cells or otherwise bound to cells) nucleic acids are derived. In certain embodiments, the body fluid sample is a plasma sample, which is a fluid portion of whole blood that does not include cells (such as red blood cells and white blood cells). In some embodiments, the body fluid sample is a serum sample, i.e., plasma lacking fibrinogen. In some aspects of the present disclosure, the sample is a "non-body fluid sample" or "non-plasma sample," i.e., a biological sample other than a "body fluid sample," such as a cell and / or tissue sample, which is a source of nucleic acids other than cell-free nucleic acids. In some embodiments, the sample may include body tissue or a tissue biopsy.
[0087] Sensitivity: "Sensitivity" as used herein in the context of a particular assay or method refers to the ability of the assay or method to detect and distinguish between targeted analytes (eg, nucleic acid variants) and non-targeted analytes.
[0088] Sequence fragment: As used herein, sequence fragment construction allele k-mer data structure can include known allele sequence is divided into a certain number of k-mer.For example, there is a certain number of k-mer of about 100 nucleotides to about 200 nucleotides length.In embodiments, a certain number of k-mer can have the length of 125-175 nucleotides, 130-160 nucleotides, 135-155 nucleotides, 140-150 nucleotides.In embodiments, a certain number of k-mer can have the length of 140, 141, 142, 143, 144 or 145 nucleotides.Constructing allele k-mer data structure can include each k-mer is associated with metadata.Metadata can include the indication of the quantity of the allele that for example comprises k-mer, and for each allele that comprises k-mer, can include the starting position of allele identifier and k-mer.
[0089] Sequence read: As used herein, a "read," "sequence read," or "sequencing read" refers to a sequence of base pairs corresponding to all or part of a sequence fragment.
[0090] Sequencing: As used herein, "sequencing" refers to any of a number of techniques used to determine the sequence (eg, the identity and order of monomeric units) of a biological molecule, eg, a nucleic acid such as DNA or RNA. Exemplary sequencing methods include, but are not limited to, targeted sequencing, single molecule real-time sequencing, exon or exome sequencing, intron sequencing, electron microscopy-based sequencing, panel sequencing, transistor-mediated sequencing, direct sequencing, random shotgun sequencing, Sanger dideoxy terminator sequencing, whole genome sequencing, hybridization sequencing, pyrosequencing, capillary electrophoresis, duplex sequencing, cycle sequencing, single base extension sequencing, solid phase sequencing, high throughput sequencing, massively parallel signature sequencing, emulsion PCR, low denaturing temperature co-amplification-PCR (COLD-PCR), multiplex PCR, reversible dye terminator sequencing, paired end sequencing, near-term sequencing, exonuclease sequencing, ligation sequencing, short read sequencing, single molecule sequencing, synthesis sequencing, real-time sequencing, reverse terminator sequencing, nanopore sequencing, 454 sequencing, Solexa Genome Analyzer sequencing, SOLiD TMSequencing, MS-PET sequencing, and combinations thereof. In some embodiments, sequencing can be performed by a genetic analyzer, such as, for example, a genetic analyzer commercially available from Illumina, Inc., Pacific Biosciences, Inc., or Applied Biosystems / Thermo Fisher Scientific, etc.
[0091] Sequence information: As used herein, "sequence information" in the context of a nucleic acid polymer means the order and / or identity of monomeric units (eg, nucleotides, etc.) in the polymer.
[0092] Single nucleotide variant: As used herein, "single nucleotide variant" or "SNV" means a mutation or variation occurring in a single nucleotide at a specific position in a genome or a given genomic sequence.
[0093] Specificity: "Specificity" as used herein in the context of a diagnostic analysis or assay refers to the degree to which the assay or assay detects the intended target analyte to the exclusion of other components of a particular sample.
[0094] Status: As used herein, "status" in the context of a subject refers to one or more states of a given subject, such as whether the subject has cancer.
[0095] Subject: As used herein, "subject" or "test subject" refers to an animal, such as a mammalian species (e.g., human), or an avian (e.g., bird) species, or other organisms, such as plants. More specifically, the subject can be a vertebrate, such as a mammal such as a mouse, a primate, an ape, or a human. Animals include farm animals (e.g., production cattle, dairy cows, poultry, horses, pigs, etc.), sports animals, and companion animals (e.g., pets or support animals). The subject can be a healthy individual, an individual with or suspected of having a disease or a tendency to suffer from the disease, or an individual in need of treatment or suspected of needing treatment. The term "individual" or "patient" is intended to be used interchangeably with "subject". In some embodiments, the subject is a human being suffering from cancer or suspected of having cancer. For example, the subject can be an individual who has been diagnosed with cancer, will receive cancer treatment, and / or has received at least one cancer treatment. The subject can be in remission of cancer. As another example, the subject can be an individual diagnosed with an autoimmune disease. As another example, the subject can be a female individual who is pregnant or planning to become pregnant, who may have been diagnosed with or suspected of having a disease, such as cancer, autoimmune disease. "Reference subject" refers to a subject known to have or lack a specific characteristic (e.g., a known cancer or disease state, a known nucleic acid variant, a known cell of origin, a known tumor score, a known coverage, and / or the like).
[0096] Threshold: As used herein, "threshold" refers to a value determined individually for characterizing or classifying experimentally determined values. In certain embodiments, for example, "threshold value" refers to a selected value to which a quantitative value is compared in order to determine that a specific target nucleic acid variant is not present at a specific genetic locus.
[0097] Value: As used herein, a "value" or "score" generally refers to an entry in a data set and can be anything that characterizes the feature to which the value refers. This includes, but is not limited to, a number, a word or phrase, a symbol (e.g., + or -), or a degree.
[0098] Detailed Description
[0099] II. Introduction
[0100] Provided herein are methods and systems for determining allele types from nucleic acid samples obtained from test subjects. In some aspects, nucleic acid samples can be, but are not limited to, cell-free nucleic acid (cfNA), genomic DNA, or RNA. In embodiments, nucleic acid samples can be derived from a specific region of a specific chromosome and / or chromosome. In embodiments, nucleic acid samples can be derived from all or part of the major histocompatibility complex (MHC) region of human chromosome 6. In embodiments, nucleic acid samples can be derived from all or part of the killer cell immunoglobulin-like receptor (KIR) region of human chromosome 19. In embodiments, nucleic acid samples can be derived from both the MHC region of human chromosome 6 and the KIR region of human chromosome 19 in whole or in part.
[0101] a. Major histocompatibility complex (MHC)
[0102] MHC is a group of cell surface molecules encoded by a large family of genes that control major parts of the immune system in all vertebrates. The main function of the major histocompatibility complex is to bind peptide fragments derived from pathogens and display them on the cell surface for recognition by appropriate T cells.
[0103] The MHC comprises two types of polymorphic MHC genes (class I and class II genes encoding two sets of structurally distinct but homologous proteins), as well as other non-polymorphic genes whose products are involved in antigen presentation.
[0104] The human MHC is called human leukocyte antigen (HLA). HLA proteins are encoded by the genes of MHC. HLA class I antigens include HLA-A, HLA-B, and HLA-C. HLA class II antigens include HLA-DR, HLA-DQ, HLA-DP, HLA-DM, HLA-DOA, HLA-DOB. HLA corresponding to MHC class I (A, B, and C) present peptides from inside the cell. HLA corresponding to MHC class II (DP, DM, DOA, DOB, DQ, and DR) present antigens from outside the cell to T lymphocytes. MHC molecules mediate the binding of a given T cell receptor to a given antigen, so MHC polymorphisms between individuals regulate the response of T cells to a given antigen. Clinical applications of HLA typing include vaccine trials, disease associations, adverse drug reactions, platelet transfusions, and organ and stem cell transplants.
[0105] There are many alleles at each HLA locus (A1, A2, A3, etc.). Each person inherits a complete set of HLA alleles (haplotypes) from their respective parents, and this combination of encoded proteins constitutes a person's HLA type (e.g., the different antigens of A23, A31, B7, B44, C7, C8, DR4, DR7, DQ2, DQ7, DP2, DP3). There are more than 50,000 different known HLA types.
[0106] Certain diseases, especially those of an autoimmune nature, are associated with specific HLA types. The level of association varies between different diseases, and there is often a lack of strong concordance between HLA type and disease. The exact mechanism of most HLA-disease associations is unclear, and other genetic and environmental factors may also play a role. Among the most prominent associations are narcolepsy with HLA-DQB1*0602 / HLA-DRB1*1501, ankylosing spondylitis with HLA-B27, and celiac disease with HLA-DQB1*02. The HLA-A1, B8, DR17 haplotype is often associated with autoimmune disorders. Rheumatoid arthritis is associated with a specific sequence of amino acid positions 66 to 75 in the DRβ1 chain that is shared by the major subtypes of HLA-DR4 and DR1. Type I diabetes is associated with HLA-DR3,4 heterozygotes, and the absence of asparagine at position 57 on the DQβ1 chain has been shown to confer susceptibility to the disease.
[0107] HLA-A, HLA-B and HLA-DR have long been considered the main transplant antigens. Recent clinical data indicate that HLA-C matching also affects the clinical outcome of hematopoietic stem cell transplantation. Allogeneic hematopoietic stem cell transplantation is used to treat hematological malignancies, severe aplastic anemia, severe congenital immunodeficiency and selected inherited metabolic diseases. The HLA system is the main tissue compatibility barrier in stem cell transplantation, and the degree of HLA matching can predict clinical outcomes. HLA mismatch between the recipient and the stem cell donor represents a risk factor for transplant rejection / failure and acute graft-versus-host disease (GVHD). The latter is caused by the immunocompetent donor T cells contained in the stem cell product. T cell depletion of donor bone marrow leads to a lower incidence of acute GVHD, but a higher incidence of transplant failure, graft rejection, relapse of malignant disease (i.e., loss of graft-versus-leukemia effect), impaired immune recovery and subsequent complications of Epstein-Barr virus-associated lymphoproliferative disorder.
[0108] b. Killer cell immunoglobulin-like receptor (KIR)
[0109] Natural Killer (NK) cells are part of the innate immune system and are specialized for early defense against infection and tumors. NK cells were first discovered due to their ability to kill tumor cell targets. Unlike cytolytic T cells, NK cells can kill targets in a non-major histocompatibility complex (non-MHC) restricted manner. As an important part of the innate immune system, NK cells account for about 10% of the total circulating lymphocytes in the human body.
[0110] Due to its ability to kill other cells, NK cells are usually kept under strict control. All normal cells in the body express MHC class I molecules on their surface. These molecules protect normal cells from being killed by NK cells because they act as ligands for many receptors found on NK cells. Cells that lack sufficient class I MHC on their surface are recognized as "abnormal" by NK cells and killed. While killing abnormal cells, NK cells also cause cytokine responses.
[0111] Natural killer cells constitute a rapid-response force against cancer and viral infections. These specialized white blood cells originate in the bone marrow, circulate in the blood, and concentrate in the spleen and other lymphatic tissues. The activity of NK cells depends on a subset of HLA proteins, which are present on the surface of healthy cells but shed by cells weakened by viruses and cancer. When NK cells encounter cells lacking HLA proteins, they attack and destroy them—thus preventing the cell from further spreading the virus or cancer. What distinguishes NK cells from other immune system cells is the rapidity and breadth of their protective response. Other white blood cells are slower to start taking action and target specific pathogens—cancers, viruses, or bacteria—rather than damaged cells in general.
[0112] The natural killer cell immunoglobulin-like receptor (KIR) gene family is one of several receptor families that encode important proteins found on the surface of NK cells. A subset of KIR genes, the inhibitory KIRs, interact with HLA class I molecules encoded within the human MHC. Such interactions allow communication between NK cells and other cells of the body, including normal cells, virus-infected cells, or cancer cells. This communication between KIR molecules on NK cells and HLA class I molecules on all other cells helps determine whether a cell in the body is recognized by the NK cells as self or non-self. Cells that are considered "non-self" are targeted for killing by NK cells.
[0113] The KIR gene family consists of 16 genes (KIR2DL1, KIR2DL2, KIR2DL3, KIR2DL4, KIR2DL5A, KIR2DL5B, KIR2DS1, KIR2DS2, KIR2DS3, KIR2DS4, KIR2DS5, KIR3DL1 / S1, KIR3DL2, KIR3DL3, KIR2DP1 and KIR3DP1). The KIR gene cluster is located in a 100-200 kb region of the leukocyte receptor complex (LRC) on chromosome 19 (19q13.4). This gene complex is thought to have arisen from a gene duplication event that occurred after the evolutionary separation between mammals and rodents. The KIR genes are arranged in a head-to-tail manner, with only a 2.4 kb sequence separating the genes, except for a 14 kb sequence between 3DP1 and 2DL4. Because the KIR genes were generated by gene duplication, they are very similar in sequence, showing 90%-95% identity to each other. Human individuals differ in the number and type of inherited KIR genes; KIR genotypes within individuals and ethnic groups may be very different. At the chromosome level, there are two different types of KIR haplotypes (see Martin et al. Immunogenetics. (2008) December; 60 (12): 767-774). The A-haplotype does not contain stimulatory genes (2DS and 3DS1) other than 2DS4, does not contain 2DL5 genes, and does not contain 2DL2 genes. The gene content of the B-haplotype varies more, and different B-haplotypes contain different numbers of stimulatory genes, one or two 2DL5 genes, etc. (Martin MP et al. (2008) KIR haplotypes defined by segregation analysis in 59 Centre d'Etude Polymorphisme Humain (CEPH) families. Immunogenetics, December; 60 (12): 767-774.).
[0114] All KIR proteins are anchored to the cell membrane, with two or three extracellular immunoglobulin-like domains and a cytoplasmic tail. Nine KIR genes (KIR2DL and KIR3DL) encode proteins with long cytoplasmic tails, which contain immunotyrosine-based inhibitory motifs (ITIMs). When the extracellular domains come into contact with their ligands, these KIR proteins can send inhibitory signals to natural killer cells. The remaining KIR genes encode proteins with short cytoplasmic tails. These proteins send activation signals via adapter molecules such as DAP12.
[0115] The structure of KIR receptors and the identity of HLA class I ligands of each KIR receptor are described in Parham P. et al. Alloreactive killer cells: hindrance and help for hematopoietic transplants. Nature Rev. Immunology. (2003) 3: 108-122. The nomenclature of killer cell immunoglobulin-like receptors (KIR) describes the number of extracellular immunoglobulin-like domains (2D or 3D) and the length of the cytoplasmic tail region (L represents long and S represents short). Each immunoglobulin-like domain is depicted as a ring, each immunoreceptor tyrosine-based inhibitory motif (ITIM) in the cytoplasmic tail region is depicted as a rectangle, and each positively charged residue in the transmembrane region is depicted as a rhombus.
[0116] The strength of the interaction between KIR and their HLA class I ligands can depend on both the KIR sequence and the HLA sequence. Although the HLA region has been studied for more than 40 years, KIR molecules were first described in the mid-1990s (as NKB1) (Lanier et al. (1995) The NKB1 and HP-3E4 NK cells receptors are structurally distinct glycoproteins and independently recognize polymorphic HLA-B and HLA-C molecules. J. Immunol. April 1; 154 (7): 3320-3327 and Litwin V. et al. (1994) NKB1: a natural killer cell receptor involved in the recognition of polymorphic HLA-B molecules. J Exp Med. August 1; 180 (2): 537-543). The first few years of discovery were mainly devoted to describing different KIR genes and developing methods to determine the genotype of a single KIR. Using these methods, the association of KIR genes with autoimmune diseases and recipient survival after allogeneic hematopoietic cell transplantation has been shown (Parham P. (2005) MHC class I molecules and KIRs in human history, health and survival. Nature reviews, March; 5 (3): 201-214). It is now clear that each KIR gene has more than one sequence; that is, each KIR gene has variable sequences due to single nucleotide polymorphisms (SNPs) and, in some cases, insertions or deletions within the coding sequence. Studies have shown that KIR3DL1 polymorphisms can affect not only the expression level of KIR3DL1 on natural killer cells, but also the binding affinity of KIR3DL1 to its ligand.
[0117] Studies designed to investigate the role of KIR in human disease have shown that various KIR genes are associated with viral infections such as CMV, HCV and HIV, autoimmune diseases, cancer and preeclampsia (Parham P. (2005) MHC class I molecules and KIRs in human history, health and survival. Nature reviews, March; 5(3): 201-214). In a recent study of genetic susceptibility to Crohn's disease (an inflammatory autoimmune bowel disease), patients who were heterozygous for KIR2DL2 and KIR2DL3 and homozygous for the C2 ligand were found to be susceptible to the disease, while the C1 ligand was protective. (Hollenbach JA et al. (2009) Susceptibility to Crohn's Disease is mediated by KIR2DL2 / KIR2DL3 heterozygosity and the HLAC ligand. Immunogenetics. October; 61(10): 663-71). Other studies on KIR and unrelated hematopoietic cell transplantation (HCT) for acute myeloid leukemia (AML) have shown that B / x donors have significantly higher 3-year overall survival and a 30% overall improvement in relapse-free survival risk compared to A / A donors. (Cooley S et al. (2009) Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia. Blood. January 15; 113(3): 726-732; and Miller JS et al. (2007) Missing KIR-ligands is associated with less relapse and increased graft versus host disease (GVHD) following unrelated donor allogeneic HCT. Blood, 109(11): 5058-5061). Such studies have been conducted with knowledge of the KIR genotypes of patients and controls, but have not been conducted for KIR at the allele level.Although specific HLA alleles have been shown to be important in human disease (e.g., HLA-DR3 and HLA-DR4 are associated with type I diabetes and HLA-DR8 is associated with juvenile rheumatoid arthritis), the ability to genotype KIRs at the allele level will improve the study of KIR association with human disease.
[0118] In embodiments, the disclosed methods and systems may be applied to nucleic acid samples derived from one or more genes of the MHC region of human chromosome 6. In embodiments, the nucleic acid sample may be derived from one or more genes of the KIR region of human chromosome 19. In embodiments, the nucleic acid sample may be derived in whole or in part from one or more genes of the MHC region of human chromosome 6 and one or more genes of the KIR region of human chromosome 19. Substantially any number of genes may be assessed using the methods and related aspects of the present disclosure. In some embodiments, for example, as described herein, the group of genes targeted for analysis includes at least about 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 40, 50, 100, 1,000, 10,000 or more genes. A non-exhaustive list of genes is provided in Table 1, one or more of which are optionally selected for evaluation using the methods and related aspects disclosed herein.
[0119] Table 1
[0120] HLA-A HLA-X HLA-DQB3 MICC HLA-B HLA-Y HLA-DOA MICD HLA-C HLA-Z HLA-DOB MICE HLA-E HLA-DRA HLA-DMA KIR2DL1 HLA-F HLA-DRB1 HLA-DMB KIR2DL2 / L3 HLA-G HLA-DRB2 HLA-DPA1 KIR2DL4 HLA-H HLA-DRB3 HLA-DPB1 KIR2DL5A HLA-J HLA-DRB4 HLA-DPA2 KIR2DL5B HLA-K HLA-DRB5 HLA-DPB2 KIR2DS1 HLA-L HLA-DRB6 HLA-DPA3 KIR2DS2 HLA-N HLA-DRB7 HFE KIR2DS3 HLA-P HLA-DRB8 TAP1 KIR2DS4 HLA-S HLA-DRB9 TAP2 KIR2DS5 HLA-T HLA-DQA1 PSMB9 KIR3DL1 / S1 HLA-U HLA-DQB1 PSMB8 KIR3DL2 HLA-V HLA-DQA2 MICA KIR3DL3 HLA-W HLA-DQB2 MICB
[0121] III. Exemplary Systems and Methods
[0122] Figure 1AIt is a flow chart schematically depicting an example technology for performing allele typing in a cell-free nucleic acid (cfDNA) sample obtained from a test subject. Allele typing can be used to determine one or more alleles present at a chromosome locus. As shown, in step 102A, method 100A may include obtaining data. Data may include sequence data, such as allele sequence data. For example, step 102A may include obtaining (or otherwise determining, retrieving, receiving, etc.) known allele sequences. For example, known allele sequences may be downloaded from IPD-IMGT / HLA databases and / or IPD-KIR databases. For example, known HLA allele sequences may be downloaded from ftp.ebi.ac.uk / pub / databases / ipd / imgt / hla, and known KIR allele sequences may be downloaded from ftp.ebi.ac.uk / pub / databases / ipd / kir.
[0123] The known allele sequence can be any allele sequence type. In embodiments, the known allele sequence can be a known human leukocyte antigen (HLA) allele sequence. In embodiments, the known allele sequence can be a known killer cell immunoglobulin-like receptor (KIR) allele sequence.
[0124] In step 104A, data can be pre-processed. For example, step 104A can include building an allele k-mer data structure. The allele k-mer data structure can be a database. The allele k-mer data structure can be a flat file. The allele k-mer data structure can be any form of data structure. Building an allele k-mer data structure can include dividing a known allele sequence into a certain number of k-mers. For example, a certain number of k-mers with about 100 nucleotides to about 200 nucleotides in length. In an embodiment, a certain number of k-mers can have a length of 143 nucleotides. Building an allele k-mer data structure can include associating each k-mer with metadata. Metadata can include, for example, an indication of the number of alleles comprising a k-mer, and for each allele comprising a k-mer, the starting position of an allele identifier and a k-mer can be included.
[0125] In step 106A, sequence processing can be performed. For example, step 106A may include obtaining (or otherwise determining, retrieving, receiving, etc.) sequence read pairs (e.g., test sequence reads) from a cell-free nucleic acid (cfDNA) sample obtained from a test subject. Step 106A may include comparing between the test sequence reads and the known allele sequence. For example, step 106A may include comparing between the test sequence reads and the k-mer in the allele k-mer data structure. Sequence processing can determine the alleles supported by the test sequence reads. The alleles can be supported by more than one test sequence read. The test sequence reads can support more than one allele. In an embodiment, if the test sequence reads are aligned with the alleles (e.g., the k-mer of the allele) and have a percentage identity exceeding a threshold, it can be found that the test sequence reads support the alleles. For example, the threshold percentage identity can be 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, 100%, etc. In an embodiment, the threshold identity percentage may be 100%, requiring a "perfect" match between the test sequence read and the allele (eg, a k-mer of the allele).
[0126] In an embodiment, step 106A may include determining the number of test sequence read families that support the allele (e.g., the number of nucleic acid molecules that support the allele). Each test sequence read may include a barcode. The barcode may identify the nucleic acid molecule associated with the test sequence read (e.g., a test sequence read family). In an embodiment, if the test sequence read family is aligned with the allele and has a percentage identity exceeding a threshold, the test sequence read family may be found to support the allele. For example, the threshold percentage identity may be 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, 100%, etc. In an embodiment, the threshold percentage identity may be 100%, requiring a "perfect" match between the test sequence read family and the allele (e.g., a k-mer of the allele).
[0127] In step 108A, a clustering operation can be performed. Alleles can be sorted based on the number of supporting test sequence reads (or by the number of supporting test sequence read families), and one or more allele supersets can be constructed. An allele superset can be constructed by determining a first allele associated with the highest number of supporting test sequence reads (or associated with the highest number of supporting test sequence read families). The first allele can form the basis of the allele superset. If a given allele is related to a supporting test sequence read (or a supporting test sequence read family), and the supporting test sequence read (or the supporting test sequence read family) itself is a subset of the supporting test sequence reads (or the supporting test sequence read family) of the first allele, then additional alleles can be added to the allele superset. Alleles of the allele superset that are not incorporated into the first allele can be used to construct one or more additional allele supersets in a similar manner.
[0128] An allele superset can be a data structure. An allele superset can be a database. An allele superset can be a flat file. An allele superset can include a representation of a Hasse diagram. A Hasse diagram is a representation of the relationship of elements of a partially ordered set with an implicit upward direction. Points or nodes can represent each element of the partially ordered set, and the nodes can be connected to line segments according to the following rules: 1) If p < q in the partially ordered set, then the point corresponding to p appears lower in the diagram than the point corresponding to q; 2) If p is related to q, then the two points p and q will be connected by a line segment. In an embodiment, the Hasse diagram can be represented as a graphical data structure, such as a directed acyclic graph (DAG) and / or the like. For example, if node A strictly contains node B, and there is no node C such that node A strictly contains node C and node C strictly contains node B, then the DAG includes a line from node A to node B.
[0129] In step 110A, alleles can be classified. For example, in step 110A, the allele type of a given allele can be determined. Alleles can be classified based on one or more allele supersets. In an embodiment, in the case where only one allele superset is constructed, the first allele of the superset can be classified as the allele present at a locus on the chromosome (e.g., a haploid locus). In an embodiment, in the case where more than one allele superset is constructed, the first alleles of two supersets with the cumulative maximum number of different supporting test sequence reads (or the cumulative maximum number of different supporting test sequence read families) can be classified as the alleles present at a locus on the chromosome (e.g., a diploid locus).
[0130] The classification of alleles can be used to guide the treatment of the subject. It may not be known whether the subject suffers from the disease before, or it may be known that the subject suffers from the disease. The disease may be cancer. The method may include administering one or more therapies to the subject to treat the disease. The therapy may include administering immunotherapy, administering chemotherapy, administering radiotherapy, or performing surgery to remove all or part of the tumor. The method may include assisting in communicating the determination of the allele classification to the subject associated with the test sample.
[0131] In embodiments, method 100A may be performed using known HLA allele sequences to determine a subject's HLA genotype and / or method 100A may be performed using known KIR allele sequences to determine a subject's KIR genotype.
[0132] Figure 1B It is a flow chart schematically depicting an example technology for performing allele typing and / or variant calling in a cell-free nucleic acid (cfDNA) sample obtained from a test subject. Allele typing can be used to determine one or more alleles present at a chromosome locus. Variant calling can be used to identify the presence of known or unknown variants. Variant calling can be used to characterize cancer progression. As shown, in step 102B, method 100B may include obtaining data. The data may include sequence data, such as allele sequence data and / or decoy sequence data.
[0133] For example, step 102B may include obtaining (or otherwise determining, retrieving, receiving, etc.) known allele sequences. For example, known allele sequences may be downloaded from the IPD-IMGT / HLA database and / or the IPD-KIR database. For example, known HLA allele sequences may be downloaded from ftp.ebi.ac.uk / pub / databases / ipd / imgt / hla, and known KIR allele sequences may be downloaded from ftp.ebi.ac.uk / pub / databases / ipd / kir Download. The known allele sequence can be any allele sequence type. In embodiments, the known allele sequence can be a known human leukocyte antigen (HLA) allele sequence. In embodiments, the known allele sequence can be a known killer cell immunoglobulin-like receptor (KIR) allele sequence.
[0134] For example, step 102B may include obtaining (or otherwise determining, retrieving, receiving, etc.) a bait sequence. The bait sequence may be any type of bait sequence. In an embodiment, the bait sequence may be one or more of the following: an "alt" sequence, an unprobed known HLA allele sequence, a probed known HLA allele sequence (to resolve small germline inaccuracies), a 3-group vs. 4-group number, a combination thereof, etc. The bait sequence is a sequence of genomic material (usually human) that is similar to the sequence we want to observe (e.g., the region we want to genotype). These are not yet part of the reference because they encode alternative forms of regions or genes (hence the name "alt"). The problem for us is that we deploy targeted sequencing, which is a method of selecting molecules only from parts of the genome that match a certain region (these "specific regions" are called probes or baits, and in our case are 120 bases long): sometimes what happens is that a probe designed to capture molecules from a region of interest instead captures molecules from one of these "alt" sequences. We can detect this because in these cases the reads (or read pairs) align better on the decoy than on the human reference.
[0135] In an embodiment, a bait sequence may include a bait sequence selected to identify contamination in a test sample. One or more bait sequences may include one or more non-human reference sequences. For example, one or more bait sequences may include a cattle reference sequence, a rat reference sequence, a microbial reference sequence, a combination thereof, and the like. Any test sequence pair aligned with a non-human bait sequence can be used to support the conclusion that the test sample has been contaminated by DNA from a source other than the test subject. The idea is the same as above, except that we use the sequence of the contaminant we suspect as "bait" here. For example, suppose we suspect that there is some cow DNA in our sample (this happens!), then we add the entire cow genome to our bait list, and when we align a read pair with both the human reference and the cow genome (bait), we find that the contaminant molecule aligns better on cows than on humans.
[0136] In step 104B, data can be pre-processed. For example, step 104B can include building an allele k-mer data structure. The allele k-mer data structure can be a database. The allele k-mer data structure can be a flat file. The allele k-mer data structure can be any form of data structure. Building an allele k-mer data structure can include dividing a known allele sequence into a certain number of k-mers. For example, a certain number of k-mers with about 100 nucleotides to about 200 nucleotides in length. In an embodiment, a certain number of k-mers can have a length of 143 nucleotides. Building an allele k-mer data structure can include associating each k-mer with metadata. Metadata can include, for example, an indication of the number of alleles comprising a k-mer, and for each allele comprising a k-mer, the starting position of an allele identifier and a k-mer can be included.
[0137] For example, step 104B may include building a decoy data structure. The decoy data structure may be a database. The decoy data structure may be a flat file. The decoy data structure may be any form of data structure. Building the algorithm like this (i.e., with target sequences plus decoy sequences) allows us to maintain some flexibility. The idea is that we can always add any number of as-yet unknown "problematic" sequences to the decoy, where problematic in this case means sequences that are similar to one of our targets (in other words, sequences that we may have accidentally picked up by our targeted sequencing technology developers that are not in the target region).
[0138] In step 106B, sequence processing can be performed. For example, step 106B may include obtaining (or otherwise determining, retrieving, receiving, etc.) sequence reads (e.g., test sequence reads) from a cell-free nucleic acid (cfDNA) sample obtained from a test subject. Step 106B may include comparing between the test sequence reads and the known allele sequence. For example, step 106B may include comparing between the test sequence reads and the k-mer in the allele k-mer data structure. Sequence processing can determine the alleles supported by the test sequence reads. The alleles can be supported by more than one test sequence reads. The test sequence reads can support more than one allele. In an embodiment, if the test sequence reads are aligned with the alleles (e.g., the k-mer of the alleles) and have a percentage identity exceeding a threshold, it can be found that the test sequence reads support the alleles. For example, the threshold percentage identity can be 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, 100%, etc. In an embodiment, the threshold identity percentage can be 100%, requiring a "perfect" match between the test sequence read and the allele (e.g., a k-mer of the allele), indicating no mismatches and no insertions / deletions. In an embodiment, the threshold identity percentage can be less than 100%, requiring an "incomplete" match between the test sequence read and the allele (e.g., a k-mer of the allele), indicating at least one mismatch and / or at least one insertion / deletion. An indication of the identity percentage can be determined for each comparison and stored for subsequent processing. The result of the comparison can be represented by the comparison score described in further detail about the comparison component 215. The comparison score can be equal to the sum of the number of mismatches and the number of insertions / deletions.
[0139] In an embodiment, step 106B may include determining the number of test sequence read families supporting the allele (e.g., the number of nucleic acid molecules supporting the allele). Each test sequence read may include a barcode. The barcode may identify the nucleic acid molecule associated with the test sequence read (e.g., a test sequence read family). In an embodiment, if the test sequence read family is aligned with the allele and has a percentage identity exceeding a threshold, the test sequence read family may be found to support the allele. For example, the threshold percentage identity may be 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, 100%, etc. In an embodiment, the threshold percentage identity may be 100%, requiring a "perfect" match between the test sequence read family and the allele (e.g., the k-mer of the allele).
[0140] Step 106B may include comparing between the test sequence reads and the bait sequence. For example, step 106B may include comparing between the test sequence reads and the bait sequence in the bait data structure. Sequence processing may determine the bait sequence supported by the test sequence reads. In an embodiment, if the test sequence reads are aligned with the bait sequence and have a percentage identity exceeding a threshold, it may be found that the test sequence reads support the bait sequence. For example, the threshold percentage identity may be 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, 100%, etc. In an embodiment, the threshold percentage identity may be 100%, requiring a "perfect" match between the test sequence reads and the bait sequence, indicating no mismatch and no insertion / deletion. An indication of the percentage identity may be determined for each comparison and stored for subsequent processing. In an embodiment, one or more test sequence reads aligned with 100% identity to one or more bait sequences may be discarded and not used for further processing. In embodiments, to the extent the bait sequence comprises one or more non-human sequences, any test sequence reads that match the non-human bait sequence with 100% identity can be used to support identification of the test sample as contaminated.A notification associated with potential contamination can be generated and / or sent.
[0141] The result of the alignment can be represented by an alignment score as described in further detail with respect to the alignment component 215. The alignment score can be equal to the sum of the number of mismatches and the number of indels.
[0142] In step 108B, clustering operations can be performed based on the comparison between the test sequence reads and the known allele sequences. Known alleles can be sorted by the number of supporting test sequence reads (or by the number of supporting test sequence read families), and one or more allele supersets can be constructed. Allele supersets can be constructed by determining the first allele associated with the highest number of supporting test sequence reads (or associated with the highest number of supporting test sequence read families). The first allele can form the basis of the allele superset. If a given allele is related to supporting test sequence reads (or supporting test sequence read families), supporting test sequence reads (or supporting test sequence read families) themselves are subsets of the supporting test sequence reads (or supporting test sequence read families) of the first allele, then other alleles can be added to the allele superset. Alleles of the allele superset that are not mixed with the first allele can be used to construct one or more other allele supersets in a similar manner.
[0143] An allele superset can be a data structure. An allele superset can be a database. An allele superset can be a flat file. An allele superset can include a representation of a Hasse diagram. A Hasse diagram is a representation of the relationship of elements of a partially ordered set with an implicit upward direction. Points or nodes can represent each element of the partially ordered set, and the nodes can be connected with line segments according to the following rules: 1) If p < q in the partially ordered set, the point corresponding to p appears lower in the diagram than the point corresponding to q; 2) If p is related to q, the two points p and q will be connected by a line segment. In an embodiment, the Hasse diagram can be represented as a graphical data structure, such as a directed acyclic graph (DAG) and / or the like. For example, if node A strictly contains node B and there is no node C such that node A strictly contains node C and node C strictly contains node B, the DAG includes a line from node A to node B.
[0144] In step 110B, alleles can be classified. For example, in step 110B, the allele type of a given allele can be determined. Alleles can be classified based on one or more allele supersets. In an embodiment, in the case where only one allele superset is constructed, the first allele of the superset can be classified as an allele present at a locus of a chromosome (e.g., a haploid locus). In an embodiment, in the case where more than one allele superset is constructed, the first alleles of two supersets having a cumulative maximum number of different supporting test sequence reads (or a cumulative maximum number of different families of supporting test sequence reads) can be classified as alleles present at a locus of a chromosome (e.g., a diploid locus).
[0145] The classification of alleles can be used to guide the treatment of a subject. It may previously be unknown whether the subject has a disease, or it may be known that the subject has a disease. The disease can be cancer. The method can include administering one or more therapies to the subject to treat the disease. The therapies can include administering immunotherapy, administering chemotherapy, administering radiotherapy, or performing surgery to remove all or part of a tumor. The method can include assisting in communicating the determination of the allele classification to the subject associated with the test sample.
[0146] In an embodiment, method 100B can be performed using known HLA allele sequences to determine the HLA genotype of the subject and / or method 100B can be performed using known KIR allele sequences to determine the KIR genotype of the subject.
[0147] In step 112B, the comparison scores of the remaining test sequence reads that are not aligned with 100% identity to the known allele sequence or the bait sequence can be compared. The remaining test sequence reads can have a comparison score associated with the known allele sequence (e.g., a germline comparison score) and a comparison score associated with the bait sequence (e.g., a bait comparison score). The test sequence reads associated with the germline comparison score less than the bait comparison score can be discarded. In step 110B, the test sequence reads associated with the germline comparison score greater than the bait comparison score can be sent for variant calling. If the test sequence reads are aligned with two or more known allele sequences (e.g., aligned with two or more entries in the fasta file), the first entry with the highest comparison score in the fasta file is selected for alignment.
[0148] In step 110B, the test sequence reads associated with the germline alignment score greater than the bait alignment score can be analyzed to determine and / or identify the test sequence reads as variants. Variant calling is the process of identifying the true difference between the sequence reads of the test sample and the reference sequence. Variant calling can be performed as further described below about variant caller component 219. In an embodiment, the test sequence reads can be identified as somatic variants. In an embodiment, the test sequence reads can be identified as variants, which are candidate variants associated with somatic events. In step 110B, candidate variants can be identified in the test sequence reads. In one embodiment, candidate variants can be identified by comparing the test sequence reads with the reference sequence of the target region of the reference genome (e.g., human reference genome hg19). The edge of the test sequence reads can be compared with the genomic position of the reference sequence and the mismatch edge and the mismatched nucleotide bases adjacent to the edge recorded as the candidate variant position. In some embodiments, the genomic position of the nucleotide bases with the left and right mismatches is recorded as the position of the called variant. In addition, candidate variants can be identified based on the sequencing depth of the target region. In particular, more confidence can be obtained when identifying variants in target regions with greater sequencing depth, for example, because a greater number of sequence reads help resolve (e.g., using redundancy) mismatches or other base pair variations between sequences.
[0149] In an embodiment, the reference sequence for variant calling may include one or more reference sequences. One or more reference sequences may be selected to identify contamination in a test sample. One or more reference sequences may include one or more non-human reference sequences. For example, one or more reference sequences may include bovine reference sequences, rat reference sequences, microbial reference sequences, combinations thereof, etc. Any test sequence pairs identified as non-human variants may be used to support the conclusion that the test sample has been contaminated by DNA from sources other than the test subject.
[0150] Clinical applications of HLA typing and / or variant calling include vaccine trials, disease associations, adverse drug reactions, platelet transfusions, and organ and stem cell transplantation.
[0151] In some embodiments, the method includes determining the HLA type of the subject as described herein, and if the presence of one or more of HLA-DRB1*04:01, *04:04, and *04:08; HLA-DRB1*04:05; HLA-DRB1*01:01 and *01:02; HLA-DRB1*14:02; HLA-DRB1*10:01; and / or HLA-DRB1*01:01, *04:01, *04:04, and *04:05 has been determined, the subject is determined to be susceptible to developing rheumatoid arthritis (RA).
[0152] In some embodiments, the method includes determining the HLA type of the subject as described herein, and if the presence of HLA-DRB1*15:01, HLA-DQB1*06:02, HLA-DRB1*01:08, HLA-DRB1*03:01 and / or HLA-DRB1*13:03 alleles has been determined, the subject is determined to be susceptible to developing multiple sclerosis (MS).
[0153] In some embodiments, the method includes determining the HLA type of the subject as described herein, and if the presence of HLA-DRB1, HLA-DR2 (DRB1*15:01), HLA-DR3 (DRB1*03:01), HLA-DRB1*08:01 and / or HLA-DQA1*01:02 alleles has been determined, the subject is determined to be susceptible to developing systemic lupus erythematosus (SLE).
[0154] In some embodiments, the method comprises determining the HLA type of the subject as described herein, and if the presence of HLA-DQB1*03:02 and / or DQB1*02:01 has been determined, determining that the subject is susceptible to developing type 1 diabetes (T1D).
[0155] In some embodiments, the method comprises determining the HLA type of the subject as described herein, and if the presence of the DQA1*05:01, DQB1*02:01, and DRB1*03:01 alleles has been determined, determining that the subject is susceptible to developing Sjögren's syndrome (SS).
[0156] In some embodiments, the method comprises determining the HLA type of the subject as described herein, and if the presence of HLA-DQ2 (encoded by HLA-DQA1*05:01-DQB1*02:01) and / or HLA-DQ8 (encoded by DQA1*03:01-DQB1*03:02) has been determined, the subject is determined to be susceptible to developing celiac disease (CD).
[0157] In embodiments, the method comprises determining the KIR type of a female as described herein, and if the presence of a KIR2DL1 allele has been determined, determining that the female is susceptible to developing pre-eclampsia.
[0158] In embodiments, both HLA and KIR genotypes can be determined for the same subject. The method may include determining that the individual is susceptible to clearing HCV infection, slowing the progression of HIV infection to AIDS or Crohn's disease when certain KIR alleles have been found in the individual in combination with certain HLA alleles. In embodiments, the method includes determining the KIR type of the subject as described herein, and if the presence of the KIR2DL3 allele has been determined, determining that the subject is likely to clear HCV infection. In some embodiments, the method also includes determining the HLA-C genotype of the subject, and if the presence of the KIR2DL3 allele and the HLA-C1 allele has been determined, determining that the subject is likely to clear HCV infection.
[0159] In other embodiments, the method comprises determining the KIR type of the subject as described herein, and if the presence of the KIR3DS1 allele has been determined, determining that the subject is unlikely to progress from HIV infection to AIDS. In some embodiments, the method further comprises determining the HLA genotype of the subject, and if the presence of a combination of the KIR3DS1 allele and the HLA-Bw4 allele has been determined, determining that the subject is unlikely to progress from HIV infection to AIDS.
[0160] In yet other embodiments, the methods comprise determining the subject's KIR type as described herein, and if the presence of a KIR2DS1 allele has been determined, determining that the subject is susceptible to developing an autoimmune disease.
[0161] In yet other embodiments, the method comprises determining the subject's KIR type as described herein, and if the presence of KIR2DL2 / KIR2DL3 heterozygosity has been determined, the subject is determined to be susceptible to developing Crohn's disease. In some embodiments, the method further comprises determining the subject's HLA genotype, and if the presence of a combination of KIR2DL2 / KIR2DL3 heterozygosity and an HLA-C2 allele has been determined, the subject is determined to be susceptible to developing Crohn's disease.
[0162] In other embodiments, the methods comprise determining a subject's KIR type as described herein, and if the presence of a group B KIR haplotype has been determined, determining whether the subject is a suitable candidate for a donor in an unrelated hematopoietic cell transplant.
[0163] Figure 2 An example of a system 200 for determining the allele type and / or variant of a test subject 211 according to an embodiment of the present disclosure is shown. The system 200 can process one or more samples 201 from a subject 211 to generate sequence reads. The system 200 may include a laboratory system 202, a computer system 210, and / or other components. It should be noted that the laboratory system 202 and the computer system 210 may be remote from each other and connected to each other via a computer network (not shown). The laboratory system 202 may include a sample collection and preparation pipeline 203, a sequencing pipeline 205, a sequence read data storage 209, and / or other components. The sequencing pipeline 205 may include one or more sequencing devices 207 (in Figure 2 . . n).
[0164] The methods of the present disclosure may have a wide range of uses in the manipulation, preparation, identification, quantification and / or analysis of cell-free nucleic acids. Figure 2 As shown in , the sample collection and preparation pipeline 203 can include obtaining a cfDNA reference sample 201 from one or more reference subjects and obtaining a cfDNA test sample 211 from a test subject. As described herein, a polynucleotide can include any type of nucleic acid, such as DNA and / or RNA. For example, if the polynucleotide is DNA, it can be genomic DNA, complementary DNA (cDNA), or any other deoxyribonucleic acid. The polynucleotide can also be a cell-free nucleic acid, such as cell-free DNA (cfDNA). For example, the polynucleotide can be circulating cfDNA. Circulating cfDNA can include DNA shed from body cells via apoptosis or necrosis. The cfDNA shed via apoptosis or necrosis can be derived from normal (e.g., healthy) body cells.
[0165] a.Sample
[0166] The separation and extraction of cell-free polynucleotides can be carried out by collecting samples using a variety of techniques. The sample can be any biological sample separated from a subject. The sample can include body tissue, whole blood, platelets, serum, plasma, feces, red blood cells, white blood cells or leukocytes, endothelial cells, tissue biopsy (for example, from a biopsy of a known or suspected solid tumor), cerebrospinal fluid, synovial fluid, lymphatic fluid, ascites, interstitial fluid or extracellular fluid (for example, from fluid in the intercellular space), gingival fluid, gingival sulcus fluid, bone marrow, pleural effusion, cerebrospinal fluid, saliva, mucus, sputum, semen, sweat, urine. The sample is preferably a body fluid, especially blood and its fraction, and urine. Nucleic acid can include DNA and RNA and can be double-stranded and single-stranded forms. The sample can be in the form initially separated from the subject, or can have been subjected to additional processing to remove or add components, such as cells, enrich a component relative to another component, or convert a form of nucleic acid into another, such as RNA to DNA, or single-stranded nucleic acid to double-stranded. Thus, for example, the bodily fluid sample used for analysis is plasma or serum containing cell-free nucleic acid, such as cell-free DNA (cfDNA).
[0167] In some embodiments, the volume of the body fluid sample taken from the subject depends on the expected depth of reads for the region sequenced. Exemplary volumes are about 0.4ml-40ml, about 5ml-20ml, about 10ml-20ml. For example, the volume can be about 0.5ml, about 1ml, about 5ml, about 10ml, about 20ml, about 30ml, about 40ml or more milliliters. The volume of the sampled plasma is usually between about 5ml and about 20ml.
[0168] Samples can contain varying amounts of nucleic acid. Typically, the amount of nucleic acid in a given sample is equal to more than one genome equivalent. For example, a sample of about 30 ng DNA may contain about 10,000 (10 4 ) haploid human genome equivalents, and in the case of cfDNA, can contain approximately 200 billion (2×10 11 ) individual polynucleotide molecules. Similarly, a sample of about 100 ng of DNA may contain about 30,000 haploid human genome equivalents, and in the case of cfDNA, about 600 billion individual molecules.
[0169] In some embodiments, the sample comprises nucleic acids from different sources, such as nucleic acids from cells and from cell-free sources (e.g., blood samples, etc.). In some embodiments, the sample comprises nucleic acids from a genomic DNA region that comprises alleles that allow allelic typing, such as HLA alleles or KIR alleles.
[0170] Exemplary amounts of cell-free nucleic acid in a sample prior to amplification are generally in the range of from about 1 femtogram (fg) to about 1 microgram (μg), such as about 1 picogram (pg) to about 200 nanograms (ng), about 1 ng to about 100 ng, about 10 ng to about 1000 ng. In some embodiments, the sample comprises up to about 600 ng, up to about 500 ng, up to about 400 ng, up to about 300 ng, up to about 200 ng, up to about 100 ng, up to about 50 ng, or up to about 20 ng of cell-free nucleic acid molecules. Optionally, the amount is at least about 1 fg, at least about 10 fg, at least about 100 fg, at least about 1 pg, at least about 10 pg, at least about 100 pg, at least about 1 ng, at least about 10 ng, at least about 100 ng, at least about 150 ng, or at least about 200 ng of cell-free nucleic acid molecules. In certain embodiments, the amount is up to about 1 fg, about 10 fg, about 100 fg, about 1 pg, about 10 pg, about 100 pg, about 1 ng, about 10 ng, about 100 ng, about 150 ng, or about 200 ng of cell-free nucleic acid molecules. In some embodiments, the method comprises obtaining between about 1 fg and about 200 ng of cell-free nucleic acid molecules from a sample.
[0171] The cell-free nucleic acids typically have a size distribution between about 100 nucleotides in length and about 500 nucleotides in length, with molecules from about 110 nucleotides in length to about 230 nucleotides in length representing about 90% of the molecules in the sample, a mode of about 168 nucleotides in length, and a second, minor peak ranging between about 240 and about 440 nucleotides in length. In certain embodiments, the cell-free nucleic acids are about 160 to about 180 nucleotides in length, or about 320 to about 360 nucleotides in length, or about 440 to about 480 nucleotides in length.
[0172] In some embodiments, cell-free nucleic acid is separated from body fluid by partitioning step, in which the cell-free nucleic acid such as being present in the solution is separated from intact cells and other non-soluble components of the body fluid. In some of these embodiments, partitioning includes techniques such as centrifugation or filtration. Optionally, the cells in the body fluid are lysed, and cell-free nucleic acid and cell nucleic acid are processed together. Typically, after adding buffer and washing steps, cell-free nucleic acid is precipitated with, for example, ethanol. In certain embodiments, additional purification steps are used, such as silica-based columns to remove pollutants or salts. For example, non-specific bulk carrier nucleic acid is optionally added throughout the reaction to optimize certain aspects of the exemplary procedure, such as yield. After such processing, the sample typically includes various forms of nucleic acid, including double-stranded DNA, single-stranded DNA and / or single-stranded RNA. Optionally, single-stranded DNA and / or single-stranded RNA are converted into double-stranded forms, so they are included in subsequent processing and analysis steps. Additional details regarding cfDNA partitioning and related analysis of epigenetic modifications that are optionally suitable for performing the methods disclosed herein are described, for example, in WO 2018 / 119452, filed December 22, 2017, which is incorporated by reference.
[0173] b. Nucleic acid labeling
[0174] In certain embodiments, tags providing molecular identifiers or barcodes are incorporated or otherwise attached to adaptors by methods such as chemical synthesis, ligation, or overlap extension PCR. In some embodiments, assignment of unique or non-unique identifiers or molecular barcodes in reactions follows methods and utilizes systems described in, for example, U.S. Patent Applications 20010053519, 20030152490, 20110160078, and U.S. Patents Nos. 6,582,908, 7,537,898, and 9,598,731, all of which are incorporated by reference.
[0175] The label is randomly or non-randomly connected (linked) (e.g., connected (ligated)) to the sample nucleic acid. In some embodiments, the label is introduced into the micropore with an expected identifier ratio (e.g., a combination of unique and / or non-unique barcodes). For example, the identifier can be loaded so that more than about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 50, 100, 500, 1000, 5000, 10000, 50,000, 100,000, 500,000, 1,000,000, 10,000,000, 50,000,000 or 1,000,000,000 identifiers can be loaded per genome sample. In some embodiments, the identifiers are loaded such that less than about 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 50, 100, 500, 1000, 5000, 10000, 50,000, 100,000, 500,000, 1,000,000, 10,000,000, 50,000,000, or 1,000,000,000 identifiers are loaded per genomic sample. In certain embodiments, the average number of identifiers loaded per sample genome is less than or greater than about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 50, 100, 500, 1000, 5000, 10000, 50,000, 100,000, 500,000, 1,000,000, 10,000,000, 50,000,000 or 1,000,000,000 identifiers per genome sample. Identifiers are typically unique or non-unique.
[0176] An exemplary format uses about 2 to about 1,000,000 different tags, or about 5 to about 150 different tags, or about 20 to about 50 different tags attached to both ends of the target nucleic acid molecule. For 20-50 x 20-50 tags, a total of 400-2500 tags are created. Such a number of tags is sufficient so that different molecules with the same start and end points have a high probability (e.g., at least 94%, 99.5%, 99.99%, 99.999%) of receiving different tag combinations.
[0177] In some embodiments, identifier is a predetermined, random or semi-random sequence oligonucleotide. In other embodiments, more than one barcode can be used so that the barcode does not have to be unique relative to each other in the more than one barcode. In these embodiments, barcodes are usually attached (for example, by connection or pcr amplification) to individual molecules so that the combination of barcodes and sequences to which they can be attached produces a unique sequence that can be tracked individually. As described herein, the detection of the barcodes of non-unique tags is combined with the sequence data at the beginning (start) and end (termination) parts of the sequence reads and usually allows unique identity to be assigned to specific molecules. The length or base pair number of the independent sequence reads are also optionally used to specify unique identity for a given molecule. As described herein, the fragment from the nucleic acid single strand having specified a unique identity can thereby allow subsequent identification of the fragment from the parental chain and / or complementary chain.
[0178] In some embodiments, nucleic acid molecules (from polynucleotide samples) can be tagged with sample indexes and / or molecular barcodes (commonly referred to as "tags"). Tags can be incorporated into adapters or otherwise connected to adapters by methods such as chemical synthesis, connection (e.g., blunt end connection or sticky end connection) or overlap extension polymerase chain reaction (PCR). Such adapters can ultimately be connected to target nucleic acid molecules. In other embodiments, one or more rounds of amplification cycles (e.g., PCR amplification) are typically applied to introduce sample indexes into nucleic acid molecules using conventional nucleic acid amplification methods. Amplification can be performed in one or more reaction mixtures (e.g., more than one microwell in an array). Molecular barcodes and / or sample indexes can be introduced simultaneously or in any order. In some embodiments, molecular barcodes and / or sample indexes are introduced before and / or after performing a sequence capture step. In some embodiments, only molecular barcodes are introduced before probe capture, and sample indexes are introduced after performing a sequence capture step. In some embodiments, both molecular barcodes and sample indexes are introduced before performing a probe-based capture step. In some embodiments, sample indexes are introduced after performing a sequence capture step. In some embodiments, the molecular barcode is incorporated into the nucleic acid molecule (e.g., cfDNA molecule) in the sample by a linker via connection (e.g., blunt end connection or sticky end connection). In some embodiments, the sample index is incorporated into the nucleic acid molecule (e.g., cfDNA molecule) in the sample by overlap extension polymerase chain reaction (PCR). Typically, sequence capture schemes include the introduction of a single-stranded nucleic acid molecule complementary to a target nucleic acid sequence, such as a coding sequence of a genomic region, and mutations in such a region are associated with cancer types.
[0179] In some embodiments, the label can be located at one end or both ends of the sample nucleic acid molecule. In some embodiments, the label is an oligonucleotide of a predetermined or random or semi-random sequence. In some embodiments, the length of the label can be less than about 500, 200, 100, 50, 20, 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1 nucleotides. The label can be randomly or non-randomly connected to the sample nucleic acid.
[0180] In some embodiments, each sample is uniquely labeled with a sample index or a combination of sample indexes. In some embodiments, each nucleic acid molecule of a sample or subsample is uniquely labeled with a molecular barcode or a combination of molecular barcodes. In other embodiments, more than one barcode may be used so that the molecular barcodes do not have to be unique relative to each other in the more than one barcode (e.g., non-unique molecular barcodes). In these embodiments, molecular barcodes are usually attached to individual molecules (e.g., by connection) so that the combination of molecular barcodes and sequences that can be attached thereto produces a unique sequence that can be traced back individually. In an embodiment, a technique for distinguishing between real genome changes and technical errors may be used, such as Lee et al. "Accurate Detection of Rare Mutant Alleles byTarget Base-Specific Cleavage with the CRISPR / Cas9 System," ACSSynth.Biol.2021,10,6,1451–1464,May 19,2021, described herein, incorporated by reference in its entirety. Detection of a non-unique molecular barcode in combination with endogenous sequence information (e.g., corresponding to the start (start) and / or end (stop) genomic loci / positions of the original nucleic acid molecule sequence in the sample, corresponding to the start and end genomic positions of the original nucleic acid molecule sequence in the sample, the start (start) and / or end (stop) genomic loci / positions of sequence reads mapped to a reference sequence, the start and end genomic positions of sequence reads mapped to a reference sequence, a subsequence of the sequence reads at one or both ends, the length of the sequence reads, and / or the length of the original nucleic acid molecule in the sample) generally allows a unique identity to be assigned to a specific molecule. In some embodiments, the start region includes the first 1, first 2, first 5, first 10, first 15, first 20, first 25, first 30, or at least the first 30 base positions at the 5' end of the sequencing reads aligned to the reference sequence. In some embodiments, the end region includes the last 1, last 2, last 5, last 10, last 15, last 20, last 25, last 30, or at least the last 30 base positions of the 3' end of the sequencing reads aligned to the reference sequence. The length or number of base pairs of the individual sequence reads is also optionally used to assign a unique identity to a given molecule. As described herein, fragments from a single strand of nucleic acid to which a unique identity has been assigned can thereby allow subsequent identification of fragments from a parental strand and / or a complementary strand.
[0181] In certain embodiments, the number of different tags used to uniquely identify the number of molecules (z) in a class can be between any of 2*z, 3*z, 4*z, 5*z, 6*z, 7*z, 8*z, 9*z, 10*z, 11*z, 12*z, 13*z, 14*z, 15*z, 16*z, 17*z, 18*z, 19*z, 20*z, or 100*z (e.g., a lower limit) and any of 100,000*z, 10,000*z, 1000*z, or 100*z (e.g., an upper limit). In some embodiments, the molecular barcodes are introduced with a set of identifiers (e.g., a combination of unique or non-unique molecular barcodes) and an expected ratio of molecules in the sample. One example form uses about 2 to about 1,000,000 different molecular barcode sequences, or about 5 to about 150 different molecular barcode sequences, or about 20 to about 50 different molecular barcode sequences attached to both ends of the target molecule. Alternatively, about 25 to about 1,000,000 different molecular barcode sequences can be used. For example, 20-50×20-50 molecular barcode sequences can be used (i.e., one of 20-50 different molecular barcode sequences can be attached to each end of the target molecule). This number of identifiers is generally sufficient to allow different molecules with the same starting and ending points to have a high probability of receiving different identifier combinations (e.g., at least 94%, 99.5%, 99.99% or 99.999%). In some embodiments, about 80%, about 90%, about 95%, or about 99% of the molecules have the same molecular barcode combination.
[0182] c. Nucleic Acid Amplification
[0183] As part of the sample collection and preparation pipeline 203, sample nucleic acids flanked by adapters are typically amplified by PCR and other amplification methods that use nucleic acid primers that bind to primer binding sites in the adapters flanking the DNA molecules to be amplified. In some embodiments, the amplification method includes cycles of extension, denaturation, and annealing caused by thermal cycling, or can be isothermal, such as in transcription-mediated amplification. Other exemplary amplification methods that are optionally used include ligase chain reaction, strand displacement amplification, nucleic acid sequence-based amplification, and autonomous continuous sequence-based replication, as well as other methods.
[0184] One or more amplification cycles are usually applied to introduce molecular tags and / or sample indexes / tags into nucleic acid molecules using conventional nucleic acid amplification methods. Amplification is usually carried out in one or more reaction mixtures. Molecular tags and sample indexes / tags are optionally introduced simultaneously or in any order. In some embodiments, molecular tags and sample indexes / tags are introduced before and / or after the sequence capture step. In some embodiments, only molecular tags are introduced before probe capture, and sample indexes / tags are introduced after the sequence capture step. In certain embodiments, both molecular tags and sample indexes / tags are introduced before the probe-based capture step. In some embodiments, sample indexes / tags are introduced after the sequence capture step. Typically, the sequence capture scheme includes the introduction of a single-stranded nucleic acid molecule complementary to the targeted nucleic acid sequence, such as a coding sequence of a genomic region, and the mutation of such a region is associated with a cancer type. Typically, the amplification reaction produces more than one non-unique or uniquely labeled nucleic acid amplicon having a molecular tag and a sample index / tag, the nucleic acid amplicon having a size range of about 200 nucleotides (nt) to about 700 nt, 250 nt to about 350 nt, or about 320 nt to about 550 nt. In some embodiments, the amplicon has a size of about 300 nt. In some embodiments, the amplicon has a size of about 500 nt.
[0185] In some aspects, amplification can occur before and / or after enrichment.
[0186] d. Nucleic acid enrichment
[0187] In some embodiments, as part of sample collection and preparation pipeline 203, sequences are enriched before nucleic acid sequencing. Enrichment is optionally performed for a specific target region or performed non-specifically ("target sequence"). In some embodiments, the targeted region of interest can be enriched using differential tiling and capture schemes (differential tiling and capture schemes) with nucleic acid capture probes ("baits") selected for one or more bait set panels. In some embodiments, CRISPR-mediated enrichment can be used to enrich the targeted region of interest. Differential tiling and capture schemes typically use bait sets of different relative concentrations to differentially tile (e.g., with different "resolutions") in the genomic portion associated with the bait, subject to a restricted set (e.g., sequencer limitations, such as sequencing loading, the utility of each bait, etc.), and capture the targeted nucleic acid at the level required for downstream sequencing. These targeted genomic portions of interest optionally include natural or synthetic nucleotide sequences of nucleic acid constructs. In some embodiments, biotin-labeled beads with probes to one or more moieties of interest can be used to capture target sequences, and optionally subsequently amplify these moieties to enrich for regions of interest.
[0188] Sequence capture generally includes the use of oligonucleotide probes that hybridize with the target nucleic acid sequence. In certain embodiments, the probe set strategy includes tiling the probe in the part of interest. The length of such probe can be, for example, from about 60 to about 120 nucleotides. The set can have a depth of about 2x, 3x, 4x, 5x, 6x, 8x, 9x, 10x, 15x, 20x, 50x or larger. The effectiveness of sequence capture generally depends in part on the length of the sequence complementary (or almost complementary) to the probe sequence in the target molecule.
[0189] In some embodiments, probes can be designed to be specific for the allele of interest. Thus, different alleles from the same gene have an equal chance of being captured.
[0190] In some aspects, following enrichment, amplification can be performed (as described above).
[0191] e. Nucleic acid sequencing
[0192] like Figure 2As shown in , after extracting and isolating cfDNA from a sample via a sample collection and preparation pipeline 203, the cfDNA can be sequenced via a sequencing pipeline 205 including one or more sequencing devices 207. With or without prior amplification, the sample nucleic acid, optionally flanked by adapters, is typically subjected to sequencing. The sequencing methods or commercially available formats optionally utilized include, for example, Sanger sequencing, high-throughput sequencing, bisulfite sequencing, pyrophosphate sequencing, synthetic sequencing, single-molecule sequencing, nanopore-based sequencing, semiconductor sequencing, ligation sequencing, hybridization sequencing, RNA-Seq (Illumina), digital gene expression (Helicos), next generation sequencing (NGS), single-molecule synthetic sequencing (SMSS) (Helicos), massively parallel sequencing, clonal single molecule arrays (Solexa), shotgun sequencing, Ion Torrent, Oxford nanopore, Roche Genia, Maxim-Gilbert sequencing, primer walking, sequencing using PacBio, SOLiD, Ion Torrent or nanopore platforms. Sequencing reactions can be performed in a variety of sample processing units, which may include multiplexed, multi-channel, multi-well, or other devices that process more than one sample set substantially simultaneously. A sample processing unit may also include more than one sample chamber, enabling more than one run to be processed simultaneously.
[0193] Sequencing reaction can be carried out to one or more nucleic acid fragment types or parts known to contain interested alleles.Sequencing reaction can also be carried out to any nucleic acid fragment present in the sample.Sequencing reaction can provide genome at least about 5%, 10%, 15%, 20%, 25%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 99%, 99.9% or 100% genome sequence coverage.In other cases, genome sequence coverage can be genome less than about 5%, 10%, 15%, 20%, 25%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 99%, 99.9% or 100%.
[0194] The sequencing reaction can be performed using multiple sequencing techniques simultaneously. In some embodiments, the cell-free polynucleotides are sequenced using at least about 1000, 2000, 3000, 4000, 5000, 6000, 7000, 8000, 9000, 10000, 50000 or 100,000 sequencing reactions. In other embodiments, the cell-free polynucleotides are sequenced using less than about 1000, 2000, 3000, 4000, 5000, 6000, 7000, 8000, 9000, 10000, 50000 or 100,000 sequencing reactions. The sequencing reactions are typically performed sequentially or simultaneously. Subsequent data analysis is typically performed on all or part of the sequencing reactions. In some embodiments, data analysis is performed on at least about 1000, 2000, 3000, 4000, 5000, 6000, 7000, 8000, 9000, 10000, 50000, or 100,000 sequencing reactions. In other embodiments, data analysis is performed on less than about 1000, 2000, 3000, 4000, 5000, 6000, 7000, 8000, 9000, 10000, 50000, or 100,000 sequencing reactions. Exemplary read depths are about 1000 to about 50,000 reads per site (base position).
[0195] In some embodiments, nucleic acid colonies are prepared for sequencing by enzymatic formation of flat ends on double-stranded nucleic acids with single-stranded overhangs at one or both ends. In these embodiments, the colony is usually processed with an enzyme with 5'-3' DNA polymerase activity and 3'-5' exonuclease activity in the presence of nucleotides (e.g., A, C, G and T or U). The exemplary enzyme or its catalytic fragment optionally used includes Klenow large fragment and T4 polymerase. At the 5' overhang, the enzyme usually extends the 3' end recessed on the relative chain until it is flush with the 5' end, producing a flat end. At the 3' overhang, the enzyme usually digests from the 3' end until the 5' end of the relative chain, and sometimes exceeds the 5' end. If this digestion proceeds to the 5' end exceeding the relative chain, the vacancy can be filled with an enzyme with the same polymerase activity as for the 5' overhang. The formation of flat ends on the double-stranded nucleic acid is conducive to the attachment of, for example, adapters and subsequent amplification.
[0196] In some embodiments, the nucleic acid population is subjected to additional processing, such as conversion of single-stranded nucleic acid to double-stranded and / or conversion of RNA to DNA. These forms of nucleic acid are also optionally connected to adapters and amplified.
[0197] With or without prior amplification, the nucleic acid undergoing the above-described process of forming a blunt end and optionally other nucleic acids in the sample can be sequenced to produce sequenced nucleic acids. Sequenced nucleic acids can refer to the sequence (i.e., sequence information) of a nucleic acid or a nucleic acid whose sequence has been determined. Sequencing can be performed to provide sequence data for a single nucleic acid molecule in a sample directly or indirectly from the consensus sequence of the amplification products of the single nucleic acid molecules in the sample.
[0198] In some embodiments, after the double-stranded nucleic acid with single-stranded overhangs in the sample is formed with a barcode adapter at both ends, and sequencing determines the nucleic acid sequence and the in-line barcode introduced by the adapter. The flat-ended DNA molecule is optionally connected to the flat end of an at least partially double-stranded adapter (e.g., a Y-shaped adapter or a bell-shaped adapter). Optionally, the flat ends of the sample nucleic acid and the adapter can be tailed with complementary nucleotides to facilitate connection (e.g., sticky end connection).
[0199] The nucleic acid sample is typically contacted with a sufficient number of adapters so that the probability that any two copies of the same nucleic acid receive the same combination of adapter barcodes from the adapters connected to the two ends is low (e.g., <1 or 0.1%). Using adapters in this way allows identification of families of nucleic acid sequences having the same starting and ending points on the reference nucleic acid and connected to the same combination of barcodes. Such a family represents the sequence of the amplified product of the nucleic acid in the sample before amplification. Through blunt end formation and adapter attachment modification, the sequence of the family members can be compiled to obtain one or more common nucleotides or a complete common sequence of the nucleic acid molecule in the original sample. In other words, the nucleotides occupying the specified position of the nucleic acid in the sample are determined to occupy the common nucleotides occupying the corresponding position in the family member sequence. The family can include the sequence of one or two chains of a double-stranded nucleic acid. If a member of the family includes sequences from two chains of a double-stranded nucleic acid, the sequence of one chain is converted into their complementary sequences for the purpose of compiling all sequences to obtain one or more common nucleotides or sequences. Some families include only a single member sequence. In this case, the sequence can be obtained as the sequence of the nucleic acid in the sample before amplification. Alternatively, families with only a single member sequence can be excluded from subsequent analysis.
[0200] Additional details about nucleic acid sequencing, including the formats and applications described herein, are also provided, for example, in Levy et al., Annual Review of Genomics and Human Genetics, 17:95-115 (2016), Liu et al., J. of Biomedicine and Biotechnology, Volume 2012, Article ID 251364:1-11 (2012), Voelkerding et al., Clinical Chem., 55:641-658 (2009), MacLean et al., Nature Rev. Microbiol., 7:287-296 (2009), Astier et al., J Am Chem. Soc., 128(5):1705-10(2006), U.S. Patent No. 6,210,891, U.S. Patent No. 6,258,568, U.S. Patent No. 6,833,246, U.S. Patent No. 7,115,400, U.S. Patent No. 6,969,488, U.S. Patent No. 5,912,148, U.S. Patent No. 6,130,073, U.S. Patent No. 7,169,560, U.S. Patent No. 7,282,337, U.S. U.S. Patent No. 7,482,120, U.S. Patent No. 7,501,245, U.S. Patent No. 6,818,395, U.S. Patent No. 6,911,345, U.S. Patent No. 7,501,245, U.S. Patent No. 7,329,492, U.S. Patent No. 7,170,050, U.S. Patent No. 7,302,146, U.S. Patent No. 7,313,308, and U.S. Patent No. 7,476,503, all of which are incorporated by reference in their entirety.
[0201] In some embodiments, the primers used for sequencing can be specific to the adapters added to the ends of the DNA fragments, or can be specific to the target region of interest. For example, if the target region of interest is the HLA region, primers for specific HLA genes can be used for sequencing. In some embodiments, primers can be designed to cover HLA regions containing multiple HLA alleles. In some embodiments, primers can be designed to cover HLA regions containing single HLA alleles.
[0202] f. Sequencing group
[0203] In order to improve the possibility of detecting a genomic region of interest, the DNA portion of sequencing can include a group of genes or a genomic portion including a known genomic region. Selecting a limited portion for sequencing (e.g., a limited group) can reduce the required total sequencing (e.g., the total amount of nucleotides sequenced). The sequencing group can target more than one different gene or region, such as HLA alleles or KIR alleles. Alternatively, DNA can be sequenced by whole genome sequencing (WGS) or other unbiased sequencing methods without using a sequencing group. Suitable groups and examples of targets used in groups can be those comprising allele typing regions such as HLA allele regions and / or KIR allele regions.
[0204] In some aspects, a group targeting more than one different gene or genomic region (e.g., HLA genes, KIR genes and / or the like) is selected so that a subject can use the group for HLA typing or KIR typing. The group can be selected to limit the region for sequencing to a fixed number of base pairs. The group can be selected to sequence the DNA of the desired amount. The group can also be selected to achieve a desired sequence read depth. The group can be selected to achieve a desired sequence read depth or sequence read coverage for a certain amount of sequencing base pairs. The group can be selected to achieve the theoretical sensitivity, theoretical specificity and / or theoretical accuracy of allele typing in the sample.
[0205] The genes included in the panel may include one or more of the HLA or KIR genes, such as, but not limited to, HLA-A, HLA-B, HLA-C, HLA-E, HLA-F, HLA-G, HLA-H, HLA-J, HLA-K, HLA-L, HLA-N, HLA-P, HLA-S, HLA-T, HLA-U, HLA-V, HLA-W, HLA-DRA, HLA-DRB1, HLA-DRB2, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-DRB6, HLA-DRB7, HLA-DRB8, HLA-DRB9, HLA-DQA1, HLA-DQB2, HLA-DQA3, HLA-DQA4, HLA-DQA5, HLA-DQA6, HLA-DQA7, HLA-DQA8, HLA-DQA9, HLA-DQA10, HLA-DQA2, HLA-DQA3, HLA-DQA4, HLA-DQA5, HLA-DQA6, HLA-DQA7, HLA-DQA8, HLA-DQA9, HLA-DQA11, HLA-DQA2, HLA-DQA3, HLA-DQA4, HLA-DQA5, HLA-DQA6, HLA-DQA7, HLA-DQA8, HLA-DQA9, HLA-DQA12, HLA-DQA2, HLA-DQA3, HLA-DQA4, HLA-DQA5, HLA-DQA2, HLA-DQA3, HLA-DQA2, HLA-D LA-DQB2, HLA-DQB3, HLA-DOA, HLA-DOB, HLA-DMA, HLA-DMB, HLA-DPA1, HLA-DPB1, HLA-DPA2, HLA-DPB2, HLA-DPA3, HFE, TAP1, TAP2, PSMB9, PSMB8, MICB, MIC A. MICC, MICD, MICE, KIR2DL1, KIR2DL2 / L3, KIR2DL4, KIR2DL5A, KIR2DL5B, KIR2DS1, KIR2DS2, KIR2DS3, KIR2DS4, KIR2DS5, KIR3DL1 / S1, KIR3DL2, and KIR3DL3.
[0206] Probes for detecting this set of regions can include probes for detecting genomic regions of interest (allele typing regions) as well as nucleosome-aware probes (e.g., KRAS codons 12 and 13) and can be designed to optimize capture based on analysis of cfDNA coverage and fragment size variation and GC sequence composition as affected by nucleosome binding patterns.
[0207] Some examples of genomic locations of interest can be chromosome location 6p21 or 19q13. In some embodiments, the genomic locations used in the methods of the present disclosure include at least a portion of at least 5, at least 10, at least 15, at least 20, at least 25, at least 30, at least 35, at least 40, at least 45, or at least 50 genes in Table 1.
[0208] In some embodiments, one or more regions in the group comprise one or more loci from one or more genes used for allele typing.Genomic locations can be selected for inclusion in the sequencing group based on the presence of genes of interest used for allele typing (such as HLA typing and KIR typing).
[0209] The genes included in the group for sequencing can include a fully transcribed region, a promoter region, an enhancer region, a regulatory element and / or a downstream sequence. In some embodiments, only exons can be included in the group. The group can include all exons of the selected gene, or only one or more exons of the selected gene. The group can include exons from each of more than one different gene. The group can include at least one exon from each of more than one different gene.
[0210] At least one complete exon from each different gene in a group of genes can be sequenced. In some aspects, all exons of a gene can be sequenced. The sequencing group can include all or some exons from more than one gene. The group can include exons from 2 to 100 different genes, 2 to 70 genes, 2 to 50 genes, 2 to 30 genes, 2 to 15 genes, or 2 to 10 genes.
[0211] The selected group may include different numbers of exons. In some aspects, the selected group may include all exons of a gene. The group may include 2 to 3000 exons. The group may include 2 to 1000 exons. The group may include 2 to 500 exons. The group may include 2 to 100 exons. The group may include 2 to 50 exons. The group may include no more than 300 exons. The group may include no more than 200 exons. The group may include no more than 100 exons. The group may include no more than 50 exons. The group may include no more than 40 exons. The group may include no more than 30 exons. The group may include no more than 25 exons. The group may include no more than 20 exons. The group may include no more than 15 exons. The group may include no more than 10 exons. The group may include no more than 9 exons. The group may include no more than 8 exons. The group may contain no more than 7 exons.
[0212] The group may include one or more exons from more than one different gene. The group may include one or more exons from each of a certain proportion of the more than one different genes. The group may include at least two exons from each of at least 25%, 50%, 75% or 90% of the different genes. The group may include at least three exons from each of at least 25%, 50%, 75% or 90% of the different genes. The group may include at least four exons from each of at least 25%, 50%, 75% or 90% of the different genes.
[0213] The size of a sequencing group can vary. A sequencing group can be larger or smaller (in terms of nucleotide size), depending on several factors, including, for example, the total amount of nucleotides sequenced or the number of unique molecules sequenced for a particular region in the group. The size of a sequencing group can be 5kb to 50kb. The size of a sequencing group can be 10kb to 30kb. The size of a sequencing group can be 12kb to 20kb. The size of a sequencing group can be 12kb to 60kb. The size of a sequencing group can be 50kb to 10Mb. The size of a sequencing group can be 500kb to 5Mb. The size of the sequencing group can be at least 10 kb, 12 kb, 15 kb, 20 kb, 25 kb, 30 kb, 35 kb, 40 kb, 45 kb, 50 kb, 60 kb, 70 kb, 80 kb, 90 kb, 100 kb, 110 kb, 120 kb, 130 kb, 140 kb, 150 kb, 200 kb, 250 kb, 300 kb, 350 kb, 400 kb, 450 kb, or 500 kb. The size of the sequencing group can be less than 100 kb, 90 kb, 80 kb, 70 kb, 60 kb, or 50 kb. The size of the sequencing group can be at least 1 Mb, 2 Mb, 3 Mb, 4 Mb, 5 Mb, 6 Mb, 7 Mb, 8 Mb, 9 Mb, or 10 Mb.
[0214] The group selected for sequencing can include at least 1, 5, 10, 15, 20, 25, 30, 40, 50, 60, 80 or 100 genome positions (for example, each includes a genome region of interest). In some cases, the genome position in the group is selected to make the size of the position relatively small. In some cases, the region in the group has a size of about 10kb or less, about 8kb or less, about 6kb or less, about 5kb or less, about 4kb or less, about 3kb or less, about 2.5kb or less, about 2kb or less, about 1.5kb or less or about 1kb or less. In some cases, the genome position in the group has a size of about 0.5kb to about 10kb, about 0.5kb to about 6kb, about 1kb to about 11kb, about 1kb to about 15kb, about 1kb to about 20kb, about 0.1kb to about 10kb or about 0.2kb to about 1kb. For example, the regions in a group may have a size from about 0.1 kb to about 5 kb.
[0215] The group may include one or more positions comprising an interested genomic region from each of one or more genes. In some cases, the group may include one or more positions comprising an interested genomic region from each of at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 40, 50 or 80 genes. In some cases, the group may include one or more positions comprising an interested genomic region from each of at most 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 40, 50 or 80 genes. In some cases, the group may include one or more positions comprising an interested genomic region from each of about 1 to about 80, 1 to about 50, about 3 to about 40, 5 to about 30, 10 to about 20 different genes.
[0216] The concentration (2 to 6ng / μL) of the probe or bait used in the group can be increased to capture more nucleic acid molecules in the sample. The concentration of the probe or bait used in the group can be at least 2ng / μL, 3ng / μL, 4ng / μL, 5ng / μL, 6ng / μL or higher. The concentration of the probe can be about 2ng / μL to about 3ng / μL, about 2ng / μL to about 4ng / μL, about 2ng / μL to about 5ng / μL, about 2ng / μL to about 6ng / μL. The concentration of the probe or bait used in the group can be 2ng / μL or higher to 6ng / μL or lower. In some cases, this can allow more molecules in the biological sample to be analyzed, thereby being able to detect lower frequency alleles.
[0217] In an embodiment, using sequencing pipeline 205, the group can be subjected to one or more of the following: whole genome bisulfite sequencing (WGBS) to explore whole genome methylation patterns, whole genome sequencing (WGS) and / or targeted sequencing methods to explore copy number variants (CNVs) and single nucleotide variants (SNVs).
[0218] g. Sequence Analysis Pipeline
[0219] In an embodiment, after sequencing, the sequence reads and any associated data may be stored in a sequence data store 209. The sequence reads may be stored in any format. The sequence data store 209 may be local and / or remote to the location where the sequencing was performed. Figure 2 As shown in , the stored reads can be subjected to a sequence analysis pipeline 212 .
[0220] i. Sequence quality control
[0221] The sequence analysis pipeline 212 may include a sequence quality control (QC) component 213 that can filter sequence reads from the laboratory system 102. The sequence QC component 213 can assign a quality score to one or more sequence reads. The quality score can be a representation of a sequence read that indicates whether these sequence reads can be used for subsequent analysis based on a threshold. In some cases, some sequence reads do not have enough quality or length to perform subsequent mapping steps. Sequence reads with a quality score of at least 60%, 70%, 80%, 90%, 95%, 99%, 99.9%, 99.99% or 99.999% may be filtered out from the data set of the sequence reads. In other cases, sequence reads assigned a quality score of at least 90%, 95%, 99%, 99.9%, 99.99% or 99.999% may be filtered out from the data set.
[0222] Sequence reads that meet a specified quality score threshold can be mapped to a reference genome by the sequence QC component 213. After mapping alignment, the sequence reads can be assigned a mapping score. The mapping score can be a representation of the sequence reads mapped back to the reference sequence, indicating that each position is or is not uniquely mappable. Sequence reads with a mapping score of at least 60%, 70%, 80%, 90%, 95%, 99%, 99.9%, 99.99% or 99.999% may be filtered out from the data set. In other cases, sequencing reads that are assigned a mapping score of less than 90%, 95%, 99%, 99.9%, 99.99% or 99.999% may be filtered out from the data set.
[0223] ii. Preprocessor
[0224] The preprocessor 214 can retrieve / receive data from the analytical data store 218. For example, the preprocessor 214 can retrieve / receive data representing more than one known allele sequence, more than one test sequence read, and / or more than one decoy sequence. The preprocessor 214 can also be configured to retrieve sequence data from another source (e.g., an external source). For example, the preprocessor 214 can be configured to download more than one known allele sequence, for example, from an IPD-IMGT / HLA database and / or an IPD-KIR database.
[0225] Preprocessor 214 can be configured to divide known allele sequence into more than one k-mer sequence.In other examples, k can be about 25 to about 250.For example, k can be 135 or 140.In embodiments, the length of k can be 125-175 nucleotide, 130-160 nucleotide, 135-155 nucleotide, 140-150 nucleotide.In embodiments, the length of k can be 140,141,142,143,144 or 145 nucleotide.
[0226] The preprocessor 214 can create a database containing k-mer sequences and additional data. The preprocessor 214 can create a data structure containing k-mer sequences and additional data. The data structure can be, for example, a table or a flat file. Figure 3 Instance data structure 300 is shown.Data structure 300 can comprise the entry of each k-mer sequence.For each k-mer sequence, data structure 300 can indicate the quantity of the allele associated with k-mer, and for each in those alleles, can indicate the allele identifier and the starting position of finding the k-mer sequence on this allele.Preprocessor 214 can create the database that comprises decoy sequence and other data.Preprocessor 214 can create the data structure that comprises decoy sequence and other data.Data structure can be for example table or flat file.
[0227] iii. Comparison components
[0228] The alignment component 215 can retrieve / receive data from the analysis data store 218. For example, the alignment component 215 can retrieve / receive data representing more than one known allele sequence, k-mer sequences generated from more than one known allele sequence, more than one test sequence read, and / or more than one decoy sequence.
[0229] In various embodiments, the alignment component 215 can be configured to align the test sequence reads with a reference sequence or another test sequence read. The alignment component 215 can be configured to align the test sequence reads with one or more k-mer sequences generated from more than one known allele sequence. The alignment component 215 can be configured to align the test sequence reads (e.g., pairs) with one or more bait sequences.
[0230] The comparison score is a score indicating the similarity of two sequences determined using the comparison method. In some embodiments, the comparison score takes into account the number of edits (e.g., deletions, insertions, and substitutions of characters in a string). In some embodiments, the comparison score takes into account the number of matches. In some embodiments, the comparison score takes into account both the number of matches and the number of edits. In some embodiments, the number of matches and edits is weighted equally for the comparison score. For example, the comparison score can be calculated as: number of matches-number of insertions-number of deletions-number of substitutions. In other embodiments, the number of matches and edits can be weighted differently. For example, the comparison score can be calculated as: number of matches × 5-number of insertions × 4-number of deletions × 4-number of substitutions × 6.
[0231] Paired comparisons generally involve placing a sequence along a portion of the target, introducing a gap according to an algorithm, scoring the degree of matching of the two sequences, and preferably repeating for each position along the reference. The best-scoring match is considered to be aligned and represents the inference of the homology between the comparison portions of the sequence. In some embodiments, the comparison of a pair of nucleic acid sequences is scored to include setting the value of the score for substitution and insertion / deletion. When comparing a single base, a match or mispairing contributes to the comparison score by replacing the probability, and the replacement probability can be 1 for a match, and can be -0.33 for a mispairing. Insertion / deletion deducts a gap penalty from the comparison score, and the gap penalty can be, for example, -1. Gap penalty and replacement probability can be based on empirical knowledge or a priori assumptions about how the sequence evolves. Their values can affect the comparison of the resulting. In particular, the relationship between the gap penalty and the replacement probability affects whether the resulting comparison will tend to replace or insert / deletion.
[0232] For example, the comparison component 215 can utilize a Burrows-Wheeler aligner (BWA). Typically, the length of the test sequence read can be significantly less than the length of the k-mer sequence generated by more than one known allele sequence. The test sequence read and the k-mer sequence can include a sequence of symbols. The comparison of the test sequence read and the k-mer sequence can include a limited number of mismatches between the symbol of the test sequence read and the symbol of the k-mer sequence. Typically, the test sequence read can be compared with a portion of the k-mer sequence to minimize the number of mismatches between the test sequence read and the k-mer sequence.
[0233] In a particular embodiment, the symbols of the test sequence reads and the symbols of the k-mer sequences can represent the composition of the biomolecule. For example, the symbols can correspond to the identity of nucleotides in nucleic acids (such as RNA or DNA). In some embodiments, the symbols can have a direct correlation with these subcomponents of the biomolecule. For example, each symbol can represent a single base of a polynucleotide. In other embodiments, each symbol can represent two or more adjacent subcomponents of a biomolecule, such as two adjacent bases of a polynucleotide. In addition, the symbols can represent overlapping sets of adjacent subcomponents or different sets of adjacent subcomponents. For example, when each symbol represents two adjacent bases of a polynucleotide, two adjacent symbols representing overlapping sets can correspond to three bases of a polynucleotide sequence, while two adjacent symbols representing different sets can represent a sequence of four bases. In addition, the symbols can directly correspond to subcomponents, such as nucleotides, or they can correspond to color calls or other indirect measurements of subcomponents. For example, a symbol can correspond to the incorporation or non-incorporation of a particular nucleotide stream.
[0234] In an embodiment, the alignment component 215 can be configured to determine those test sequence reads that have the same or substantially the same alignment with one or more k-mer sequences.
[0235] If the sequence of nucleotides or amino acid residues in two sequences is respectively the same when the alignment as described herein is used to obtain maximum correspondence, then two nucleic acid sequences or polypeptide sequences are said to be "identical". In the context of two or more nucleic acids or polypeptide sequences, the term "identical" or "identity" percentage refers to two or more sequences or subsequences that are identical or have a specific identical amino acid residue or nucleotide percentage when comparing and comparing using one of the following sequence comparison algorithms or by manually comparing and visually inspecting the maximum correspondence within the comparison window measured. The term "substantially identical" used in the context of two nucleic acids or polypeptides refers to a sequence with at least 50% sequence identity with a reference sequence. The identity percentage can be any integer from 50% to 100%. Using a program (such as BLAST) described herein to compare with a reference sequence, some embodiments include at least: 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%.
[0236] For sequence comparison, usually a sequence is used as a reference sequence, and a test sequence is compared with it. When using a sequence comparison algorithm, the test sequence and the reference sequence are input into a computer, and subsequence coordinates are specified as needed, and sequence algorithm program parameters are specified. Default program parameters can be used, or alternative parameters can be specified. Then, the sequence comparison algorithm calculates the sequence identity percentage of the test sequence relative to the reference sequence based on the program parameters.
[0237] As used herein, a "comparison window" includes, after two sequences are optimally aligned, a segment referring to any one of the number of consecutive positions selected from the group consisting of from 20 to 600, typically from about 50 to about 200, more typically from about 100 to about 150, in which a sequence can be compared to a reference sequence of the same number of consecutive positions. Methods of sequence alignment for comparison are well known in the art. Optimal alignment of sequences for comparison can be performed, for example, by the local homology algorithm of Smith & Waterman, Adv. Appl. Math. 2:482 (1981), by the homology alignment algorithm of Needleman & Wunsch, J. Mol. Biol. 48:443 (1970), by the similarity search method of Pearson & Lipman, Proc. Nat'l. Acad. Sci. USA 85:2444 (1988), by computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Dr., Madison, Wis.).
[0238] Algorithms suitable for determining percentages of sequence identity and sequence similarity are BLAST and BLAST 2.0 algorithms, which are described in Altschul et al. (1990) J. Mol. Biol. 215: 403-410 and Altschul et al. (1977) Nucleic Acids Res. 25: 3389-3402, respectively. Software for performing BLAST analysis is available to the public through the website of the National Center for Biotechnology Information (NCBI). The algorithm involves first identifying high scoring sequence pairs (HSPs) by identifying short words of length W in the query sequence that match or satisfy a positive threshold score T when aligned with words of the same length in the database sequence. T is referred to as the neighborhood word score threshold (Altschul et al., supra). These initial neighborhood word hits are used as seeds for initiating searches to find longer HSPs containing them. Then, word hits are extended in both directions along each sequence to the extent that the cumulative alignment score cannot be increased. For nucleotide sequences, the cumulative score is calculated using the parameters M (reward score for matching residue pairs; always > 0) and N (penalty score for mismatched residues; always < 0). For amino acid sequences, a scoring matrix is used to calculate the cumulative score. Extension of the word hits in each direction will cease when: the cumulative alignment score drops by the amount X from its maximum achieved value; the cumulative score becomes zero or below due to the accumulation of one or more negative scoring residue alignments; or the end of either sequence is reached. The BLAST algorithm parameters W, T, and X determine the sensitivity and speed of the alignment. The BLASTN program (for nucleotide sequences) uses as defaults: word size (W) of 28, expectation (E) of 10, M = 1, N = -2, and comparison of both chains. For amino acid sequences, the BLASTP program uses as defaults: word size (W) of 3, expectation (E) of 10, and the BLOSUM62 scoring matrix (see, Henikoff and Henikoff, Proc. Natl. Acad. Sci. USA 89: 10915 (1989)).
[0239] The BLAST algorithm also performs a statistical analysis of the similarity between two sequences (see, e.g., Karlin and Altschul, Proc. Nat'l. Acad. Sci. USA 90:5873-5787 (1993)). One measure of similarity provided by the BLAST algorithm is the smallest sum probability (P(N)), which provides an indication of the probability that a match between two nucleotide or amino acid sequences would occur by chance. For example, if the smallest sum probability in a comparison of a test nucleic acid to a reference nucleic acid is less than about 0.01, more preferably less than about 10 -5 and most preferably less than about 10 -20, the nucleic acid is considered similar to the reference sequence.
[0240] Nucleic acid or protein sequences substantially identical to a reference sequence include "conservatively modified variants". With respect to a particular nucleic acid sequence, conservatively modified variants refer to those nucleic acids encoding the same or substantially identical amino acid sequences, or when the nucleic acid does not encode an amino acid sequence, to substantially identical sequences. Due to the degeneracy of the genetic code, a large number of functionally identical nucleic acids encode any given protein. For example, the codons GCA, GCC, GCG, and GCU all encode the amino acid alanine. Therefore, at each position where alanine is specified by a codon, the codon can be changed to any of the corresponding codons described that do not change the encoded polypeptide. Such nucleic acid variations are "silent variations", which are one of conservatively modified variations. Each nucleic acid sequence encoding a polypeptide herein also describes each possible silent variation of the nucleic acid. The skilled person will recognize that each codon in the nucleic acid (except AUG, which is usually the only codon for methionine) can be modified to produce functionally identical molecules. Therefore, each silent variation of a nucleic acid encoding a polypeptide is implicit in each of the described sequences.
[0241] After the comparison component 215 has compared more than one test sequence reads with one or more k-mers generated from a known allele sequence, a list of test sequence reads aligned (supported) with the k-mer sequence of the allele can be generated for each allele. In an embodiment, only test sequence reads aligned identically to the k-mer sequence (e.g., no mismatch and no insertion / deletion) are included in the list. In an embodiment, only test sequence reads aligned substantially identically to the k-mer sequence (e.g., at least one mismatch and / or at least one insertion / deletion) are included in the list. In an embodiment, the comparison component can discard the actual comparison. In an embodiment, the test sequence reads can be aligned (identical or substantially identical) with more than one allele. Each test sequence read can be associated with a test sequence read identifier. Therefore, for each allele, a list of test sequence read identifiers associated with supporting test sequence reads can be generated. A list of test sequence reads aligned with a decoy sequence can also be generated. In an embodiment, only test sequence reads that align identically to the bait sequence (e.g., no mismatches and no indels) are included in the list. In an embodiment, only test sequence reads that align substantially identically to the bait sequence (e.g., at least one mismatch and / or at least one indel) are included in the list. Alignment component 215 can be configured to discard any test sequence reads that align with the bait sequence without mismatches and without indels.
[0242] iv. Superset Components
[0243] The clustering component 216 can retrieve / receive data from the analysis data store 218. For example, the clustering component 216 can retrieve / receive data representing more than one known allele sequence, k-mer sequences generated from more than one known allele sequence, more than one test sequence reads, and results from the alignment component 215.
[0244] In an embodiment, a superset of one or more of more than one known allele sequence can be computationally generated by constructing one or more graph data structures. The graph data structure may include nodes (also referred to as vertices) representing known allele sequences and edges connecting nodes, which indicate that the support reads of one node are subsets of the support reads of another node. Considering the computationally intensive nature of graph data structure construction, such construction can be parallelized.
[0245] In an embodiment, the graph data structure is stored in a memory subsystem (e.g., Figure 2 , memory 222), which may include a pointer for identifying the physical location of each vertex stored in memory 222. Typically, the nodes in the graph data structure each represent an element in the group, and the edges represent the relationship between the elements. The graph data structure may include a directed graph, a tree, a directed acyclic graph (DAG), and / or the like. A directed graph is a graph in which the edges have directions. A tree is a directed graph data structure type having a root node (a rootnode) and many other nodes, each of which is an internal node or a leaf node. The root node and the internal node each have one or more "child" nodes, and each is called the "parent" of its child node. The leaf node does not have any child nodes. The edges in the tree are usually from the parent to the child. In a tree, a node has only one parent. A generalization of a tree, called a directed acyclic graph (DAG), allows a node to have more than one parent, but does not allow edges to form loops.
[0246] In an embodiment, a graph data structure (superset) can represent a Hasse diagram. For a given locus of a chromosome, alleles can be sorted by the number of support test sequence reads. A graph data structure can be constructed by determining the first allele associated with the highest number of support test sequence reads. The first allele can form the basis of a graph data structure (e.g., a top-level node). The support test sequence reads of the first allele can define a group of support test sequence reads. If a given allele is associated with the support test sequence reads, other alleles can be added to the graph data structure, and the support test sequence reads themselves are subsets of the support test sequence read set of the first allele. The alleles of the allele superset not mixed with the first allele can be used to construct one or more other allele supersets in a similar manner. For example, a given allele can have the highest number of support test sequence reads, and each support test sequence read can be associated with a test sequence read identifier. In this case, a set of test sequence read identifiers of the support test sequence reads of the first allele can be formed. In a basic example, the first allele may be supported by test sequence reads with identifiers "1", "2", "3", and "4". The set of test support reads may be represented as A = {1, 2, 3, 4}. The power set P(A) of A is the set of all subsets of A. For A = {1, 2, 3, 4}:
[0247] Figure 4 A Hasse diagram 400 of P(A) is shown, containing partial orderings by set, where X→Y means The root node 402 of the Hasse graph 400 is a set containing all test support reads 1, 2, 3, and 4. Second level nodes (such as node 404) are each associated with a three-member set of test support reads. Third level nodes (such as node 406) are each associated with a set containing two test support reads. Fourth level nodes (such as node 408) each contain a single test support read. The lowest level node is an empty set 410.
[0248] Figure 5An example graph data structure 500 is shown constructed as a Hasse graph to represent a superset. Allele A*03:01:01:05 represents the known allele sequence with the highest number of supporting test sequence reads. Allele A*03:01:01:05 can represent the first allele inserted into the graph data structure 500 as node 502. Allele A*03:01:01:05 can be associated with supporting test sequence reads with the following test sequence read identifiers: {0; 1; 2; 23; 1,030; 2,340; ...}. The remaining known allele sequences can be analyzed to determine which, if any, of the remaining known allele sequences are associated with supporting test sequence reads, which support test sequence reads have test sequence read identifiers that are a subset of {0; 1; 2; 23; 1,030; 2,340; ...}. In graph data structure 500, allele A*03:01:01:07 is associated with supporting test sequence reads having test sequence read identifiers {0; 1; 2; 1,030...}, which are a subset of {0; 1; 2; 23; 1,030; 2,340;...}, resulting in allele A*03:01:01:07 being inserted as node 504, whose edge is connected to node 502 in graph data structure 500. In graph data structure 500, allele A*03:01:01:01 is associated with supporting test sequence reads having test sequence read identifiers {1; 2; 2,340; ...}, which are a subset of {0; 1; 2; 23; 1,030; 2,340; ...}, resulting in allele A*03:01:01:01 being inserted as node 506, whose edge is connected to node 502 in graph data structure 500. In graph data structure 500, allele A*03:01:01:23 is associated with supporting test sequence reads having test sequence read identifiers {0; 2; ...}, which are subsets of {0; 1; 2; 1,030 ...}, resulting in allele A*03:01:01:23 being inserted as node 508, whose edge is connected to node 504 in graph data structure 500. In graph data structure 500, allele A*03:01:01:23 is associated with supporting test sequence reads having test sequence read identifiers {0; 1; 2; ...}, which are subsets of {0; 1; 2; 1,030 ...}, resulting in allele A*03:01:01:23 being inserted as node 510, whose edge is connected to node 504 in graph data structure 500.
[0249] In graph data structure 500, allele A*03:01:01:47 is associated with supporting test sequence reads having test sequence read identifiers {2; 2,340; ...}, which are subsets of {1; 2; ; 2,340 ...}, resulting in allele A*03:01:01:47 being inserted as node 512, with an edge connected to node 506 in graph data structure 500. In graph data structure 500, allele A*03:01:01:25 is associated with supporting test sequence reads having test sequence read identifiers {2; ...}, which are subsets of {0; 2; ...} and {0; 1; 2; ...}, resulting in allele A*03:01:01:25 being inserted as node 514, with edges connected to nodes 508 and 510 in graph data structure 500. In graph data structure 500, allele A*03:01:01:24 is associated with supporting test sequence reads having test sequence read identifiers {2,340; ...}, which are a subset of {2; 2,340; ...}, resulting in allele A*03:01:01:24 being inserted as node 516, whose edge is connected to node 512 in graph data structure 500.
[0250] When no other known allele sequence is associated with the supporting test sequence read with the test sequence read identifier, the graph data structure 500 is completed, and the test sequence read identifier is a subset of node 502. Other graph data structures can be constructed using the remaining known allele sequences. In an embodiment, after all known allele sequences are inserted into the graph data structure (superset). The root node (first allele) represents a candidate allele. The candidate allele can be a candidate for the allele present at the locus.
[0251] In an embodiment, the graph data structure 500 may be traversed to determine known allele sequences associated with a given set of test sequence read identifiers.
[0252] In an embodiment, a graph data structure (e.g., representing a superset) is stored in a memory subsystem (e.g., Figure 2 , memory 222), which may include pointers identifying the physical location where each vertex is stored in memory 222. In an embodiment, the graph data structure is stored in memory 222 using adjacency lists. In some embodiments, there is an adjacency list for each vertex.
[0253] Figure 6A graph data structure 600 including a vertex object 605 and an edge object 609 is shown. The identifiers of known allele sequences and related supporting test sequence reads are identified as blocks, and those blocks are converted into objects 605 stored in a tangible memory device. Objects 605 are connected to create paths so that there is a path for a subset of identifiers for each known allele sequence and related supporting test sequence reads. The path can indicate the known allele sequences associated with the subset of identifiers supporting test sequence reads. The connection that creates the path itself can be implemented as an object so that the block is represented by a vertex object 605, and the connection is represented by an edge object 609. Therefore, a directed graph includes vertices and edge objects stored in a tangible memory device. As used herein, node objects 605 and edge objects 609 refer to objects created using a computer system.
[0254] Figure 6 Also shown is an adjacency list 610 for vertex 605. The disclosed methods and systems can use a processor to create a graph data structure 600 including vertex objects 605 and edge objects 609 by using adjacency, such as an adjacency list or index-free adjacency. Thus, the processor can use index-free adjacency to create a graph data structure 600 in which a vertex 605 includes a pointer to another vertex 605 to which it is connected, and the pointer identifies the physical location on the memory device 222 where the connected vertex is stored. The graph data structure 600 can be implemented using adjacency lists so that each vertex or edge stores a list of such objects that are adjacent to it. Each adjacency list includes a pointer to a specific physical location within the memory device for an adjacent object.
[0255] The graph data structure 600 will typically be stored on physical devices of the memory subsystem 222 in a manner that provides very fast traversal. In this sense, Figure 6 The bottom portion of shows that objects are stored at specific physical locations on the tangible portion of the memory subsystem 222. Each node 605 is stored at a physical location referenced by a pointer in any adjacency list 610 that references the node. Each node 605 has an adjacency list 610 that includes each adjacent node in the graph data structure 600. The entries in the list 610 are pointers to adjacent nodes.
[0256] In some embodiments, there is an adjacency list for each vertex and edge, and the adjacency list of a vertex or edge lists the edges or vertices that are adjacent to the vertex or edge.
[0257] Figure 7 The use of adjacency lists 710 for each vertex 705 and edge 709 is shown. Figure 7As shown, the disclosed methods and systems can create a graph data structure 700 using an adjacency list 710 for each vertex and edge, wherein the adjacency list 710 for a vertex 705 or an edge 709 lists the edges or vertices adjacent to the vertex or edge. Each entry in the adjacency list 710 is a pointer to an adjacent vertex or edge.
[0258] Each pointer identifies a physical location in the memory subsystem where adjacent objects are stored. In a preferred embodiment, a pointer or native pointer can be operated as a memory address because it points to a physical location on the memory and allows access to the desired data by means of pointer dereferencing. That is, a pointer is a reference to a datum stored somewhere in the memory; to obtain the datum, the pointer is dereferenced. The feature that distinguishes pointers from other kinds of references is that the value of the pointer is interpreted as a memory address at a low level or hardware level. Such a graphical representation provides a means for rapid random access, modification, and retrieval of data.
[0259] In some embodiments, fast random access is supported and graph object storage is implemented with index-free adjacency because each element contains direct pointers to its neighboring elements, which avoids the need for index lookups, allowing traversal to be very fast. Index-free adjacency is another example of low-level or hardware-level memory references for data retrieval. Specifically, index-free adjacency can be implemented so that the pointers contained in the elements are references to physical locations in memory.
[0260] Because implementations of the technique using physical memory addressing (such as native pointers) can access and use data in such a lightweight manner without the need for separate index tables or other intermediate lookup steps, the functionality of a given computer (e.g., any modern consumer-grade desktop computer) is extended to allow full manipulation of genome-scale graphs (e.g., graph data structure 700 representing a superset of known allele sequences). Thus, using an object library with native pointers or other implementations that provide index-free adjacency to store graph elements (e.g., nodes and edges) actually improves the ability of the technique to provide storage, retrieval, and alignment for sequence information because it uses the computer's physical memory in a specific manner.
[0261] v. Allele caller - selects alleles from a superset
[0262] Allele caller 217 can retrieve / receive data from analysis data store 218. For example, allele caller 217 can retrieve / receive data representing more than one known allele sequence, k-mer sequences generated from more than one known allele sequence, more than one test sequence read, results from alignment component 215, and / or one or more graph data structures (supersets) generated by clustering component 216.
[0263] Allele caller 217 may be configured to determine the allele type of a given allele.Allele caller 217 may be configured to classify alleles based on one or more graph data structures (supersets).
[0264] In an embodiment, where only one graph data structure (superset) is constructed (e.g., all known allele sequences fall within a single graph data structure), the allele associated with the root node of the graph data structure (the first allele) can be classified as an allele present at a locus on a chromosome (e.g., a haploid locus).
[0265] In an embodiment, where more than one graph data structure (superset) is constructed, the allele (first allele) associated with the root node of the two supersets having the largest cumulative number of different supporting test sequence reads can be classified as an allele present at a locus on a chromosome (e.g., a diploid locus).
[0266] A set operation may be performed on the combination of root nodes to determine the two root nodes with the largest cumulative number of different supporting test sequence reads. In an embodiment, a union operation (∪) may be used. Figure 8As shown, clustering component 216 constructs three graph data structures, and the root nodes obtained from each graph data structure are shown as root node 802, root node 804, and root node 806. Union operations can be performed between root node 802 and root node 804, between root node 802 and root node 806, and between root node 804 and root node 806. It is expected that the root nodes may be associated with hundreds or thousands of test sequence read identifiers, however, to simplify the explanation, root node 802 is depicted as being associated with a set of 9 test sequence read identifiers consisting of the set {0; 1; 2; 23; 1,030; 1,223; 2,001; 2,300; 2,340}, root node 804 is depicted as being associated with a set of 10 test sequence read identifiers consisting of the set {1; 3; 5; 6; 7; 21; 1,708; 2,000; 2,001; 2,340}, and root node 806 is depicted as being associated with a set of 11 test sequence read identifiers consisting of the set {0; 6; 7; 9; 10; 11; 21; 58; 1,200; 2,000; 2,900}. The union operation between node 802 and node 804 produces the set {0; 1; 2; 3; 5; 6; 7; 21; 23; 1,030; 1,223; 1,708; 2,000; 2,001; 2,300; 2,340}, which includes 16 accumulated different test sequence read identifiers because the union operation discards duplicates. The union operation between node 802 and node 806 produces the set {0; 1; 2; 6; 7; 9; 10; 11; 21; 23; 58; 1,030; 1,200; 1,223; 2,000; 2,001; 2,300; 2,340; 2,900}, which includes 19 accumulated different test sequence read identifiers because the union operation discards duplicates. The union operation between node 804 and node 806 produces the set {0; 1; 3; 5; 6; 7; 9; 10; 11; 21; 58; 1,200; 1,708; 2,000; 2,001; 2,340; 2,900}, which includes 17 cumulative different test sequence read identifiers because the union operation discards duplicates. The union operation between node 802 and node 806 results in the maximum cumulative number of different test sequence read identifiers, and therefore results in different test sequence reads. Therefore, allele caller 217 can classify the known allele sequence (e.g., the first allele) associated with node 802 (DQB1*03:02:01:01) and node 806 (DQB1*03:04:03) as the allele present at the locus. Allele caller 217 can continue to process the graph data structure / root node of any number of loci.
[0267] vi. Variant caller
[0268] Variant caller 219 can retrieve / receive data from analytical data storage 218. For example, variant caller 219 can retrieve / receive data representing more than one sequence read. Variant caller 219 can retrieve test sequence reads that align with the bait sequence and with known alleles and have at least one mismatch and / or at least one insertion / deletion and have a greater alignment score with known alleles. Test sequence reads can be analyzed to determine one or more variants. Variants can include, for example, single nucleotide variants (SNVs), insertions / deletions, fusions, and / or copy number variations. Any known variant calling technology can be used. In an embodiment, nucleotide variations in sequenced nucleic acids can be determined by comparing sequenced nucleic acids with reference sequences. Reference sequences are typically known sequences, for example, known full genomes or partial genome sequences (such as full genome sequences of human subjects) from subjects. Reference sequences can be, for example, hG19 or hG38. As described above, sequenced nucleic acids can represent the directly determined sequences of nucleic acids in a sample, or the consensus sequences of amplification products of such nucleic acids. Comparisons can be made at one or more specified positions on a reference sequence. When the corresponding sequences are aligned to the greatest extent, a subset of sequenced nucleic acids can be identified, including positions corresponding to designated positions of a reference sequence. Within such a subset, it can be determined which (if any) sequenced nucleic acids include nucleotide variations at designated positions, the length of a given cfDNA fragment is determined based on the locations of the endpoints of a given cfDNA fragment (i.e., its 5' and 3' terminal nucleotides) mapped to the reference sequence, the offset of the midpoint of a given cfDNA fragment from the midpoint of a genomic region in the cfDNA fragment, and optionally which (if any) include reference nucleotides (i.e., the same as in the reference sequence). If the number of sequenced nucleic acids in a subset that include nucleotide variants exceeds a selected threshold, the variant nucleotide can be called at the designated position. The threshold value can be a simple numerical value, such as at least 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 nucleic acids sequenced in the subset comprising nucleotide variants, or it can be a ratio, such as at least 0.5, 1, 2, 3, 4, 5, 10, 15 or 20 nucleic acids sequenced in the subset comprising nucleotide variants, and other possibilities. Any position of interest in the reference sequence can be repeated for comparison. Sometimes it is possible to compare the positions of the appointments occupying at least about 20, 100, 200 or 300 continuous positions on the reference sequence, for example, about 20-500 or about 50-300 continuous positions.
[0269] Variant caller 417 can be configured to assign somatic or germline markers to a given variant. Regarding the additional details of classifying variants as somatic or germline, it is optionally suitable for performing the method disclosed herein, described in, for example, U.S. Patent Application Publication No. US20210265013A1, filed on February 17, 2021, which is incorporated by reference. In an embodiment, one or more germline variant callers can be used to verify germline status. Germline variant callers include HAPLOTYPE CALLER, samtools, and / or freebayes. In an embodiment, one or more somatic cell variant callers can be used to verify somatic cell status. Somatic cell variant callers include SEURAT, STRELKA, and / or MUTECT.
[0270] Any data analyzed, determined, and / or output by the sequence analysis pipeline 212 may be stored in the analysis data store 218. In general, the processor 220 may implement (be programmed by) various components of the sequence analysis pipeline 212, such as the sequence quality control component 213, the preprocessor 214, the alignment component 215, the clustering component 216, the allele caller 217, the variant caller 219, and / or other components. Optionally, it should be noted that these components of the sequence analysis pipeline 212 may include hardware modules. Although described separately for convenience, one or more of the various components or instructions, such as the sequence quality control component 213, the preprocessor 214, the alignment component 215, the clustering component 216, the allele caller 217, and / or the variant caller 219 may be integrated with each other.
[0271] Computer system 210 may exchange data with computer system 224 using network 223. For example, computer system 224 may retrieve data from analytical data store 218. Computer system 224 may be configured to determine / classify the alleles present at a locus.
[0272] h. Instance methods
[0273] In the implementation scheme, Fig. 9 As shown, a method 900 for allele calling is disclosed. In an embodiment, the sequence QC component 213, the preprocessor 214, the alignment component 215, the clustering component 216, the allele caller 217, the variant caller 219, additional components not shown (e.g., components of the computer system 210) individually and / or in combination thereof can be configured to access the sequence data store 209 and / or the analysis data store 218 and perform the method 900 in whole and / or in part. The method 900 can be performed in whole or in part by a single computing device using parallel computing in one or more cores, or using more than one computing device, such as using a distributed computer system, etc.
[0274] Method 900 may include determining more than one known allele sequence at 901. The more than one known allele sequence may include more than one known human leukocyte antigen (HLA) allele sequence or more than one known killer cell immunoglobulin-like receptor (KIR) region allele sequence. Determining more than one known allele sequence may include retrieving sequence data of the known alleles, determining more than one k-mer sequence based on the sequence data of the known alleles, and assembling the more than one k-mer sequence into a data structure including more than one entry, wherein each entry may include a k-mer sequence, a number of alleles containing the k-mer sequence, an allele identifier for each allele containing the k-mer sequence, and a start and end position of the k-mer sequence in each allele.
[0275] Method 900 may include determining more than one sequence read of a target region of a chromosome of a subject at 902. The target region of the chromosome may include one or more loci. Method 900 may also include obtaining a sample from the subject and sequencing the sample to obtain more than one sequence read of the target region of the chromosome. The target region may include one or more of the following genes: HLA-A, HLA-B, HLA-C, HLA-E, HLA-F, HLA-G, HLA-H, HLA-J, HLA-K, HLA-L, HLA-N, HLA-P, HLA-S, HLA-T, HLA-U, HLA-V, HLA-W, HL A-DRA, HLA-DRB1, HLA-DRB2, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-DRB6, HLA-DRB7, HLA-DRB8, HLA-DRB9, HLA-DQA1, HLA-DQB1, HLA-DQA2, HLA-DQB2, H LA-DQB3, HLA-DOA, HLA-DOB, HLA-DMA, HLA-DMB, HLA-DPA1, HLA-DPB1, HLA-DPA2, HLA-DPB2, HLA-DPA3, HFE, TAP1, TAP2, PSMB9, PSMB8, MICB, MICA, MICC, MICD, MICE, KIR2DL1, KIR2DL2 / L3, KIR2DL4, KIR2DL5A, KIR2DL5B, KIR2DS1, KIR2DS2, KIR2DS3, KIR2DS4, KIR2DS5, KIR3DL1 / S1, KIR3DL2 or KIR3DL3. The target region may comprise chromosome position 6p21 or chromosome position 19q13. The target region may comprise at least a portion of a major histocompatibility complex (MHC) region, and the chromosome is human chromosome 6. The target region may comprise at least a portion of a killer cell immunoglobulin-like receptor (KIR) region, and the chromosome is human chromosome 19.
[0276] Method 900 may include, at 903 , aligning more than one sequence read to more than one known allele sequence.
[0277] Method 900 may include determining, based on the alignment, for each of more than one known allele sequence, the number of sequence reads aligned to each known allele sequence at 904. In some embodiments, the sequence reads aligned to each known allele sequence may be grouped into one or more sequence read families (i.e., based on molecular barcodes and genomic positions). Thus, the number of sequence read families aligned to each known allele sequence may be determined.
[0278] Based on the alignment, for each known allele sequence in more than one known allele sequence, determining the number of sequence reads aligned to each known allele sequence may include determining the number of sequence reads aligned to each known allele sequence and having 100% identity. Method 900 may include determining the number of sequence read families aligned to each known allele sequence at 904. Determining the number of sequence read families aligned to each known allele sequence may include grouping the reads based on the barcode.
[0279] Method 900 may include, at 905, determining, for one or more loci, known allele sequences present at the one or more loci based on the number of sequence reads aligned to each known allele sequence. Method 900 may include, at 905, determining, for one or more loci, known allele sequences present at the one or more loci based on the number of sequence read families aligned to each known allele sequence. The known allele sequences present at the one or more loci may include a human leukocyte antigen (HLA) type at the locus or a killer cell immunoglobulin-like receptor (KIR) type at the locus.
[0280] Based on the number of sequence reads aligned to each known allele sequence, for one or more loci, determining the known allele sequences present at the one or more loci may include determining the one or more known allele sequences having the highest number of aligned sequence reads. Based on the number of sequence read families aligned to each known allele sequence, for one or more loci, determining the known allele sequences present at the one or more loci may include determining the one or more known allele sequences having the highest number of aligned sequence read families.
[0281] The method 900 may further include determining, for each of the more than one sequence reads, based on the alignment, one or more known allele sequences to which each read aligns.
[0282] The method 900 may further include determining a length of a portion of each known allele sequence that aligns to two or more of the more than one sequence reads.
[0283] Method 900 may also include, for a locus, sorting known allele sequences present at the locus by the number of sequence reads aligned to each known allele sequence, for the locus, determining a first known allele sequence having a highest number of aligned sequence reads, inserting the first known allele sequence having the highest number of aligned sequence reads into a superset, determining one or more known allele sequences aligned to reads that are a subset of the reads aligned to the first known allele sequence, and inserting the one or more known allele sequences into the superset. The superset may include a graph data structure. The graph data structure may include a directed acyclic graph. The graph data structure may represent a Hasse graph.
[0284] The method 900 can also include determining that the locus is associated with a single superset, and determining a first known allele sequence of the single superset as the allele present at the locus.
[0285] Method 900 may also include determining more than one superset of the loci. Method 900 may also include determining two supersets having the largest cumulative number of different reads based on the more than one superset of the loci, and determining the first known allele sequence in each of the two supersets as the allele present at the locus.
[0286] The method 900 may further include facilitating communication of known allele sequences present at one or more loci to a medical provider.
[0287] Method 900 may also include obtaining a sample from the cells to be transplanted into the subject, and sequencing the sample to obtain more than one sequence read of the target region of the chromosome. Method 900 may also include determining whether the HLA type of the subject matches the HLA type at the locus. Method 900 may also include transplanting the cells into the subject if the HLA type of the subject matches the HLA type at the locus.
[0288] Method 900 can also include transplanting the cells into the subject if the subject's HLA type matches the HLA type at the locus, and administering an agent that reduces the likelihood of transplant rejection in the subject.
[0289] Method 900 may also include determining that the subject is susceptible to developing rheumatoid arthritis (RA), wherein the known allele sequences present at one or more loci may include HLA-DRB1*04:01, *04:04, and *04:08; HLA-DRB1*04:05; HLA-DRB1*01:01 and *01:02; HLA-DRB1*14:02; HLA-DRB1*10:01; and HLA-DRB1*01:01, *04:01, *04:04, and *04:05.
[0290] Method 900 may also include determining that the subject is susceptible to developing multiple sclerosis (MS), wherein the known allele sequences present at one or more loci may include HLA-DRB1*15:01, HLA-DQB1*06:02, HLA-DRB1*01:08, HLA-DRB1*03:01 and / or HLA-DRB1*13:03.
[0291] Method 900 may also include determining that the subject is susceptible to developing systemic lupus erythematosus (SLE), wherein the known allele sequences present at one or more loci may include HLA-DRB1, HLA-DR2 (DRB1*15:01), HLA-DR3 (DRB1*03:01), HLA-DRB1*08:01 and / or HLA-DQA1*01:02.
[0292] Method 900 may further include determining that the subject is susceptible to developing type 1 diabetes (T1D), wherein the known allele sequences present at the one or more loci may include HLA-DQB1*03:02 and / or DQB1*02:01.
[0293] Method 900 may also include determining that the subject is susceptible to developing Sjögren's syndrome (SS), wherein the known allele sequences present at the one or more loci may include DQA1*05:01, DQB1*02:01, and DRB1*03:01.
[0294] Method 900 may also include determining that the subject is susceptible to developing celiac disease (CD), wherein the known allele sequences present at one or more loci may include HLA-DQ2 (encoded by HLA-DQA1*05:01-DQB1*02:01) and / or HLA-DQ8 (encoded by DQA1*03:01-DQB1*03:02).
[0295] Method 900 can further include determining that the subject is susceptible to developing pre-eclampsia, wherein the known allelic sequences present at the one or more loci can include KIR2DL1.
[0296] Method 900 can also include determining that the subject is unlikely to progress from HIV infection to AIDS, wherein the known allele sequences present at the one or more loci can include KIR3DS1.
[0297] Method 900 can also include determining that the subject is unlikely to progress from HIV infection to AIDS, wherein the known allele sequences present at the one or more loci can include a combination of KIR3DS1 and HLA-Bw4.
[0298] Method 900 can also include determining that the subject is susceptible to developing an autoimmune disease, wherein the known allelic sequences present at the one or more loci can include KIR2DS1.
[0299] Method 900 can further include determining that the subject is susceptible to developing Crohn's disease, wherein the known allele sequences present at one or more loci can include KIR2DL2 / KIR2DL3 heterozygosity.
[0300] Method 900 can further include determining that the subject is susceptible to developing Crohn's disease, wherein the known allele sequences present at the one or more loci can include a combination of KIR2DL2 / KIR2DL3 heterozygosity and HLA-C2 alleles.
[0301] Method 900 can also include determining whether the subject is a suitable candidate for a donor in an unrelated hematopoietic cell transplant, wherein the known allele sequences present at the one or more loci can include a group B KIR haplotype.
[0302] In the implementation scheme, Fig.10 As shown, a method 1000 for allele and / or variant calling is disclosed. In an embodiment, sequence QC component 213, preprocessor 214, alignment component 215, clustering component 216, allele caller 217, variant caller 219, additional components not shown (e.g., components of computer system 210) individually and / or in combination thereof can be configured to access sequence data store 209 and / or analysis data store 218 and perform method 900 in whole and / or in part. Method 900 can be performed in whole or in part by a single computing device using parallel computing in one or more cores, or using more than one computing device, such as using a distributed computer system, etc.
[0303] Method 1000 may include determining more than one sequence read pair of a target region of a chromosome of a subject at 1001, wherein the target region of the chromosome comprises one or more loci. Method 1000 may also include obtaining a sample from the subject and sequencing the sample to obtain more than one sequence read pair of the target region of the chromosome. The target region may include one or more of the following genes: HLA-A, HLA-B, HLA-C, HLA-E, HLA-F, HLA-G, HLA-H, HLA-J, HLA-K, HLA-L, HLA-N, HLA-P, HLA-S, HLA-T, HLA-U, HLA-V, HLA-W, HL A-DRA, HLA-DRB1, HLA-DRB2, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-DRB6, HLA-DRB7, HLA-DRB8, HLA-DRB9, HLA-DQA1, HLA-DQB1, HLA-DQA2, HLA-DQB2, H LA-DQB3, HLA-DOA, HLA-DOB, HLA-DMA, HLA-DMB, HLA-DPA1, HLA-DPB1, HLA-DPA2, HLA-DPB2, HLA-DPA3, HFE, TAP1, TAP2, PSMB9, PSMB8, MICB, MICA, MICC, MICD, MICE, KIR2DL1, KIR2DL2 / L3, KIR2DL4, KIR2DL5A, KIR2DL5B, KIR2DS1, KIR2DS2, KIR2DS3, KIR2DS4, KIR2DS5, KIR3DL1 / S1, KIR3DL2 or KIR3DL3. The target region may comprise chromosome position 6p21 or chromosome position 19q13. The target region may comprise at least a portion of a major histocompatibility complex (MHC) region, and the chromosome is human chromosome 6. The target region may comprise at least a portion of a killer cell immunoglobulin-like receptor (KIR) region, and the chromosome is human chromosome 19.
[0304] Method 1000 may include generating a germline alignment of more than one sequence read pair to more than one known allele sequence at 1002. The more than one known allele sequence may include more than one known human leukocyte antigen (HLA) allele sequence or more than one known human killer cell immunoglobulin-like receptor (KIR) region allele sequence.
[0305] Method 1000 may include generating a bait alignment of more than one sequence read pair to more than one bait allele sequence at 1003. The more than one bait sequence may include more than one non-human sequence. The more than one non-human sequence may include one or more of more than one bovine sequence, more than one rat sequence, or more than one microbial sequence.
[0306] Generating a germline alignment of more than one sequence read pairs to more than one known allele sequence may include determining, for one of the more than one sequence read pairs, one or more known allele sequences that align with each read in one of the more than one sequence read pairs without mismatches or insertions / deletions based on the germline alignment.
[0307] Method 1000 may also include determining, based on the germline alignment, for each known allele sequence in more than one known allele sequence, a number of sequence read pairs that align with each known allele sequence in more than one sequence read pairs, and determining, for one or more loci, known allele sequences present at the one or more loci based on the number of sequence read pairs that align with each known allele sequence.
[0308] Generating a bait alignment of more than one sequence read pairs with more than one bait allele sequence may include, based on the bait alignment, determining, for one of the more than one sequence read pairs, one or more bait allele sequences that align with each read in one of the more than one sequence read pairs without mismatches or insertions / deletions, and discarding one of the sequence read pairs.
[0309] Generating bait alignments of more than one sequence read pairs to more than one bait allele sequences may include determining, based on the bait alignments, for one of the more than one sequence read pairs, one or more non-human bait sequences that align with each read in the one sequence read pair without mismatches or insertions / deletions, and identifying the more than one sequence read pairs as originating from a contaminated sample.
[0310] Generating a germline alignment of more than one sequence read pairs to more than one known allele sequence may include determining, based on the germline alignment, for one of the more than one sequence read pairs, one or more known allele sequences that align with each read in one of the more than one sequence read pairs and have at least one mismatch or insertion / deletion, and generating a germline alignment score.
[0311] Generating a bait alignment of more than one sequence read pairs with more than one bait allele sequence may include, based on the bait alignment, determining, for one of the more than one sequence read pairs, one or more bait allele sequences that align with each read in one of the more than one sequence read pairs and have at least one mismatch or insertion / deletion, and generating a bait alignment score.
[0312] Generating a germline alignment of more than one sequence read pair to more than one known allele sequence can include determining an alignment of a sequence read pair to at least two allele sequences of the more than one known allele sequence and selecting one known allele sequence of the at least two allele sequences.
[0313] Generating a bait alignment of more than one sequence read pair to more than one bait allele sequence may include determining that a sequence read pair is aligned to at least two bait allele sequences of the more than one bait allele sequence, and selecting one bait allele sequence of the at least two bait allele sequences.
[0314] Method 1000 may include determining, at 1004, a sequence read pair among more than one sequence read pairs having both a germline alignment (having at least one mismatch and / or insertion / deletion) and a decoy alignment (having at least one mismatch and / or insertion / deletion), wherein the sequence read pair is associated with a germline alignment score that is greater than a decoy alignment score.
[0315] Method 1000 may include identifying the sequence read pair as a candidate somatic variant at 1005. Identifying a sequence read pair as a candidate somatic variant may include identifying a reference variant in the one or more reference variants as a candidate variant based on aligning the sequence read pair with the one or more reference variants. Identifying a sequence read pair as a candidate somatic variant may include identifying a non-human reference variant in the one or more non-human reference variants as a candidate variant based on aligning the sequence read pair with the one or more non-human reference variants, and identifying more than one sequence read pair as originating from a contaminated sample.
[0316] IV. System and computer readable medium
[0317] The various processing operations and / or methods depicted in the figure can be completed using some or all of the system components described in detail herein, and in some embodiments, multiple operations can be performed in different orders, and multiple operations can be omitted. Additional operations can be performed together with some or all of the operations shown in the depicted flow chart. One or more operations can be performed simultaneously. Therefore, the operations shown (and described in more detail herein) are provided as examples, and therefore, should not be considered restrictive.
[0318] The methods of the present invention may be computer-implemented, such that any or all operations except the wet chemical steps described in the specification or the appended claims may be performed in a suitably programmed computer. The computer may be a mainframe computer, a personal computer, a tablet computer, a smartphone, the cloud, an online data store, a remote data store, etc. The computer may operate in one or more locations.
[0319] Various operations of the methods of the present invention may utilize information and / or programs and generate results that are stored on a computer-readable medium (e.g., a hard drive, auxiliary storage, external storage, a server; a database, a portable storage device (e.g., a CD-R, a DVD, a ZIP disk, a flash memory card), etc.).
[0320] The present disclosure also includes an article of manufacture for analyzing a nucleic acid population, the article of manufacture comprising a machine-readable medium containing one or more programs that, when executed, perform the steps of the method of the present invention.
[0321] The present disclosure may be implemented in hardware and / or software. For example, different aspects of the present disclosure may be implemented in client-side logic or server-side logic. The present disclosure or its components may be embodied in a fixed medium program component containing logic instructions and / or data that, when loaded into a suitably configured computing device, causes the device to perform in accordance with the present disclosure. The fixed medium containing the logic instructions may be delivered to an observer on a fixed medium for physical loading into the observer's computer, or the fixed medium containing the logic instructions may reside on a remote server that the observer accesses via a communication medium to download the program component.
[0322] The present disclosure provides a computer controlled system programmed to implement the method of the present disclosure. Figure 2, the processor 220 may include a single-core or multi-core processor, or more than one processor for parallel processing. The storage device 222 may include random access memory, read-only memory, flash memory, hard disk and / or other types of memory. The computer system 210 may include a communication interface (e.g., a network adapter) and peripheral devices such as cache, other memory, data storage and / or an electronic display adapter for communicating with one or more other systems. The components of the computer system 210 may communicate with each other through an internal communication bus such as a motherboard. The storage device 222 may be a data storage unit (or data repository) for storing data. The computer system 210 may be operably coupled to a network 223 ("network") by means of a communication interface. The network 223 may be the Internet, an intranet and / or an extranet, or an intranet and / or an extranet that communicates with the Internet. In some cases, the network 223 is a telecommunications and / or data network. The network 223 may include a local area network. The network 223 may include one or more computer servers that may support distributed computing, such as cloud computing. In some cases, network 223 can implement a peer-to-peer network with computer system 210, which can enable devices coupled to computer system 220 to operate as clients or servers. Computer system 210 can exchange data with computer system 224 using network 223. For example, computer system 224 can retrieve data from analytical data store 218.
[0323] The processor 220 may execute a series of machine-readable instructions that may be embodied in a program or software. The instructions may be stored in a memory location, such as a storage device 222. The instructions may be directed to the processor 220, which may then program or otherwise configure the processor 220 to implement the methods of the present disclosure. Examples of operations performed by the processor 220 may include reading, decoding, performing, and writing back.
[0324] Processor 220 may be part of a circuit such as an integrated circuit. One or more other components of system 200 may be included in the circuit. In some cases, the circuit may include an application specific integrated circuit (ASIC).
[0325] Storage device 222 may store files, such as drivers, libraries, and saved programs. Storage device 222 may store user data, such as user preferences and user programs. In some cases, computer system 210 may include one or more additional data storage units that are external to computer system 210, such as located on a remote server that communicates with computer system 210 via an intranet or the Internet.
[0326] Computer system 210 can communicate with one or more remote computer systems via a network. For example, computer system 210 can communicate with a user's remote computer system. Examples of remote computer systems include personal computers (e.g., portable PCs), slate or tablet PCs (e.g., iPad, Galaxy Tab), phones, smartphones (e.g. iPhone, Android supported devices, ) or a personal digital assistant. A user can access the computer system 210 via a network.
[0327] The methods as described herein may be implemented by means of machine (e.g., computer processor) executable code stored in an electronic storage location of the computer system 210, such as, for example, on the storage device 222. The machine executable code or machine readable code may be provided in the form of software (e.g., computer readable medium). During use, the code may be executed by the processor 220. In some cases, the code may be retrieved from the storage device 222 and stored on the storage device 222 for immediate access by the processor 220.
[0328] The code may be precompiled and configured for use with a machine having a processor suitable for executing the code, or may be compiled during runtime. The code may be provided in a programming language that may be selected so that the code can be executed in a precompiled or as-compiled manner.
[0329] Aspects of the systems and methods provided herein, such as computer system 210, can be embodied in programming. Aspects of the technology can be considered to be "products" or "articles of manufacture" in the form of machine (or processor) executable code and / or related data, typically carried or embodied in a machine-readable medium. The machine executable code can be stored in an electronic storage unit such as a memory (e.g., read-only memory, random access memory, flash memory) or a hard disk.
[0330] "Storage" type media may include computers, processors, etc. or their related modules, such as any or all tangible memories of various semiconductor memories, tape drives, disk drives, etc., which can provide non-temporary storage for software programming at any time. All or part of the software can sometimes communicate through the Internet or various other communication networks. For example, such communication can make it possible to load the software from one computer or processor to another computer or processor, for example, from a management server or a mainframe to a computer platform of an application server. Therefore, another type of medium that can carry software elements includes light waves, electric waves, and electromagnetic waves such as across physical interfaces between local devices, through wired and optical fiber landline networks, and used on various air links (air-link). Physical elements that carry such waves, such as wired or wireless links, optical links, etc., can also be considered as media that carry software. As used herein, unless limited to non-transient, tangible storage media, "medium" may include other types of (intangible) media.
[0331] Terms such as "storage" media, such as computer or machine "readable media," refer to any tangible (eg, physical), non-transitory media that participate in providing instructions to a processor for execution.
[0332] Thus, machine-readable media, such as computer executable code, may take many forms, including but not limited to tangible storage media, carrier media, or physical transmission media. Non-volatile storage media include, for example, optical or magnetic disks, such as any storage device shown in the accompanying drawings in any computer, etc., such as may be used to implement a database, etc. Volatile storage media include dynamic memory, such as the main memory of such a computer platform. Tangible transmission media include coaxial cables; copper wire and optical fiber, including the wires that make up a bus within a computer system. Carrier transmission media may take the form of electrical or electromagnetic signals, or acoustic or light waves, such as those generated during radio frequency (RF) and infrared (IR) data communications. Thus, common forms of computer-readable media include, for example: a floppy disk, a flexible disk, a hard disk, a magnetic tape, any other magnetic medium, a CD-ROM, a DVD or DVD-ROM, any other optical medium, a punched card stock tape, any other physical storage medium with a pattern of holes, a RAM, a ROM, a PROM and an EPROM, a FLASH-EPROM, any other memory chip or cartridge, a carrier wave that transports data or instructions, a cable or link that transports such a carrier wave, or any other medium from which a computer can read programming code and / or data. Many of these forms of computer-readable media can participate in carrying one or more strings of one or more instructions to a processor for execution.
[0333] Computer system 210 may include or communicate with an electronic display 935 that includes a user interface (UI) for providing, for example, reports. Examples of UIs include, but are not limited to, graphical user interfaces (GUIs) and web-based user interfaces.
[0334] The methods and systems of the present disclosure may be implemented in the form of one or more algorithms. The algorithms may be implemented in the form of software when executed by the processor 220.
[0335] V. Example
[0336] Example 1
[0337] Disclosed herein are examples of accurate genotyping of HLA and KIR alleles using cfDNA assays and k-mer-based algorithms for immunotherapy.
[0338] HLA and KIR genotypes show great promise as emerging biomarkers for immune checkpoint inhibitors (ICIs) and understanding patient prognosis. Multiple studies have shown that HLA-I heterozygosity and high sequence differences between alleles are positively correlated with response to ICIs. However, the high polymorphism and allelic sequence similarity of HLA and KIR pose challenges to accurate allele calling. To address these difficulties, Kmerizer, a new allele caller optimized for short fragments (such as germline reads from cfDNA assays), was developed.
[0339] Methods and Results
[0340] HLA and KIR typing using Kmerizer can include HLA and KIR panel coverage, including HLA loci: A, B, C, DPA1, DPB1, DQA1, DQB1, DRB1, DRB3, DRB4, DRB5, E, F, G; and KIR loci: 2DL1, 2DL2, 2DL3, 2DL4, 2DL5, 2DP1, 2DS1, 2DS2, 2DS3, 2DS4, 2DS5, 3DL1, 3DL2, 3DL3, 3DP1, 3DS1.
[0341] HLA and KIR sequences show high levels of homology between allele sets ( Fig.11 ). Kmerizer calls HLA and KIR alleles in a sample based on a set of known alleles. The module kmerizer can be run in two modes: build index mode or call allele mode ( Fig.12). In build index mode, running without sample bam files in input will cause the algorithm to generate a kmer mapping index file. In call allele mode, running with sample bam files in input will cause the algorithm to call alleles based on the kmer mapping index file generated with "build index" mode. Build index generates kmer mappings based on given kmer sizes and known allele fasta files. Calling alleles is based on sample bam files and kmer mappings are generated as done in build index.
[0342] Kmerizer uses the existing HLA nomenclature system to encode alleles as a tree, where each leaf node represents an allele sequence and each leaf node propagates its count to its parent node. Fig.13 is an example of a hierarchical structure of allele names. HLA allele names are encoded by a string such as A*01:02:03:04, which contains the gene name (A, for HLA-A) and up to four sets of numbers. When examining two allele names: matching the first two sets of numbers - the alleles encode the same protein, but they may have different genomic contents at the exon level; matching the first three sets of numbers - the alleles have the same genomic content at the exon level (their bases are the same in the exons); and matching all four sets of numbers - the alleles have the same genomic content in both exons and introns. For KIR, when examining two allele names: matching the first three numbers - the alleles encode the same protein; and matching the first five numbers - the alleles have the same genomic content at the exon level (their bases are the same in the exons). The system can be configured to emit the most likely candidate alleles based on the desired resolution: for example, classification based on the second level produces allele types at peptide resolution; classification based on the third / fourth level produces allele types at nucleic acid resolution.
[0343] Kmerizer has been used in HLA typing with simulated samples ( Fig.15 ) and KIR typing ( Fig.16 ). The simulation randomly selected 2 alleles from each locus in the IMGT database and simulated allele reads from NGS with sequencing errors. In a separate evaluation simulation, Kmerizer was challenged with allele pairs with sequence identity exceeding 95%. We also performed HISAT genotyping analysis on the same set of samples for method comparison.
[0344] The kmerizer was also tested for typing performance on gDNA derived from cell lines validated by orthogonal methods. Fig.17 The HLA typing performance of the kmerizer was evaluated on 19 cell line samples from 1999 to 2011, of which 15 samples were derived from sonicated gDNA and 4 samples were derived from cell line culture media. Finally, the typing consistency of the kmerizer was evaluated on plasma cfDNA collected from healthy donors compared with buffy coat gDNA.
[0345] In 19 cell lines and 12 plasma samples for HLA typing (A, B, C, and DQB1 loci), kmerizer provided 100% sensitivity and 98% specificity. On simulated datasets, for both homozygous and heterozygous pairs, kmerizer achieved 99% sensitivity and specificity on all MHC class 1 and class 2 loci and 90% sensitivity and specificity on all KIR loci. The allele caller kmerizer also demonstrated a light footprint on computing resource requirements: on average, one deep sequenced plasma sample can be processed in less than 2 minutes, which is about 15 times faster than the most commonly used HLA typing tool, HISAT Genotyping, which does not support KIR typing.
[0346] in conclusion
[0347] The fragment sizes in cfDNA are shorter than in genomic DNA, and existing state-of-the-art methods such as HISAT genotyping have limited ability to accurately call alleles. A new algorithm, Kmerizer, was developed and it is able to type HLA and KIR alleles with cfDNA-like fragments.
[0348] The Kmerizer achieved high sensitivity and specificity on both simulated data and well-characterized cell lines, and it achieved high concordance between plasma and buffy coat DNA.
[0349] The simplicity of Kmerizer enables transparency between sequencing data and the final reported alleles, and it has a fast turnaround time and minimal hardware required.
[0350] As ICI use increases, it is critical to use genetic and genomic information to accurately identify patients who are more likely to respond to ICIs. The ability to type HLA / KIR in cfDNA workflows is important to provide cost-effective and comprehensive cancer care through liquid biopsies.
[0351] Example 2
[0352] HLA germline genotype and somatic mutations show great promise as emerging biomarkers for immune checkpoint inhibitors (ICIs) and understanding patient prognosis. Multiple studies have shown that HLA homozygosity or loss-of-function somatic mutations are negatively correlated with ICI response rates. High HLA fidelity can be used to accurately model the patient neoantigen landscape and provide further prognostic insights for these patients and identify patients who may particularly benefit from IO therapy.
[0353] Additional data about the methods and systems described herein (referred to as Kmerizer) are presented, which are configured to perform HLA germline typing and / or somatic mutation detection from cfDNA input material. These results can be used for computer simulation of new antigens and patient outcome prediction.
[0354] Methods and Results
[0355] Kmerizer can leverage the high depth of coverage of targeted sequencing to rapidly identify germline alleles by matching k-mers from input reads to k-mers of known HLA and KIR alleles. Somatic variant calling can be performed after realigning reads to the called germline.
[0356] MHC-I germline allele calls can be combined with patient mutation data to generate in silico TCR binding affinity predictions using, for example, netMHC-4.01. These predictions can be compared across cohorts to assess how cancer type and bTMB vary with predicted neoantigens and TCR binding affinity.
[0357] In 19 cell lines, 12 plasma samples, and 8 gDNA samples with confirmed HLA typing information, Kmerizer provided high sensitivity and specificity for both MHC-I and II genes based on methylation epigenome detection of cfDNA sequencing data. High accuracy for class I and class II genes was achieved for both homozygous and heterozygous states (Table 2). Table 2 shows the Kmerizer germline allele calling performance on a data set with confirmed HLA typing information.
[0358]
[0359] The prevalence of HLA germline alleles between samples tested for the methylation epigenome was consistent with that of a reference cohort of similar geographic origin in MHC class I genes ( Fig.18 ). Fig.18Shown is a comparison of HLA germline allele prevalence between methylation epigenome assay samples (n=2004) and Allele Frequency Net Database (AFND) genotype data from different geographic regions (Europe, n=1000; North America, n=496; Northeast Asia, n=1510; Central and South America, n=1463; Southeast Asia, n=5266). Alleles of particular clinical interest are highlighted by the "X" above.
[0360] Counts of germline HLA alleles predicted to be immunogenic neoantigens (ic50 rating <1%; subset of 9mer length neoantigens) were plotted across methylated epigenomic assay development samples. Fig.19 The resulting distribution shown in is generally similar to Fig. 20 The overall germline HLA allele distribution among all methylated epigenome assayed samples is shown in Figure 2, indicating that neoantigen prediction is not significantly biased towards a specific allele set.
[0361] Notably, allele counts for immunogenic neoantigen predictions with netMHC support were compared with those without predictions (inset table; for methylated epigenome assay development samples only) and revealed a significant association between HLA allele groups (HLA-A / B / C) and immunogenicity predictions, with more HLA-A alleles predicted immunogenicity than HLA-B and HLA-C alleles in patients.
[0362] The Kmerizer somatic caller achieves >99.99% specificity per base, as calculated for MHC class I genes of 48 normal samples. For sensitivity assessment, simulated sequencing data were generated with randomly selected somatic variants with an expected allele frequency (AF) of 0.15% to 0.2% ( Fig.21 ). Fig.21 Shown is the random assignment of germline alleles and homozygous / heterozygous status based on AFND to generate germline reads using a reference from the IMGT / HLA database; somatic mutations are then randomly generated at exonic positions, and mutant reads are then generated from the altered reference.
[0363] For both variant detection and mutant molecule recovery, the Kmerizer somatic caller achieved 100% specificity and 97.5% aggregate sensitivity for class I genes (Table 3). Table 3 shows the Kmerizer somatic allele calling performance on simulated data. The detected variants observed an AF range of [0.08%, 2.3%] and a median of 0.18% ( Fig. 22 ). Fig. 22Variant allele frequency (AF) distributions of detected variants are shown.
[0364]
[0365] Kmerizer uses germline HLA calls for neoantigen prediction. Using matched germline allele calls and mutation data, 53,107 neoantigens were generated from 533 clinical cancer samples with netMHC-4.0. Patients' top-ranked neoantigen TCR binding affinity was strongly correlated with bTMB scores determined by methylation epigenomic profiling (ρ=-0.524, p<0.0001). Grouping patients by HLA allele associated with the strongest binding affinity prediction indicated that this association was consistent across genes ( Fig.23 ). Fig.23 TMB v. predicted neoepitope affinity across genes is shown. Spearman correlations for each group are listed.
[0366] In the absence of expression data, samples with average somatic neoantigen binding affinity greater than germline affinity were selected (N=122).
[0367] Comparison of the patients' binding affinity (ic50) of the highest predicted neoantigen binding affinity to bTMB indicated a strong negative correlation between TMB score and putative TCR binding (Rhospearman = -0.524, p < 0.0001).
[0368] To understand whether this relationship was driven by neoantigen prediction of only one or some HLA alleles, we subsetted patients by the HLA allele with the highest neoantigen prediction and recalculated the correlations, finding that the same association held across HLA genes ( Fig.23 :HLA-A / B / C; right panel).
[0369] Furthermore, we determined that this relationship persisted between alleles within the HLA gene. Looking at the HLA-A alleles with the highest overall HLA-A neoantigen prediction >5%, we identified four alleles: HLA-A*02:01, HLA-A*03:01, HLA-A*11:01, and HLA-A*31:01. Plotting samples of the neoantigens with the strongest potential binding affinity among these alleles against patient bTMB indicated that the association between increased bTMB and stronger binding affinity applied to all 4 alleles (RhoHLA-A*02:01 = -0.683, p < 0.0001; RhoHLA-A*03:01 = -0.485, p < 0.005; RhoHLA-A*11:01 = -0.682, p < 0.0005; RhoHLA-A*02:01 = -0.453, p = 0.103).
[0370] The ratio of immunogenic neoantigens (IC50 level <2%) varied significantly between different sample cancer types (χ2=12.04, p=0.017; Fig.24 , illustration table). Fig.24 The distribution of neoantigen binding affinity by cancer type is shown. Comparison of immunogenic neoantigen binding affinity across cancer types identified bladder cancer and melanoma cancer samples as those with the highest immunogenic potential and colorectal cancer as immunologically cold (ks test, p<0.005; Fig.24 ; stronger binding is indicated by smaller ic50 scores).
[0371] Dev samples were filtered to only those with a median predicted neoantigen TCR affinity greater than the matched median germline TCR affinity. In the absence of expression data to identify mutant peptide expression levels, this filtering helps subset patients more likely to have neoantigens that stimulate a CD8+ T cell response compared to the background "noise" of germline-derived antigens.
[0372] To determine if there were cancer type-specific effects on the ratio of immunogenic neoantigen targets, all predictions were classified as immunogenic (“strong binding”) or non-immunogenic (“likely no CD8+ binding”) based on netMHC percentile rank (rank < 1%). The ratio of immunogenic neoantigen targets by cancer type was compared by chi-square test, and a significant effect was found ( Fig.24 :X2=12.04, p=0.017; inset table).
[0373] Cumulative density plot of immunogenic neoantigens by cancer type ( Fig.24, right) shows the immunostimulatory potential of each group (affinity is represented by IC50, meaning lower values indicate stronger TCR binding potential). These distributions show that within this group, melanoma and bladder cancer have on average higher immunogenic potential, while colorectal cancer has the lowest potential (most likely to be a "cold" tumor).
[0374] in conclusion
[0375] Integration of Kmerizer into methylation epigenomic testing enables accurate HLA germline and somatic detection and neoantigen prediction. Kmerizer demonstrates that HLA germline prevalence correlates with public data. Kmerizer demonstrates HLA somatic specificity in 48 normal samples and sensitivity in simulations. Kmerizer demonstrates neoantigen prediction analysis in clinical samples.
[0376] Non-limiting embodiments are described below:
[0377] Embodiment 1: A method, comprising determining more than one known allele sequence, determining more than one sequence reads of a target region of a subject's chromosome, wherein the target region of the chromosome comprises one or more loci, aligning the more than one sequence reads with the more than one known allele sequence, and based on the alignment, for each known allele sequence in the more than one known allele sequence, determining the number of sequence reads aligned with each known allele sequence, and for one or more loci, determining the known allele sequence present at the one or more loci based on the number of sequence reads aligned with each known allele sequence.
[0378] Embodiment 2: The method according to embodiment 1, wherein the more than one known allele sequence comprises more than one known human leukocyte antigen (HLA) allele sequence or more than one known killer cell immunoglobulin-like receptor (KIR) region allele sequence.
[0379] Embodiment 3: The method according to embodiment 1, further comprising obtaining a sample from the subject and sequencing the sample to obtain more than one sequence read of the target region of the chromosome.
[0380] Embodiment 4: The method according to embodiment 1 further comprises, based on the alignment, determining, for each of the more than one sequence reads, one or more known allele sequences to which each read is aligned.
[0381] Embodiment 5: The method according to embodiment 1, wherein the target region comprises one or more of the following genes: HLA-A, HLA-B, HLA-C, HLA-E, HLA-F, HLA-G, HLA-H, HLA-J, HLA-K, HLA-L, HLA-N, HLA-P, HLA-S, HLA-T, HLA-U, HLA-V, HLA-W, HLA-DRA, HLA-DRB1, HLA-DRB2, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-DRB6, HLA-DRB7, HLA-DRB8, HLA-DRB9, HLA-DQA1, HLA-DQB1, HLA-DQA2, HLA-DQA3, HLA-DQA4, HLA-DQA5, HLA-DQA6, HLA-DQA7, HLA-DQA8, HLA-DQA9, HLA-DQA10, HLA-DQA21, HLA-DQA32, HLA-DQA43, HLA-DQA53, HLA-DQA64, HLA-DQA75, HLA-DQA8, HLA-DQA9, HLA-DQA11, HLA-DQA22, HLA-DQA33, HLA-DQA44, HLA-DQA55, HLA-DQA65, HLA-DQA77, HLA-DQA8 LA-DQB2, HLA-DQB3, HLA-DOA, HLA-DOB, HLA-DMA, HLA-DMB, HLA-DPA1, HLA-DPB1, HLA-DPA2, HLA-DPB2, HLA-DPA3, HFE, TAP1, TAP2, PSMB9, PSMB8, MICB, MIC A. MICC, MICD, MICE, KIR2DL1, KIR2DL2 / L3, KIR2DL4, KIR2DL5A, KIR2DL5B, KIR2DS1, KIR2DS2, KIR2DS3, KIR2DS4, KIR2DS5, KIR3DL1 / S1, KIR3DL2, or KIR3DL3.
[0382] Embodiment 6: The method according to embodiment 1, wherein the target region comprises chromosome position 6p21 or chromosome position 19q13.
[0383] Embodiment 7: The method according to embodiment 1, wherein the target region comprises at least a portion of the major histocompatibility complex (MHC) region, and the chromosome is human chromosome 6.
[0384] Embodiment 8: The method according to embodiment 1, wherein the target region includes at least a portion of a killer cell immunoglobulin-like receptor (KIR) region, and the chromosome is human chromosome 19.
[0385] Embodiment 9: A method according to embodiment 1, wherein determining more than one known allele sequence includes retrieving sequence data of the known alleles, determining more than one k-mer sequence based on the sequence data of the known alleles, and assembling the more than one k-mer sequence into a data structure comprising more than one entry, wherein each entry comprises the k-mer sequence, the number of alleles containing the k-mer sequence, an allele identifier for each allele containing the k-mer sequence, and the starting and ending positions of the k-mer sequence in each allele.
[0386] Embodiment 10: According to the method of embodiment 1, based on the comparison, for each known allele sequence in more than one known allele sequence, determining the number of sequence reads aligned with each known allele sequence includes determining the number of sequence reads aligned with each known allele sequence and having 100% identity.
[0387] Embodiment 11: A method according to embodiment 1, wherein based on the number of sequence reads aligned to each known allele sequence, for one or more loci, determining the known allele sequences present at the one or more loci includes determining one or more known allele sequences having the highest number of aligned sequence reads.
[0388] Embodiment 12: The method according to embodiment 1, wherein the reads aligned to each known allele sequence are grouped into read families, and the method further comprises determining the number of sequence read families aligned to each known allele sequence.
[0389] Embodiment 13: A method according to embodiment 1, wherein for one or more loci, known allele sequences present at the one or more loci are determined based on the number of sequence read families that align to each known allele sequence.
[0390] Embodiment 14: The method according to embodiment 1, further comprising determining the length of a portion of each known allele sequence that aligns with two or more sequence reads in the more than one sequence reads.
[0391] Embodiment 15: According to the method of embodiment 1, it also includes: for a locus, sorting the known allele sequences present at the locus by the number of sequence reads aligned with each known allele sequence, for the locus, determining a first known allele sequence with the highest number of aligned sequence reads, inserting the first known allele sequence with the highest number of aligned sequence reads into a superset, determining one or more known allele sequences aligned with reads that are a subset of the reads aligned with the first known allele sequence, and inserting the one or more known allele sequences into the superset.
[0392] Embodiment 16: A method according to Embodiment 15, wherein the superset includes a graph data structure.
[0393] Embodiment 17: A method according to Embodiment 16, wherein the graph data structure comprises a directed acyclic graph.
[0394] Embodiment 18: The method of Embodiment 16, wherein the graph data structure represents a Hasse graph.
[0395] Embodiment 19: The method of embodiment 15, further comprising determining that the locus is associated with a single superset, and determining the first known allele sequence of the single superset as the allele present at the locus.
[0396] Embodiment 20: The method of embodiment 15, further comprising determining more than one superset of loci.
[0397] Embodiment 21: The method according to embodiment 20 also includes determining two supersets with the largest cumulative number of different reads based on more than one superset of the locus, and determining the first known allele sequence in each of the two supersets as the allele present at the locus.
[0398] Embodiment 22: The method of embodiment 1, further comprising facilitating communication of known allele sequences present at one or more loci to a medical provider.
[0399] Embodiment 23: A method according to embodiment 1, wherein the known allele sequence present at the locus includes the human leukocyte antigen (HLA) type at the locus or the killer cell immunoglobulin-like receptor (KIR) type at the locus.
[0400] Embodiment 24: The method according to embodiment 1, further comprising obtaining a sample from the cells to be transplanted into the subject, and sequencing the sample to obtain more than one sequence read of the target region of the chromosome.
[0401] Embodiment 25: The method according to Embodiment 24, further comprising determining whether the subject's HLA type matches the HLA type at the locus.
[0402] Embodiment 26: The method of Embodiment 25, further comprising transplanting the cells into the subject if the subject's HLA type matches the HLA type at the locus.
[0403] Embodiment 27: The method of Embodiment 25, further comprising transplanting the cells into the subject if the subject's HLA type matches the HLA type at the locus, and administering an agent that reduces the likelihood of transplant rejection in the subject.
[0404] Embodiment 28: According to the method of embodiment 1, it also includes determining that the subject is susceptible to developing rheumatoid arthritis (RA), wherein the known allele sequences present at one or more loci include HLA-DRB1*04:01, *04:04 and *04:08; HLA-DRB1*04:05; HLA-DRB1*01:01 and *01:02; HLA-DRB1*14:02; HLA-DRB1*10:01; and HLA-DRB1*01:01, *04:01, *04:04 and *04:05.
[0405] Embodiment 29: According to the method of embodiment 1, it also includes determining that the subject is susceptible to developing multiple sclerosis (MS), wherein the known allele sequences present at one or more loci include HLA-DRB1*15:01, HLA-DQB1*06:02, HLA-DRB1*01:08, HLA-DRB1*03:01 and / or HLA-DRB1*13:03.
[0406] Embodiment 30: According to the method of embodiment 1, it also includes determining that the subject is susceptible to developing systemic lupus erythematosus (SLE), wherein the known allele sequences present at one or more loci include HLA-DRB1, HLA-DR2 (DRB1*15:01), HLA-DR3 (DRB1*03:01), HLA-DRB1*08:01 and / or HLA-DQA1*01:02.
[0407] Embodiment 31: The method according to embodiment 1 further comprises determining that the subject is susceptible to developing type 1 diabetes (T1D), wherein the known allele sequences present at one or more loci include HLA-DQB1*03:02 and / or DQB1*02:01.
[0408] Embodiment 32: The method according to embodiment 1 further comprises determining that the subject is susceptible to developing Sjögren's syndrome (SS), wherein the known allele sequences present at one or more loci include DQA1*05:01, DQB1*02:01 and DRB1*03:01.
[0409] Embodiment 33: The method according to embodiment 1 further includes determining that the subject is susceptible to developing celiac disease (CD), wherein the known allele sequences present at one or more loci include HLA-DQ2 (encoded by HLA-DQA1*05:01-DQB1*02:01) and / or HLA-DQ8 (encoded by DQA1*03:01-DQB1*03:02).
[0410] Embodiment 34: The method according to embodiment 1, further comprising determining that the subject is susceptible to developing pre-eclampsia, wherein the known allelic sequences present at the one or more loci include KIR2DL1.
[0411] Embodiment 35: The method of embodiment 1, further comprising determining that the subject is unlikely to progress from HIV infection to AIDS, wherein the known allelic sequences present at the one or more loci include KIR3DS1.
[0412] Embodiment 36: The method of embodiment 1, further comprising determining that the subject is unlikely to progress from HIV infection to AIDS, wherein the known allele sequences present at the one or more loci include a combination of KIR3DS1 and HLA-Bw4.
[0413] Embodiment 37: The method according to embodiment 1, further comprising determining that the subject is susceptible to developing an autoimmune disease, wherein the known allelic sequences present at the one or more loci include KIR2DS1.
[0414] Embodiment 38: The method according to embodiment 1, further comprising determining that the subject is susceptible to developing Crohn's disease, wherein the known allele sequences present at the one or more loci include KIR2DL2 / KIR2DL3 heterozygosity.
[0415] Embodiment 39: The method according to embodiment 1, further comprising determining that the subject is susceptible to developing Crohn's disease, wherein the known allele sequences present at the one or more loci include a combination of KIR2DL2 / KIR2DL3 heterozygosity and HLA-C2 alleles.
[0416] Embodiment 40: The method according to embodiment 1, further comprising determining whether the subject is a suitable candidate for a donor in an unrelated hematopoietic cell transplant, wherein the known allele sequences present at one or more loci include a group B KIR haplotype.
[0417] Embodiment 41: A method comprising determining more than one known human leukocyte antigen (HLA) allele sequence, determining more than one sequence reads of a target region of a chromosome of a subject, wherein the target region of the chromosome comprises one or more loci, aligning the more than one sequence reads with more than one known HLA allele sequence, and based on the alignment, for each known HLA allele sequence in the more than one known HLA allele sequence, determining the number of sequence reads aligned with each known HLA allele sequence, generating one or more supersets of known HLA allele sequences based on the number of sequence reads aligned with each known HLA allele sequence, and determining, for one or more loci, the known HLA allele sequence present at the one or more loci based on the number of different reads in the one or more supersets of known HLA allele sequences.
[0418] Embodiment 42: A method comprising determining more than one known killer cell immunoglobulin-like receptor (KIR) allele sequence, determining more than one sequence reads of a target region of a chromosome of a subject, wherein the target region of the chromosome comprises one or more loci, aligning the more than one sequence reads with more than one known KIR allele sequence, and based on the alignment, for each known KIR allele sequence in the more than one known KIR allele sequence, determining the number of sequence reads aligned with each known KIR allele sequence, generating one or more supersets of known KIR allele sequences based on the number of sequence reads aligned with each known KIR allele sequence, and determining, for one or more loci, the known KIR allele sequence present at the one or more loci based on the number of different reads in the one or more supersets of known KIR allele sequences.
[0419] Embodiment 43: A method, comprising determining more than one known allele sequence, determining more than one sequence reads of a target region of a subject's chromosome, wherein the target region of the chromosome comprises one or more loci, aligning the more than one sequence reads with the more than one known allele sequence, and based on the alignment, for each known allele sequence in the more than one known allele sequence, determining the number of sequence reads aligned with each known allele sequence, generating one or more supersets of known allele sequences based on the number of sequence reads aligned with each known allele sequence, and determining, for one or more loci, the known allele sequence present at the one or more loci based on the number of different reads in the one or more supersets of known allele sequences.
[0420] Embodiment 44: One or more non-transitory computer-readable media having stored thereon processor-executable instructions that, when executed by a processor, cause the processor to perform a method according to any one of Embodiments 1-43.
[0421] Embodiment 45: A system comprising a computing device configured to perform the method of any of Embodiments 1-43 and an output device configured to output an indication of a known allele sequence present at one or more loci.
[0422] Embodiment 46: A device comprising one or more processors and a memory storing processor-executable instructions, which when executed by the one or more processors cause the device to perform a method according to any one of Embodiments 1-43.
[0423] Embodiment 47: A method comprising determining more than one sequence read or read pair of a target region of a chromosome of a subject, wherein the target region of the chromosome comprises one or more loci, generating alignments of more than one sequence read or read pair with more than one known sequence, generating alignments of more than one sequence read or read pair with more than one bait sequence, comparing the alignments of the sequence read or read pair with the known sequences with the alignments of the sequence read or read pair with respect to the bait sequence, wherein when the alignment score of the sequence read or read pair with respect to the known sequence is greater than the alignment score of the sequence read or read pair with respect to the bait sequence, the sequence read or read pair is associated with the known sequence, and identifying the sequence read or read pair as a supporting sequence read or read pair for the sequence of interest.
[0424] Embodiment 48: The method according to Embodiment 47, further comprising obtaining a sample from the subject and sequencing the sample to obtain more than one sequence read or read pair of the target region of the chromosome.
[0425] Embodiment 49: The method of embodiment 47, wherein the target region comprises one or more of the following genes: HLA-A, HLA-B, HLA-C, HLA-E, HLA-F, HLA-G, HLA-H, HLA-J, HLA-K, HLA-L, HLA-N, HLA-P, HLA-S, HLA-T, HLA-U, HLA-V, HLA-W, HLA-DRA, HLA-DRB1, HLA-DRB2, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-DRB6, HLA-DRB7, HLA-DRB8, HLA-DRB9, HLA-DQA1, HLA-DQB1, HLA-DQA2, HLA-DQB2, HLA-DQB3, HLA-DOA, HLA-DOB, HLA-DMA, HLA-DMB, HLA-DPA1, HLA-DPB1, HLA-DPA2, HLA-DPB2, HLA-DPA3, HFE, TAP1, TAP2, PSMB9, PSMB8, MICB, MIC A. MICC, MICD, MICE, KIR2DL1, KIR2DL2 / L3, KIR2DL4, KIR2DL5A, KIR2DL5B, KIR2DS1, KIR2DS2, KIR2DS3, KIR2DS4, KIR2DS5, KIR3DL1 / S1, KIR3DL2, or KIR3DL3.
[0426] Embodiment 50: The method according to embodiment 47, wherein the target region comprises chromosome position 6p21 or chromosome position 19q13.
[0427] Embodiment 51: The method according to embodiment 47, wherein the target region comprises at least a portion of the major histocompatibility complex (MHC) region and the chromosome is human chromosome 6.
[0428] Embodiment 52: The method of embodiment 47, wherein the target region comprises at least a portion of a killer cell immunoglobulin-like receptor (KIR) region and the chromosome is human chromosome 19.
[0429] Embodiment 53: A method according to embodiment 47, wherein the more than one known sequence comprises more than one known human leukocyte antigen (HLA) allele sequence or more than one known human killer cell immunoglobulin-like receptor (KIR) region allele sequence.
[0430] Embodiment 54: A method according to Embodiment 47, wherein the more than one decoy sequence comprises more than one non-human sequence.
[0431] Embodiment 55: The method of Embodiment 54, wherein the more than one non-human sequence comprises one or more of more than one bovine sequence, more than one rat sequence, or more than one microbial sequence.
[0432] Embodiment 56: A method according to embodiment 47, wherein generating an alignment of more than one sequence read or read pair with more than one known sequence includes, based on the alignment, determining, for the sequence reads or read pairs in the more than one sequence reads or read pairs, one or more known sequences that align with each read of each sequence read or read pair without having mismatches or insertions / deletions.
[0433] Embodiment 57: According to the method of embodiment 56, it also includes determining, based on the comparison, for each known sequence of more than one known sequence, the number of sequence reads or the number of read pairs aligned with each known sequence, and based on the number of sequence reads or the number of read pairs aligned with each known sequence, determining, for one or more loci, the known sequences present at one or more loci.
[0434] Embodiment 58: A method according to embodiment 47, wherein generating an alignment of more than one sequence read or read pair with more than one bait sequence includes, based on the alignment, determining, for the sequence reads or read pairs, one or more bait sequences that align with each sequence read or read pair without mismatches or insertions / deletions, and discarding the sequence reads or read pairs.
[0435] Embodiment 59: A method according to embodiment 47, wherein generating an alignment of more than one sequence read or read pair with more than one bait sequence includes, based on the alignment, determining, for the sequence reads or read pairs, one or more non-human bait sequences that align with each sequence read or read pair without mismatches or insertions / deletions, and identifying the sequence reads or read pairs as originating from a contaminated sample.
[0436] Embodiment 60: A method according to embodiment 47, wherein generating an alignment of more than one sequence read or read pair with more than one known sequence includes, based on the alignment, determining, for the sequence reads or read pairs, one or more known sequences that are aligned with each sequence read or read pair and have at least one mismatch or insertion / deletion, and generating an alignment score for the known sequences.
[0437] Embodiment 61: A method according to embodiment 47, wherein generating an alignment of more than one sequence read or read pair with more than one bait sequence includes, based on the alignment, determining, for the sequence reads or read pairs, one or more bait sequences that are aligned with each sequence read or read pair and have at least one mismatch or insertion / deletion, and generating an alignment score for the bait sequence.
[0438] Embodiment 62: A method according to Embodiment 47, wherein the alignment score against the known sequence and the alignment score against the bait sequence each comprise at least one mismatch and / or insertion / deletion.
[0439] Embodiment 63: A method according to Embodiment 47, wherein identifying a sequence read or a read pair as a supporting sequence read or a read pair for a sequence of interest comprises identifying a reference variant among one or more reference variants as a candidate variant based on aligning the sequence read or the read pair with one or more reference variants.
[0440] Embodiment 64: A method according to embodiment 47, wherein identifying a sequence read or a read pair as a supporting sequence read or a read pair for a sequence of interest includes identifying a non-human reference variant among the one or more non-human reference variants as a candidate variant based on aligning the sequence read or the read pair with one or more non-human reference variants, and identifying the sequence read or the read pair as originating from a contaminated sample.
[0441] Embodiment 65: A method according to embodiment 47, wherein generating an alignment of more than one sequence reads or read pairs with more than one known sequence includes determining read pairs that align with at least two of the more than one known sequences and selecting one of the at least two known sequences.
[0442] Embodiment 66: A method according to embodiment 47, wherein generating an alignment of more than one sequence reads or read pairs with more than one bait sequence includes determining read pairs that align with at least two bait sequences among the more than one bait sequences, and selecting one bait sequence among the at least two bait sequences.
[0443] Embodiment 67: A method comprising determining more than one sequence read or read pair for a target region of a chromosome of a subject, wherein the target region of the chromosome comprises one or more loci, generating alignments of more than one sequence read or read pair with more than one known allele sequence, generating alignments of more than one sequence read or read pair with more than one bait allele sequence, comparing the alignments of the sequence read or read pair with the known alleles with the alignments of the sequence read or read pair with the bait allele sequence, wherein when the alignment score of the sequence read or read pair with the known allele sequence is greater than the alignment score of the sequence read or read pair with the bait allele sequence, the sequence read or read pair is associated with the germline allele, and identifying the sequence read or read pair as a supporting sequence read or read pair for a candidate somatic variant.
[0444] Embodiment 68: The method according to embodiment 67, further comprising obtaining a sample from the subject and sequencing the sample to obtain more than one sequence read or read pair of the target region of the chromosome.
[0445] Embodiment 69: The method of embodiment 67, wherein the target region comprises one or more of the following genes: HLA-A, HLA-B, HLA-C, HLA-E, HLA-F, HLA-G, HLA-H, HLA-J, HLA-K, HLA-L, HLA-N, HLA-P, HLA-S, HLA-T, HLA-U, HLA-V, HLA-W, HLA-DRA, HLA-DRB1, HLA-DRB2, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-DRB6, HLA-DRB7, HLA-DRB8, HLA-DRB9, HLA-DQA1, HLA-DQB1, HLA-DQA2, HLA-DQB2, HLA-DQB3, HLA-DOA, HLA-DOB, HLA-DMA, HLA-DMB, HLA-DPA1, HLA-DPB1, HLA-DPA2, HLA-DPB2, HLA-DPA3, HFE, TAP1, TAP2, PSMB9, PSMB8, MICB, MIC A. MICC, MICD, MICE, KIR2DL1, KIR2DL2 / L3, KIR2DL4, KIR2DL5A, KIR2DL5B, KIR2DS1, KIR2DS2, KIR2DS3, KIR2DS4, KIR2DS5, KIR3DL1 / S1, KIR3DL2, or KIR3DL3.
[0446] Embodiment 70: The method according to embodiment 67, wherein the target region comprises chromosome position 6p21 or chromosome position 19q13.
[0447] Embodiment 71: The method according to embodiment 67, wherein the target region comprises at least a portion of the major histocompatibility complex (MHC) region and the chromosome is human chromosome 6.
[0448] Embodiment 72: The method of embodiment 67, wherein the target region comprises at least a portion of a killer cell immunoglobulin-like receptor (KIR) region and the chromosome is human chromosome 19.
[0449] Embodiment 73: A method according to embodiment 67, wherein the more than one known allele sequence comprises more than one known human leukocyte antigen (HLA) allele sequence or more than one known human killer cell immunoglobulin-like receptor (KIR) region allele sequence.
[0450] Embodiment 74: A method according to embodiment 67, wherein the more than one decoy allele sequence comprises more than one non-human sequence.
[0451] Embodiment 75: The method of Embodiment 74, wherein the more than one non-human sequence comprises one or more of more than one bovine sequence, more than one rat sequence, or more than one microbial sequence.
[0452] Embodiment 76: A method according to embodiment 67, wherein generating an alignment of more than one sequence read or read pair with more than one known allele sequence includes, based on the alignment, determining, for the sequence reads or read pairs in the more than one sequence reads or read pairs, one or more known allele sequences that align with each read of each sequence read or read pair without mismatches or insertions / deletions.
[0453] Embodiment 77: According to the method of embodiment 76, it also includes determining, based on the comparison, for each known allele sequence in more than one known allele sequence, the number of sequence reads or the number of read pairs aligned with each known allele sequence, and based on the number of sequence reads or the number of read pairs aligned with each known allele sequence, determining, for one or more loci, the known allele sequences present at one or more loci.
[0454] Embodiment 78: A method according to embodiment 67, wherein generating an alignment of more than one sequence read or read pair with more than one bait allele sequence includes, based on the alignment, for the sequence reads or read pairs, determining one or more bait allele sequences that align with each sequence read or read pair without mismatches or insertions / deletions, and discarding the sequence reads or read pairs.
[0455] Embodiment 79: A method according to embodiment 67, wherein generating an alignment of more than one sequence read or read pair with more than one bait allele sequence includes, based on the alignment, determining, for the sequence reads or read pairs, one or more non-human bait allele sequences that align with each sequence read or read pair without mismatches or insertions / deletions, and identifying the sequence reads or read pairs as originating from a contaminated sample.
[0456] Embodiment 80: A method according to embodiment 67, wherein generating an alignment of more than one sequence read or read pair with more than one known allele sequence includes, based on the alignment, determining, for the sequence reads or read pairs, one or more known allele sequences that align with each sequence read or read pair and have at least one mismatch or insertion / deletion, and generating an alignment score for the known allele sequence.
[0457] Embodiment 81: A method according to embodiment 67, wherein generating an alignment of more than one sequence read or read pair with more than one bait allele sequence includes, based on the alignment, for the sequence reads or read pairs, determining one or more bait allele sequences that are aligned with each sequence read or read pair and have at least one mismatch or insertion / deletion, and generating an alignment score for the bait allele sequence.
[0458] Embodiment 82: A method according to Embodiment 67, wherein the alignment score against the known allele sequence and the alignment score against the bait allele sequence each comprise at least one mismatch and / or insertion / deletion.
[0459] Embodiment 83: A method according to embodiment 67, wherein identifying a sequence read or read pair as a supporting sequence read or read pair for a sequence of interest includes identifying a reference variant among one or more reference variants as a candidate variant based on aligning the sequence read or read pair with one or more reference variants.
[0460] Embodiment 84: A method according to embodiment 67, wherein identifying a sequence read or a read pair as a supporting sequence read or a read pair for a sequence of interest includes identifying a non-human reference variant among the one or more non-human reference variants as a candidate variant based on aligning the sequence read or the read pair with one or more non-human reference variants, and identifying the sequence read or the read pair as originating from a contaminated sample.
[0461] Embodiment 85: A method according to embodiment 67, wherein generating an alignment of more than one sequence read or read pairs with more than one known allele sequence includes determining read pairs that align with at least two sequences of the more than one known allele sequence and selecting one known allele sequence of the at least two known allele sequences.
[0462] Embodiment 86: A method according to embodiment 67, wherein generating an alignment of more than one sequence read or read pairs with more than one bait allele sequence includes determining read pairs that are aligned with at least two bait allele sequences among the more than one bait allele sequences, and selecting one bait allele sequence among the at least two bait allele sequences.
[0463] Embodiment 89: A method comprising determining more than one sequence read pairs for a target region of a chromosome of a subject, wherein the target region of the chromosome comprises one or more loci, generating germline alignments of the more than one sequence read pairs with more than one known allele sequence, generating bait alignments of the more than one sequence read pairs with more than one bait allele sequence, determining a sequence read pair among the more than one sequence read pairs having both a germline alignment (having at least one mismatch and / or insertion / deletion) and a bait alignment (having at least one mismatch and / or insertion / deletion), wherein the sequence read pair is associated with a germline alignment score that is greater than the bait alignment score, and identifying the sequence read pair as a candidate somatic variant.
[0464] Embodiment 90: The method according to embodiment 89, further comprising obtaining a sample from the subject and sequencing the sample to obtain more than one sequence read pair of the target region of the chromosome.
[0465] Embodiment 91: The method of embodiment 89, wherein the target region comprises one or more of the following genes: HLA-A, HLA-B, HLA-C, HLA-E, HLA-F, HLA-G, HLA-H, HLA-J, HLA-K, HLA-L, HLA-N, HLA-P, HLA-S, HLA-T, HLA-U, HLA-V, HLA-W, HLA-DRA, HLA-DRB1, HLA-DRB2, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-DRB6, HLA-DRB7, HLA-DRB8, HLA-DRB9, HLA-DQA1, HLA-DQB1, HLA-DQA2, HLA-DQB2, HLA-DQB3, HLA-DOA, HLA-DOB, HLA-DMA, HLA-DMB, HLA-DPA1, HLA-DPB1, HLA-DPA2, HLA-DPB2, HLA-DPA3, HFE, TAP1, TAP2, PSMB9, PSMB8, MICB, MIC A. MICC, MICD, MICE, KIR2DL1, KIR2DL2 / L3, KIR2DL4, KIR2DL5A, KIR2DL5B, KIR2DS1, KIR2DS2, KIR2DS3, KIR2DS4, KIR2DS5, KIR3DL1 / S1, KIR3DL2, or KIR3DL3.
[0466] Embodiment 92: The method of embodiment 89, wherein the target region comprises chromosome position 6p21 or chromosome position 19q13.
[0467] Embodiment 93: The method according to embodiment 89, wherein the target region comprises at least a portion of the major histocompatibility complex (MHC) region and the chromosome is human chromosome 6.
[0468] Embodiment 94: The method of embodiment 89, wherein the target region comprises at least a portion of a killer cell immunoglobulin-like receptor (KIR) region and the chromosome is human chromosome 19.
[0469] Embodiment 95: A method according to embodiment 89, wherein the more than one known allele sequence comprises more than one known human leukocyte antigen (HLA) allele sequence or more than one known human killer cell immunoglobulin-like receptor (KIR) region allele sequence.
[0470] Embodiment 96: A method according to embodiment 89, wherein the more than one bait sequence comprises more than one non-human sequence.
[0471] Embodiment 97: The method of Embodiment 96, wherein the more than one non-human sequence comprises one or more of more than one bovine sequence, more than one rat sequence, or more than one microbial sequence.
[0472] Embodiment 98: A method according to embodiment 89, wherein generating a germline alignment of more than one sequence read pairs with more than one known allele sequence includes, based on the germline alignment, determining, for one sequence read pair in the more than one sequence read pairs, one or more known allele sequences that align with each read in a sequence read pair without having mismatches or insertions / deletions.
[0473] Embodiment 99: According to the method of embodiment 98, it also includes determining, based on the germline alignment, for each known allele sequence in more than one known allele sequence, the number of sequence read pairs aligned with each known allele sequence in more than one sequence read pairs, and based on the number of sequence read pairs aligned with each known allele sequence, determining, for one or more loci, the known allele sequences present at one or more loci.
[0474] Embodiment 100: A method according to embodiment 89, wherein generating a bait alignment of more than one sequence read pairs with more than one bait allele sequence includes, based on the bait alignment, for one sequence read pair among the more than one sequence read pairs, determining one or more bait allele sequences that align with each read in a sequence read pair without having mismatches or insertions / deletions, and discarding one sequence read pair.
[0475] Embodiment 101: A method according to embodiment 89, wherein generating bait alignments of more than one sequence read pairs with more than one bait allele sequences includes, based on the bait alignments, determining, for one of the more than one sequence read pairs, one or more non-human bait sequences that align with each read in the one sequence read pair without mismatches or insertions / deletions, and identifying the more than one sequence read pairs as originating from a contaminated sample.
[0476] Embodiment 102: A method according to embodiment 89, wherein generating a germline alignment of more than one sequence read pairs with more than one known allele sequence includes, based on the germline alignment, for one sequence read pair in the more than one sequence read pairs, determining one or more known allele sequences that align with each read in a sequence read pair and have at least one mismatch or insertion / deletion, and generating a germline alignment score.
[0477] Embodiment 103: A method according to embodiment 102, wherein generating a bait alignment of more than one sequence read pairs with more than one bait allele sequence includes, based on the bait alignment, for one sequence read pair in the more than one sequence read pairs, determining one or more bait allele sequences that align with each read in a sequence read pair and have at least one mismatch or insertion / deletion, and generating a bait alignment score.
[0478] Embodiment 104: A method according to Embodiment 89, wherein identifying a sequence read pair as a candidate somatic variant comprises identifying a reference variant among the one or more reference variants as a candidate variant based on aligning the sequence read pair with the one or more reference variants.
[0479] Embodiment 105: A method according to embodiment 89, wherein identifying a sequence read pair as a candidate somatic variant includes identifying a non-human reference variant among the one or more non-human reference variants as a candidate variant based on aligning the sequence read pair with one or more non-human reference variants, and identifying more than one sequence read pair as originating from a contaminated sample.
[0480] Embodiment 106: A method according to embodiment 89, wherein generating a germline alignment of more than one sequence read pair with more than one known allele sequence includes determining a sequence read pair that aligns with at least two allele sequences of the more than one known allele sequences, and selecting one known allele sequence of the at least two allele sequences.
[0481] Embodiment 107: A method according to embodiment 89, wherein generating a bait alignment of more than one sequence read pair with more than one bait allele sequence includes determining a sequence read pair that is aligned with at least two bait allele sequences among the more than one bait allele sequences, and selecting one bait allele sequence among the at least two bait allele sequences.
[0482] All patent applications, websites, other publications, accession numbers, etc. cited above or below are incorporated by reference in their entirety for all purposes, to the extent that each individual project is specifically and individually indicated to be incorporated by reference. If different versions of a sequence are associated with an accession number at different times, it means the version associated with the accession number on the effective application date of the present application. The effective application date means the earlier of the actual application date of the accession number or the application date of the priority application (if applicable). Similarly, if different versions of publications, websites, etc. are published at different times, unless otherwise indicated, it means the most recently published version at the effective application date of the present application. The features described in the context of the individual aspects and embodiments of the present invention can be used together and / or interchangeable. Similarly, the features described in the context of a single embodiment can also be provided individually or in any suitable sub-combination. Any feature, step, element, embodiment or aspect of the present disclosure can be used in combination with any other feature, step, element, embodiment or aspect, unless otherwise specifically indicated. Although the present disclosure has been described in some detail by way of illustration and example for purposes of clarity and understanding, it will be apparent that certain changes and modifications may be practiced within the scope of the appended claims.
Claims
1. A method comprising: Determine more than one known allele sequence; determining more than one sequence read of a target region of a chromosome of a subject, wherein the target region of the chromosome comprises one or more loci; aligning the more than one sequence reads to the more than one known allele sequences; based on the alignment, for each known allele sequence of the more than one known allele sequences, determining a number of sequence reads aligned to each known allele sequence; and Based on the number of sequence reads aligned to each known allele sequence, for the one or more loci, the known allele sequences present at the one or more loci are determined.
2. The method of claim 1, wherein the more than one known allele sequences comprise more than one known human leukocyte antigen (HLA) allele sequences or more than one known killer cell immunoglobulin-like receptor (KIR) region allele sequences.
3. The method according to claim 1, further comprising: obtaining a sample from the subject; and The sample is sequenced to obtain the more than one sequence reads of the target region of the chromosome.
4. The method according to claim 1, further comprising: Based on the alignment, for each of the more than one sequence reads, one or more known allele sequences aligned to each read are determined.
5. The method of claim 1, wherein the target region comprises one or more of the following genes: HLA-A, HLA-B, HLA-C, HLA-E, HLA-F, HLA-G, HLA-H, HLA-J, HLA-K, HLA-L, HLA-N, HLA-P, HLA-S, HLA-T, HLA-U, HLA-V, HLA-W, HLA-DRA, HLA-DRB1, HLA-DRB2, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-DRB6, HLA-DRB7, HLA-DRB8, HLA-DRB9, HLA-DQA1, HLA-DQB1, HLA-DQA2, HLA-DQA3, HLA-DQA4, HLA-DQA5, HLA-DQA6, HLA-DQA7, HLA-DQA8, HLA-DQA9, HLA-DQA10, HLA-DQA2, HLA-DQA3, HLA-DQA4, HLA-DQA5, HLA-DQA6, HLA-DQA7, HLA-DQA8, HLA-DQA9, HLA-DQA11, HLA-DQA2, HLA-DQA3, HLA-DQA4, HLA-DQA5 ... LA-DQB2, HLA-DQB3, HLA-DOA, HLA-DOB, HLA-DMA, HLA-DMB, HLA-DPA1, HLA-DPB1, HLA-DPA2, HLA-DPB2, HLA-DPA3, HFE, TAP1, TAP2, PSMB9, PSMB8, MICB, MIC A. MICC, MICD, MICE, KIR2DL1, KIR2DL2 / L3, KIR2DL4, KIR2DL5A, KIR2DL5B, KIR2DS1, KIR2DS2, KIR2DS3, KIR2DS4, KIR2DS5, KIR3DL1 / S1, KIR3DL2, or KIR3DL3.
6. The method of claim 1, wherein the target region comprises chromosome position 6p21 or chromosome position 19q13.
7. The method of claim 1, wherein the target region comprises at least a portion of the major histocompatibility complex (MHC) region and the chromosome is human chromosome 6.
8. The method of claim 1, wherein the target region comprises at least a portion of a killer cell immunoglobulin-like receptor (KIR) region and the chromosome is human chromosome 19.
9. The method of claim 1, wherein determining the more than one known allele sequences comprises: Retrieve sequence data for known alleles; determining more than one k-mer sequence based on the sequence data of the known alleles; and The more than one k-mer sequences are assembled into a data structure comprising more than one entry, wherein each entry comprises a k-mer sequence, the number of alleles containing the k-mer sequence, an allele identifier for each allele containing the k-mer sequence, and a starting position and an ending position of the k-mer sequence in each allele.
10. The method of claim 1, wherein based on the alignment, for each known allele sequence in the more than one known allele sequences, determining the number of sequence reads aligned with each known allele sequence comprises determining the number of sequence reads aligned with each known allele sequence and having 100% identity.
11. A method according to claim 1, wherein based on the number of sequence reads aligned with each known allele sequence, for the one or more loci, determining the known allele sequences present at the one or more loci includes determining one or more known allele sequences having the highest number of aligned sequence reads.
12. The method of claim 1, wherein reads aligned to each known allele sequence are grouped into read families, and the method further comprises determining the number of sequence read families aligned to each known allele sequence.
13. The method of claim 12, wherein for the one or more loci, the known allele sequences present at the one or more loci are determined based on the number of sequence read families that align with each known allele sequence.
14. The method of claim 1, further comprising determining a length of a portion of each known allele sequence that aligns with two or more of the more than one sequence reads.
15. The method according to claim 1, further comprising: For a locus, sorting the known allele sequences present at the locus by the number of sequence reads that align to each known allele sequence; For the locus, determining a first known allele sequence having a highest number of aligned sequence reads; inserting the first known allele sequence having the highest number of aligned sequence reads into a superset; determining one or more known allele sequences aligned to reads that are a subset of reads aligned to the first known allele sequence; and The one or more known allele sequences are inserted into the superset.
16. The method according to claim 15, wherein: The superset includes a graph data structure.
17. The method according to claim 16, wherein: The graph data structure comprises a directed acyclic graph. The method of claim 16 , wherein the graph data structure represents a Hasse graph.
19. The method according to claim 15, further comprising: determining that the loci are associated with a single superset; and The first known allele sequence of the single superset is determined to be the allele present at the locus.
20. The method of claim 15, further comprising determining more than one superset of the loci.
21. The method according to claim 20, further comprising determining two supersets having a maximum cumulative number of distinct reads based on the more than one supersets of the loci; and The first known allele sequence in each of the two supersets is determined to be the allele present at the locus.
22. The method of claim 1, further comprising facilitating communication of the known allele sequences present at the one or more loci to a medical provider.
23. The method of claim 1, wherein the known allele sequence present at the locus comprises a human leukocyte antigen (HLA) type at the locus or a killer cell immunoglobulin-like receptor (KIR) type at the locus.
24. The method of claim 1, further comprising: obtaining a sample from cells to be transplanted into the subject; and The sample is sequenced to obtain the more than one sequence reads of the target region of the chromosome.
25. The method of claim 24, further comprising determining whether the subject's HLA type matches the HLA type at the locus.
26. The method of claim 25, further comprising transplanting the cells into the subject if the subject's HLA type matches the HLA type at the locus.
27. The method of claim 25, further comprising: transplanting the cell into the subject if the subject's HLA type matches the HLA type at the locus; and An agent that reduces the likelihood of transplant rejection is administered to the subject.
28. The method of claim 1, further comprising determining that the subject is susceptible to developing rheumatoid arthritis (RA), wherein the known allele sequences present at the one or more loci include HLA-DRB1*04:01, *04:04, and *04:08; HLA-DRB1*04:05; HLA-DRB1*01:01 and *01:02; HLA-DRB1*14:02; HLA-DRB1*10:01; and HLA-DRB1*01:01, *04:01, *04:04, and *04:
05.
29. The method according to claim 1 further includes determining that the subject is susceptible to developing multiple sclerosis (MS), wherein the known allele sequences present at the one or more loci include HLA-DRB1*15:01, HLA-DQB1*06:02, HLA-DRB1*01:08, HLA-DRB1*03:01 and / or HLA-DRB1*13:
03.
30. The method of claim 1, further comprising determining that the subject is susceptible to developing systemic lupus erythematosus (SLE), wherein the known allele sequences present at the one or more loci include HLA-DRB1, HLA-DR2 (DRB1*15:01), HLA-DR3 (DRB1*03:01), HLA-DRB1*08:01 and / or HLA-DQA1*01:
02.
31. The method of claim 1, further comprising determining that the subject is susceptible to developing type 1 diabetes (T1D), wherein the known allele sequences present at the one or more loci include HLA-DQB1*03:02 and / or DQB1*02:
01.
32. The method of claim 1, further comprising determining that the subject is susceptible to developing Sjögren's syndrome (SS), wherein the known allele sequences present at the one or more loci include DQA1*05:01, DQB1*02:01, and DRB1*03:
01.
33. The method of claim 1, further comprising determining that the subject is susceptible to developing celiac disease (CD), wherein the known allele sequences present at the one or more loci include HLA-DQ2 (encoded by HLA-DQA1*05:01-DQB1*02:01) and / or HLA-DQ8 (encoded by DQA1*03:01-DQB1*03:02).
34. The method of claim 1, further comprising determining that the subject is susceptible to developing pre-eclampsia, wherein the known allelic sequences present at the one or more loci include KIR2DL1.
35. The method of claim 1, further comprising determining that the subject is unlikely to progress from HIV infection to AIDS, wherein the known allele sequences present at the one or more loci include KIR3DS1.
36. The method of claim 1, further comprising determining that the subject is unlikely to progress from HIV infection to AIDS, wherein the known allele sequences present at the one or more loci include a combination of KIR3DS1 and HLA-Bw4.
37. The method of claim 1, further comprising determining that the subject is susceptible to developing an autoimmune disease, wherein the known allelic sequences present at the one or more loci include KIR2DS1.
38. The method of claim 1, further comprising determining that the subject is susceptible to developing Crohn's disease, wherein the known allele sequences present at the one or more loci include KIR2DL2 / KIR2DL3 heterozygosity.
39. The method of claim 1, further comprising determining that the subject is susceptible to developing Crohn's disease, wherein the known allele sequences present at the one or more loci include a combination of KIR2DL2 / KIR2DL3 heterozygosity and HLA-C2 alleles.
40. The method of claim 1, further comprising determining whether the subject is a suitable candidate for a donor in an unrelated hematopoietic cell transplant, wherein the known allele sequences present at the one or more loci include a group B KIR haplotype.
41. A method comprising: Determine more than one known human leukocyte antigen (HLA) allele sequence; determining more than one sequence read of a target region of a chromosome of a subject, wherein the target region of the chromosome comprises one or more loci; aligning the more than one sequence reads to the more than one known HLA allele sequences; based on the alignment, for each known HLA allele sequence of the more than one known HLA allele sequences, determining a number of sequence reads aligned to each known HLA allele sequence; generating one or more supersets of known HLA allele sequences based on the number of sequence reads aligned to each known HLA allele sequence; and Based on the number of different reads in the one or more supersets of the known HLA allele sequences, the known HLA allele sequences present at the one or more loci are determined for the one or more loci.
42. A method comprising: Determine the sequence of more than one known killer cell immunoglobulin-like receptor (KIR) allele; determining more than one sequence read of a target region of a chromosome of a subject, wherein the target region of the chromosome comprises one or more loci; aligning the more than one sequence reads to the more than one known KIR allele sequences; determining, for each known KIR allele sequence of the more than one known KIR allele sequences, a number of sequence reads aligned to each known KIR allele sequence based on the alignment; generating one or more supersets of known KIR allele sequences based on the number of sequence reads aligned to each known KIR allele sequence; and Based on the number of distinct reads in the one or more supersets of the known KIR allele sequences, the known KIR allele sequences present at the one or more loci are determined for the one or more loci.
43. A method comprising: Determine more than one known allele sequence; determining more than one sequence read of a target region of a chromosome of a subject, wherein the target region of the chromosome comprises one or more loci; aligning the more than one sequence reads to the more than one known allele sequences; based on the alignment, for each known allele sequence of the more than one known allele sequences, determining a number of sequence reads aligned to each known allele sequence; generating one or more supersets of known allele sequences based on the number of sequence reads aligned to each known allele sequence; and Based on the number of different reads in the one or more supersets of the known allele sequences, the known allele sequences present at the one or more loci are determined for the one or more loci.
44. One or more non-transitory computer-readable media having stored thereon processor-executable instructions that, when executed by a processor, cause the processor to perform the method of any one of claims 1-43.
45. A system comprising: A computing device configured to perform the method according to any one of claims 1 to 43; and An output device is configured to output an indication of the known allele sequence present at the one or more loci.
46. An apparatus comprising: one or more processors; and A memory storing processor-executable instructions which, when executed by the one or more processors, cause the apparatus to perform the method of any one of claims 1-43.
